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ABSTRACT 
Prostate cancer (PCa) is the most common cause of cmicer death amongst Western males. 
PCa occurs in two distinct stages. In its early stage, growth and development is dependent 
primarily on male sex hormones (androgens) such as testosterone, although other growth 
factors have roles maintaining PCa cell survival in this stage. In the later stage of PCa 
development, growth and.maintenance is independent of androgen stimulation and growth 
factors including Insulin-like Growth Factor -1 (IGf.:·l) and Epidermal Growth Factor 
(EGF) are thought to have more crucial roles in cell survival and PCa progression. 
PCa, in its late stages, is highly aggressive and metastatic, that is, tumorigenic cells migrate 
from the primary site of the body (prostate) and travel via the systemic and lymphatic 
circulation, residing and colonising in the bone, lymph node, lung, and in more rare cases, 
the brain. Metastasis involves both cell migration and tissue degradation activities. The 
degradation of the extracellular matrix (ECM), the tissue surrounding the organ, is 
mediated in part by members of a family of 26 proteins called the Matrix Metalloproteases 
(MMPs), whilst ceil adhesion molecules, of which proteins known as Integrins are 
included, mediate ce11 migration. A family of proteins known as the ADAMs (A 
Disintegrin . And Metalloprotease domain) were a recently characterised family at the 
commencement of this study and now comprise 34 members. Because of their dual nature, 
possessing an active metaiioprotease domain, homologous to that of the MMPs, and an 
integrin-binding domain capable of regulating cell-cell and cell-ECM contacts, it was 
thought likely that members of the ADAMs family may have implications for the 
progression of aggressive cancers such as those ofthe prostate. 
This study focussed on two particular ADAMs -9 and -10. ADAM-9 has an active 
metalloprotease domain, which has been shown to degrade constituents of the ECM, 
including fibronectin, in vitro. It also has an integrin-binding capacity through association 
with key integrins involved in PCa progression, such as a6~1. ADAM-10 has no such 
integrin binding activities, but its bovine orthologue, MADM, is able to degrade coHagen 
type IV, a major component of basement membranes. It is likely human ADAM-10 has the 
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same activity. It is also known to cleave Ll -a protein involved in cell anchorage activities 
- and collagen type XVII - which is a principal component of the hemidesmosomes of 
cellular tight junctions. The cleavage of these proteins enables the cell to be released from 
the surrounding environment and commence migratory activities, as required in metastasis. 
Previous studies in this laboratory showed the mRNA expression of the five ADAMs -9,-
10, -11, -15 and -17 in PCa cell lines, characteristic of androgen-dependent and androgen-
independent disease. These studies were furthered by the characterisation of AD AM-9, -10 
and -17 mRNA regulation by Dihydrotestosterone (DHT) in the androgen-responsive cell 
line (LNCaP). ADAM-9 and -10 mRNA levels were elevated in response to DHT 
stimulation. Further to these observations, the expression of ADAM-9 and -10 was shown 
in primary prostate biopsies from patients with PCa. ADAM-1 0 was expressed in the 
cytoplasm and on the ceH membrane in epithelial and basal cells ofbenign prostate glands, 
but in high-grade PCa glands, ADAM-I 0 expression was localised to the nucleus and its 
expression levels appeared to be elevated when compared to low-grade PCa glands. These 
studies provided a strong background for the hypothesis that ADAM-9 and -10 have key 
roles in the development ofPCa and provided a basis for further studies. 
The aims of this study were to: 1) characterise the expression, localisation and levels, of 
ADAM-9 and -10 mRNA and protein in cell models representing characteristics of normal 
through androgen-dependent to androgen-independent PCa, as well as to expand the 
primary PCa biopsy data for ADAM-9 and ADAM-10 to encompass PCa bone metastases 
2) establish an in vitro cell system, which could express elevated levels of ADAM-1 0 so 
that functional cell-based assays such as cell migration, invasion and attachment could be 
carried out, and 3) to extend the previous hormonal regulation data, to fully characterise the 
response of ADAM-9 and -10 mRNA and protein levels to DHT, IGF-1, DHT plus IGF-1 
and EGF in the hormonal/growth factor responsive cell line LNCaP. 
For aim 1 (expression of ADAM-9 and -10 mRNA and protein), ADAM-9 and -10 mRNA 
were characterised by R T -PCR, while their protein products were analysed by Western 
blot. Both ADAM-9 and -10 mRNA and protein were expressed at readily detectable 
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levels across progressively metastatic PCa cell lines model that represent characteristics of 
low-grade,. androgen-dependent (LNCaP and C4) to high-grade, androgen-independent 
(C4-2 and C4-2B) PCa. When the non-tumorigenic prostate cell line RWPE-1 was 
compared with the metastatic PCa cell line PC-3, differential expression patterns were seen 
by Western blot analysis. For ADAM-9, the active form was expressed at higher levels in 
RWPE-1, whilst subcellular fractionation showed that the active form of ADAM-9 was 
predominantly located in the cell nucleus. For ADAM-I 0, in both of the cell Jines, a 
nuclear specific isoform of the mature, catalytically active ADAM-I 0 was found. This 
isoforrn differed by -2 kDa in Mr (smaller) than the cytoplasmic specific isoform. 
Unprocessed ADAM-I 0 was readily detected in R WPE-1 cell lines but only occasionally 
detected in PC-3 cell lines. Immunocytochemistry using ADAM-9 and -10 specific 
antibodies confirmed nuclear, cytoplasmic and membrane expression of both ADAMs in 
these two cell lines. To examine the possibility of ADAM-9 and -10 being shed into the 
extracellular environment, membrane vesicles that are constitutively shed from the cell 
surface and contain membrane-associated proteins were collected from the media of the 
prostate cell lines RWPE-1, LNCaP and PC-3. ADAM-9 was readily detectable in RWPE-
1 and LNCaP cell membrane vesicles by Western blot analysis, but not in PC-3 cells, whilst 
the expression of ADAM-I 0 was detected in shed vesicles from each of these prostate cell 
lines. 
By Laser Capture Microdissection (LCM), secretory epithelial cells of primary prostate 
gland biopsies were isolated from benign and malignant glands. These secretory cells, by 
Western blot analysis, expressed similar Mr bands for ADAM-9 and -10 that were found in 
PCa cell lines in vitro, indicating that the nuclear specific isoforrn of ADAM-I 0 was 
present in PCa primary tumours and may represent the predominantly nuclear form of 
ADAM-I 0 expression, previously shown in high-grade PCa by immunohistochemistry 
(IHC). ADAM-9 and -10 were also examined by IHC in bone metastases taken from PCa 
patients at biopsy. Both ADAMs could be detected at levels similar to those shown for 
Prostate Specific Antigen (PSA) in these biopsies. Furthermore, both ADAM-9 and -10 
were predominantly membrane- bound with occasional nuclear expression. 
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For aim 2, to establish a cell system that over-expressed levels of ADAM-10, two full-
length ADAM-I 0 mammalian expression vectors were constructed; ADAM-I 0 was cloned 
into pcDNA3.1, which contains a CMV promoter, and into pMEP4, containing an inducible 
metallothionine promoter, whose activity is stimulated by the addition of CdC}z. The 
efficiency of these two constructs was tested by way of transient transfection in the PCa 
cell line PC-3, whilst the pcDNA3.1 construct was also tested in the RWPE-1 prostate cell 
line. Resultant Western blot analysis for all transient transfection assays showed that levels 
of ADAM-I 0 were not significantly elevated in any case, when compared to levels of the 
housekeeping gene ~-Tubulin, despite testing various levels of vector DNA, and, for 
pMEP4, the induction of the transfected cell system with different degrees of stimulation 
with CdCh to activate the metallothionine promoter post-transfection. Another study in 
this laboratory found similar results when the same full length ADAM-10 sequence was 
cloned into a Green Fluorescent Protein (GFP) expressing vector, as no fluorescence was 
observed by means of transient transfection in the same, and other, PCa cell lines. It was 
hypothesised that the Kozak sequence included in the full-length construct (human ADAM-
I 0 naturally occurring sequence) is not strong enough to initiate translation in an artificial 
system, in cells, which, as described in Aim 1, are already expressing readily detectable 
levels of endogenous ADAM-10. As a result, time constraints prevented any further 
progress with Aim 2 and functional studies including cell attachment, invasion and 
migration were unable to be explored. 
For Aim 3, to characterise the response of ADAM-9 and -10 mRNA and protein levels to 
DHT, IGF-1, DHT plus IGF-1 and EGF in LNCaP cells, the levels of ADAM-9 and -10 
mRNA were not stimulated by DHT or IGF-I alone, despite our previous observations that 
initially characterised ADAM-9 and -10 mRNA as being responsive to DHT. However, 
IGF-1 in synergy with DHT did significantly elevate mRNA levels ofboth ADAMs. In the 
case of ADAM-9 and -10 protein, the same trends of stimulation as found at the rnRNA 
level were shown by Western blot analysis when ADAM-9 and -10 signal intensity was 
normalised with the housekeeping protein ~-Tubulin. For EGF treatment, both ADAM-9 
and -10 mRNA and protein levels were significantly elevated, and further investigation 
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found this to be the case for each of these ADAMs proteins in the nuclear fractions of 
LNCaP cells. 
These studies are the first to describe extensively, the expression and hormonal/growth 
factor regulation of two members of the ADAMs family ( -9 and -1 0) in PCa. These 
observations imply that the expression of ADAM-9 and -10 have varied roles in PCa whilst 
it develops from androgen-sensitive (early stage disease), through to an androgen-
insensitive (late-stage), metastatic disease. Further studies are now required to investigate 
the several key areas of focus that this research has revealed, including: 
• Investigation of the cellular mechanisms that are involved in actively transporting the 
ADAMs to the cell's nuclear compartment and the ADAMs functional roles in the cell 
nucleus. 
• The construction of a full-length human ADAM-10 mammalian expression construct 
with the introduction of a new Kozak sequence, that elevates ADAM-I 0 expression in 
an in vitro cell system are required, so that functional assays such as cell invasion, 
migration and attachment may be carried out to fmd the functional consequences of 
ADAM expression on cellular behaviour. 
• The regulation studies also need to be extended by confirming the preliminary 
observations that the nuclear levels of ADAMs may also be elevated by hormones and 
growth factors such as DHT, IGF-1 and EGF, as well as the regulation of levels of 
plasma membrany vesicle associated ADAM expression. 
Given the data presented in this study, it is likely the ADAMs have differential roles 
throughout the development of PCa due to their differential cellular localisation and 
synergistic growth-factor regulation. These observations, along with those further studies 
outlined above, are necessary in identifying these specific components ofPCa metastasis to 
which the ADAMs may contribute. 
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CHAPTER ONE 
1.0 INTRODUCTION AND LITERATURE REVIEW 
THE ADAMS FAMILY OF PROTEASES AND PROSTATE CANCER: 
, A POTENTIAL ROLE IN EXTRACELLULAR MATRIX 
REMODELLING 
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1.1 Introduction 
The extracellular matrix (ECM) comprises a number of proteins including collagen, 
fibronectin, vitronectin, laminin and proteoglycans that act as a supportive network of 
tissue surrounding organs within the body. An equally important specialised ECM is the 
basement membrane (BM) (Rucklidge et al. 1994), of which a major protein component is 
collagen type IV. The BM forms a barrier between cells in a confined organ and the ECM. 
When cells of a particular organ become tumorigenic in nature, the surrounding BM and 
ECM proteins are degraded to allow room for those cells to 1) divide, thus enlarging the 
. organ, and 2) to migrate through the surrounding tissue. These two key mechanisms are 
central to the multistep process known as metastasis. 
A family of 26 proteins called the matrix metaJloproteases (MMPs) are currently 
subdivided into 5 categories depending on substrate specificity and preference, the 
gelatinases, stromelysins, collagenases, membrane-type MMPs (MT -MMP) and a 
heterogeneous subgroup (Egeblad and Werb, 2002;Stemlicht and Bergers, 2000). 
Collectively they mediate the degradation of most BM and ECM proteins; therefore these 
proteases are key facilitators of metastasis. Cell adhesion molecules (CAMs) including 
glycoproteins known as integrins, regulate the migration of tumorigenic cells through the 
degraded ECM. A recently characterised family of 34 predominantly membrane - bound 
proteins called the ADAMs (A Disintegrin And Metalloprotease domain) have the potential 
to act both as ECM degrading enzymes and integrin-binding/dissociation molecules for cell 
migration activity. Hence, the expression of the ADAMs by tumour cells may have 
implications in these two steps of metastasis. 
Classically, the role of the ADAMs family is to cleave/solubilise and/or activate membrane 
bound growth factors and cytokines on the cell surface. However, particular members of 
the ADAMs have also shown metalloprotease activity specifically toward BM and ECM 
proteins. With respect to cell migration, members of the ADAMs family bind key 
integrins via a conserved tri-peptide motif of an integrin - binding loop in their disintegrin 
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domain. Given these characteristics, we hypothesise that the ADAMs family may be 
mechanistic contributors to the process of metastasis. 
The expression of the ADAMs family is not well characterised in metastatic cancers such 
as lung, colon, breast and prostate. The latter two cancers, breast and prostate, are 
hormone-dependent in that key hormones such as estrogen and testosterone respectively, 
assist in their growth, development (progression) and maintenance. These honnones and 
other contributing growth factors are thought to regulate cancer progression by regulating 
the expression of proteins such as the MMPs that are involved in the metastatic process. 
This study focuses on the potential for the ADAMs family of proteins to 1) be expressed in 
prostate cancer (PCa) and 2) be regulated by testosterone and key growth factors, namely 
Insulin-like Growth Factor-1 (IGF-1) and Epidermal Growth Factor (EGF), known to 
contribute to PCa progression and cell survival. 
Therefore, the purpose of this literature review is to outline: 
1) PCa and the process of metastasis, 
2) The expression of MMPs, their regulation and ftmction, 
3) The biology and role of integrins in cell migration, and, 
4) The biology of the ADAMs and their link with MMPs and integrins. 
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I .2 Prostate Cancer 
"Prostate cancer (PCa) is the sixth most common cancer in the world, the third most 
common cancer in men, and the most common cancer in men in Europe, North America, 
and some parts of Africa" (Gronberg, 2003). Risk factors for the development of PCa 
include genetic, environmental, dietary, social and hormonal factors (Haas, 1997), whilst 
the incidence of PCa is strongly correlated with increasing age. A patient suspected of 
suffering from PCa, may have benign prostate hyperplasia (BPH) (enlarged but not 
malignant prostate gland), low or high-grade prostatic intraepithelial neoplasia (PIN) or 
low, medium or high-grade PCa. BPH has not been linked directly to PCa although 
androgen metabolism and increasing age are two common risk factors in both diseases 
(Boyle, 1994). 
To quantify and describe the progression of PCa disease, the Gleason grading system 
(Gleason, 1966) has been implemented. A numerical value is assigned to the prostate 
glands of the biopsy. Grade 1 is the lowest score reflecting the least aggressive, highly 
differentiated form of PCa whilst grade 5 is the highest score reflecting the most 
aggressive, poorly differentiated form of PCa. Two Gleason grades are given to any 
particular biopsy examined; the first number describes the most dominant type of prostate 
gland whilst the second is the next frequently occurring type of gland. An example of a 
Gleason score is 3+4=7 where most of the glands seen are Gleason grade 3, moderately 
differentiated, whilst the next frequently occurring gland is Gleason grade 4, poorly 
differentiated. 
Clinical tests for the presence ofPCa often include the intrusive procedure of Digital Rectal 
Examination (DRE) and, a less intrusive serum test for the marker Prostate Specific 
Antigen (PSA). Both methods of screening can effectively detect PCa, however the 
efficiency of each is suboptimal. The sensitivity of DRE examination has been reported to 
be as low as 18-22% (Vihko et al. 1985; Optenberg and Thompson, 1990). In the case of 
PSA screening, a serum value of> 4.0 ng/ml indicates an associative risk of having PCa. 
The sensitivity of PSA evaluation reports is as high as 80 % in some studies, whilst others 
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report as low as 29 %. Grossly elevated PSA levels are often indicative of more aggressive 
PCa. PSA specificity is however limited, as men with benign disease such as BPH and 
prostatitis often screen positive for elevated PSA serum values (Catalona et al. 1993; 
Mettlin et al. 1994; Scaletscky et al. 1994; Humphrey et al. 1994). It is controversial 
whether the early detection of PCa lowers mortality, although the incidence of metastatic 
disease over time has decreased where regular screening occurs (Labrie et al. 1996)_ These 
initial screening methods often lead to more invasive screening, including biopsies such as 
'transurethral resection ofthe prostate' (TIJRP), or 'transrectal guided ultrasound' (TRUS) 
biopsies as well as repeat screening of all invasive and non-invasive methods. 
Treatment regimes for PCa include androgen ablation therapy, radiation therapy and radical 
prostatectomy. Androgen ablation therapy gives some respite from the suffering of PCa 
morbidity. However, commonly the cancer still progresses through late-stage to an 
aggressive metastatic phenotype. The benefits of radical treatment are often not seen in 
patients with a life expectancy of less than 10 years (Adolffson, 1993; Chodak et al. 1994; 
Warner and Whitmore, 1994; Johansson et al. 1997). Radiation therapy and radical 
prostatectomy often lead to severe side effects such as erectile dysfunction and urinary 
incontinence, considerably affecting the patient's quality oflife. 
1.2.1 Metastasis 
PIN (prostatic intra-epithelial neoplasia) is a condition that is believed to precede cancer of 
the prostate gland. Development of a neoplasia such as PIN involves two factors affecting 
cellular behaviour, that is the disruption of cellular differentiation and the development of 
abnormal relationships between the cells and their microenvironment (Pusztai et al. 1996). 
Once neoplastic cells develop into a primary tumour, the cells may acquire the ability to 
migrate from their primary organ to a distant organ in the body, a process referred to as 
metastasis (Figure 1.1 ). 
"Tumour metastases have proved to be the major cause of death in cancer patients" (Zem 
and Reid, 1993). Migration of tumour cells involves a plethora of biological interactions at 
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the molecular and cellular level. The tumour cell first loses cell-cell contact by altering the 
expression of cell surface molecules known as ce11 adhesion molecules (CAMs) a11owing 
subsequent cell separation (Edelman, 1984). Epithelial cells must invade local tissue before 
migration occurs. Components of local tissue invasion include the lysis of the surrounding 
healthy cells, the degradation of the BM and invasion (Figure 1.1) through the ECM. 
Proteolytic enzymes such as metalloproteases, of which the MMPs are the major 
contributing enzymes, are believed to be responsible for the invasive event (Chang and 
W erb, 2001 ). 
Figure 1.1: The various stages a primary tumour must undergo for complete metastasis, 
ECM = vitronectin, co11agen, fibronectin, laminin, other glycoproteins. 
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Once a path of degradation is established through the BM and the ECM, the tumour cells 
can undergo migration from their primary location (Figure 1.1 ). CAMs, which include cell 
surface proteins such as cadherins and the ce11 surface glycoproteins, integrins, are 
modulators of this process (Ho11y et al. 2000). 
In addition to the loss of ce11-cell contact, invasion and migration, tumour ce11s sustain their 
growth by vascularising their local environment (angiogenesis - Figure 1.1 ). 
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Vascularisation is brought about by the secretion of growth factors such as Vascular 
Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) (Sato and 
Rifkin, 1988; Keck et al. 1989) and is necessary to supply oxygen and nutrients otherwise 
present at insufficient levels via diffusion (Vile, 1995). The capillary endothelial cells must 
also invade through the ECM and migrate to the site of the tumour. Again the MMPs and 
CAMs are believed to mediate this important step in metastasis (Pusztai et al. 1996). 
Angiogenesis provides a transport medium, in the form of capillaries, for the tumour cells 
to utilise. The tumour cells invade into the bloodstream via angiogenic capillary invasion 
(intravasation) or into the lymphatic system. Once in the blood stream, many cells escape 
immune surveillance and arrest in downstream organs. An arresting tumour cell again 
makes use of CAMs enabling its adhesion to the wall of a blood vesseL Subsequent 
extravasation occurs allowing the cell to leave the bloodstream and colonise an entirely 
different organ (Figure 1.1 ). Both intravasation and extravasation involve proteolytic 
activity for BM degradation; again mediated by the MMPs. Hence, CAM modification and 
proteolysis are two major events mediating cancer metastasis. Thus, it is imperative to 
further our knowledge of these two particular molecular mechanisms so that a greater 
understanding of cancer progression can be acquired. 
High-grade PCa commonly metastasises to bone (Carlin and Andriole, 2000) and lymph 
nodes (Bader et al. 2003) whilst other less common sites include the lung and brain (Levi et 
al. 2003; Castro et al. 2003). In the case of patients with bone metastasis, for example, 
severe morbidity, which entails painful osteosclerotic lesions and fractures, prevails. This 
may lead to nerve compression, paralysis and eventually death (Rubens, 1998). Once 
tumour cells have colonised in the bone, the normal remodelling between osteoclast bone 
resorption and osteoblast bone deposition is disrupted. In the case ofPCa, there is evidence 
suggesting that both osteolysis and osteosclerosis activities (bone resorption and deposition, 
respectively) are enhanced, presumably initial colonisation requiring the former and 
subsequent growth and progression requiring the latter (Mundy and Yoneda, 1996). With 
respect to the underlying mechanisms involved in this process, like metastasis, little to date 
is known. 
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1.2.2 Growth factors involved in prostate cancer progression and metastasis 
Early stage PCa growth and progression is dependent on male sex hormones (androgens), 
predominantly testosterone. Testosterone, secreted by the male testis, is converted 
intracellularly to 5-a-dihydrotestosterone (DHT), which binds, activates, and translocates 
the androgen receptor (AR) to the cell nucleus. The AR binds androgen response elements 
in the promoter region of genes (Reinikainen, 1996), which in turn regulate the 
transcriptional activity of many proteins involved in PCa growth. In the prostate, the AR is 
found predominantly in the secretory epithelial cells of prostate glands (Chung, 1991; Lee, 
1996). The transition from androgen sensitive (low-grade PCa) and androgen insensitive 
(high-grade PCa) is not well understood. Along with evidence suggesting that the AR is 
subject to point mutations so that it is no longer able to bind, or has reduced signalling in 
response to DHT binding (Veldscholte et aL 1990; Bente} and Tilley, 1996), there is also 
evidence that suggests particular mutations in the AR confers hypersensitivity to other 
hormones such as estrogen leading to an increase in AR transactivation (Thin et al. 2003). 
The AR mutations are predominantly found in metastatic disease but not in cases of 
primary prostate tumours (Marcelli et al. 2000). 
Other growth factors involved in the regulation of PCa groWth include the Fibroblast 
Growth Factors (FGFs), IGFs, Transforming Growth Factor a (TGF a) (Russell et al. 
1998) as well as Interleukin-6 (IL-6) (Chung et al. 1999), Leukaemia Inhibitory Factor 
(LIF) and EGF (Jarrad et al. 1994). Past studies suggest IGF-1, EGF and IL-6 are 
enhancers of the transactivation and stimulation of the sensitivity of the AR, when in the 
presence ofDHT (Culig et aL 1994; Chan et al. 1998; Ueda et al. 2001; Orio et al. 2002). 
Levels of growth factors such as these are also themselves regulated by androgens. Stromal 
cells surrounding prostate epithelia commonly express these growth factors, which act in a 
paracrine manner (Figure 1.2), diffusing through the ECM. Cell proliferation and 
transformation in the glandular epithelium of the prostate is thought to be dependent on 
these stromal growth factor secretions (Ware, 1994; Farnsworth, 1999). Figure 1.2 outlines 
schematically the interactions of DHT and growth factors on prostate stroma and epithelia, 
and their consequences on cell behaviour. 
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The IGFs are peptide GFs that share homology with insulin. They are produced by the 
liver and circulated in the blood, as well as being loca11y secreted from the prostate and 
exerting their effects in both an autocrine and paracrine manner. Their binding proteins 
(BPs), of which there are 6 described to date (Baxter, 2001), can regulate IGF 
bioavailability by binding free IGF-1, reducing the levels of the bioactive peptide. High 
levels of IGF-BPs are known to have an apoptotic effect on PCa cells (Rajah et al. 1997). 
The IGFs are thought to be the major regulators of PCa growth in its later, more metastatic 
stage, and indeed stimulates PCa cell proliferation (Daughady and Rotwein, 1989). Recent 
studies show higher serum levels of IGF-1 in PCa patients when compared to healthy 
controls (Peng et al. 2002) giving IGF-1 the potential to be a new biomarker for the 
development of PCa. The levels of IGF-1 and its BPs were examined in patients after 
prostatectomy and unexpected significantly elevated levels of IGF-1 and its BPs were 
found (Bubley et al. 2002). 
Figure 1.2: DHT can act directly on the prostate epithelia or on the surrounding stroma to 
stimulate the secretion of various growth factors. Both DHT and the growth factors act in a 
paracrine and/or autocrine fashion to allow the tumorigenic epithelial cell to undergo the 
various stages of metastasis, in red. 
t 
.. 
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This indicates that the levels ofiGF-1 in the serum are not contributed by the secretion of 
. IGF-1 from PCa cells but rather from another endocrine source, perhaps the liver. 
Therefore, elevated levels of IGF-l may be a causative PCa agent and major risk factor 
rather than a result of PCa itself. 
EGF is expressed more highly in PCa as opposed to the prostate in its benign state (Harper 
et al. 1993; Giynne-Jones et al. 1996) and has been shown to increase PC-3 cell (a late 
stage PCa cell line derived from a bone metastasis) cell invasion in vitro (Jarrad et al. 
1994). EGF has notable effects on the activation of DNA repair genes in PCa cell lines 
through its receptor (EGFR) transactivation and subsequent Mitogen Activated Protein 
Kinase (MAPK) signalling (Yacoub et al. 2003). Targeting EGFR and inhibiting its 
phosphorylation can achieve significant therapeutic effects against PCa bone metastasis, as 
was shown in a mouse model where this approach induced PCa cell apoptosis (Kim et ai. 
2002). EGF and IGF-1 are important for regulating protease expression involved in cell 
invasion and EGF is known to interact with, and regulate, the IGF axis (Jarrad et al. 1994; 
Russell et al. 1998). 
Both stromal and epithelial prostate cells express bFGF and, as PCa progresses to late-
stage, the levels of bFGF, like EGF in the epithelial cells, increase. The underlying 
mechanisms of bFGF stimulation are thought to mediate angiogenesis enabling metastasis 
to occur (Folkman, 1990). IL-6 also has a high level of expression in PCa cell lines and is 
thought to contribute to PCa morbidity (Siegsrnund et al. 1994). IL-6 can regulate cell 
growth by activating signalling pathways such as Signal Transducer and Activator of 
Transcription (STAT) and MAPK in many cell types (Steiner et aL 2003). 
Growth factors involved in the development of PCa, such as those described above, 
regulate cell signalling processes, cell migration and ECM proteolysis through the 
regulation of the levels and activation of proteins such as the MMPs and integrins, factors 
highly implicated in the successful metastasis ofPCa cells. 
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13 The Matrix Metalloproteases (MMPs) 
The MMPs, which belong to the 'metzincin' superfamily, have been extensively studied 
and play a major role in the process of tissue degradation (Nagase, 1997). They are 
believed to mediate the initial ECM degradation of metastasising tumour cells (Matrisian, 
1990). MMPs are distinguished from other metalloproteases by two unique motifs. The 
PRCG [V/N] PD motif (single letter amino acid code) found in the pro or unprocessed, 
inactive form of MMPs, and the HEXGHX[L/M]G[LIM]XH motif responsible for binding 
zinc in the catalytic domain (Nagase, 1997). Within the M:MP family a relatively new set of 
six closely related MMPs has been characterised, the Membrane-Type MMPs (MT -MMP). 
As its name suggests MT -MMPs are bound to the cell membrane via a transmembrane 
domain (Nagase, 1997). A short cytoplasmic tail, which may be involved in cell signal 
processes, is also common to all six MT -MMPs. Pro-MMPs are directed through the 
endoplasmic reticulum, and most MMPs are then directed to the outside of the cell into the 
ECM, whilst the MT -MMPs remain on the cell surface. (Stemlicht and Bergers, 2000). 
1.3.1 Activation and regulation of the catalytic activity of MMPs 
The activation mechanism of pro-MMPs is explained by a cysteine switch hypothesis 
(Springman et al. 1990; Van Wart and Birkedal-Hansen, 1990). It is proposed that the 
cysteine residue in the unique PRCG[V/N]PD motif in the pro-domain provides a 
sulfhydryl (-SH) group, which interacts with zinc preventing its association with water. 
Once the cysteine residue is removed, either proteolytically or by an SH reactive agent, the 
zinc ion is free to associate with water molecules. The association of water molecules 
provides the catalytic activity (acid-base catalysis) needed for subsequent breakdown of 
MMP substrates (Springman et ai. 1990). The high enzymatic activity portrayed by fully 
active MMPs is believed to arise by the interaction of N-tenninal Y or F residues with a 
conserved D residue, (Benbow et aL 1996) of particular importance for collagenase activity 
(Suzuki et al. 1990; Knauper et al. 1993; Reinemer et al. 1994). The pro-domain of the 
MMPs is made up of three alpha helices followed by the cysteine switch (discussed above). 
MMPs are thought to be activated in a two step, calcium dependent, mechanism where an 
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active intermediate is formed by the removal of the first alpha helix (Nagase et al. 1990; 
Cameron et al. 1995). 
Several proteases are involved in the process of proteolytically activating the pro-MMPs. 
These include the plasminogen activator system, tissue kallikreins (Clements, 1997), other 
:MMPs and MT-Mrvfi>s (Nagase, 1997). For example, MTl-MMP and MT2-MMP have 
been shO"wn to activate proMMP-2 (geiatinase A) (Will et al. 1996; Butler et aL 1997). 
Particular residues in the alpha helices are thought to mediate which proteases can activate 
individual MMPs, for example, proMMP-3 can be activated by leukocyte elastase whereas 
proMMP-1 0 cannot, due to its lack of a V at position 35 (Suzuki et al. 1990). Urokinase 
plasminogen activator (uP A) is perhaps the most characterised and most prominent MMP 
activator. uP A activates the serine protease plasminogen to form active plasmin. Plasmin 
has a very broad substrate specificity and converts zymogens {of which most of the MMPs 
are included) to active proteases. 
Activation studies have also shown that non-proteolytic reagents including mercurial 
compounds such as HgCl and 4-aminophenylmercuric acetate (APMA) (Okada et al. 1988; 
Suzuki et aL 1990), thiol-modifying agents including iodoacetate, oxidised glutathione, and 
denaturants such as urea and SDS (Koklitis et al. 1991) are ail capable of converting 
proMMPs to their active form. Although the mechanism of activation via these synthetic 
compounds is not entirely understood, they are believed to activate M11Ps in a stepwise 
manner, generating several active intermediates, as is the case when proMMP-3 is activated 
by APMA (Okada et al. I 988) ultimately dissociating the cysteine residue from the zinc ion 
in the catalytic motif. 
1.3.2 Regulation of MMP catalytic activity 
To date, major inhibitors of all MMPs are the Tissue Inhibitors of MMPs or TIMPs 
(Matrisian, 1990; Mignatti and Rifkin, 1993). TIMPs are synthesised locally and inhibit 
M:MP activation by binding in a 1:1 stoichiometry extracellularly (Murphy and Docherty, 
1992). The TIMPs comprise two distinct domains, the N-terminai domain, which is 
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responsible for the physical inhibition of metalloprotease activity, and the C-terminal 
domain, thought to confer the TIMPs binding specificity (Stetler-Stevenson et aL 1996). 
Most activated MMPs will interact with TIMPs, however, inactive MMP pro-forms are 
selective with respect to the type of TIMP they will bind to. Activated MMP-2, for 
example, is inhibited by TIMP-1 and TIMP-2. However, inactive proMMP-2 interacts 
selectively with TIMP-2 but not TIMP-1 (Goldberg et ai. 1989, 1992; Stetler-Stevenson et 
aL 1996). Additionally, there is evidence to suggest that the proMMP-2ffiMP-2 complex 
can interact with activated MMP-9, also inhibiting its activity, introducing a new degree of 
regulation in the form of ternary complexes (Murphy et al. 1989; Mollet al. 1990; Stetler-
Stevenson et al. 1996). In most cells, MMP-9 is secreted as a complex with TIMP-1, which 
inhibits its activity. Interestingly, TIMPs have recently been implicated in cell proliferation 
and survival, unrelated to their MMP inhibitory role (Blavier et al. 1999). 
1.3.3 MMP activity in cancer- The Gelatinases and MT-MMPs 
Collectively, the :M1'vf:Ps are able to cleave a broad spectrum of coiiagen substrates and 
other ECM components (see Appendix one A). Of the numerous MMPs illustrated in 
Appendix one, the more predominant MMPs that have been studied to date, in the process 
of metastasis, are MMP-2 and -9 or Gelatinases A and B respectively. Alongside these 
studies, there is emerging evidence that the MT -MMPs are likely candidates for cancer cell 
invasion and migration. MMPs -2 and -9 contain a cysteine rich repeat in their catalytic 
domain required for the binding of collagen (Sternlicht and Bergers, 2000) and both have 
type I, IV, V and X collagenase activity (Kleiner et al. 1999). In addition, MMP-2 can act 
to degrade laminin, another component of the ECM. MMP-2 and -9 also bind the integrins 
aVI33 (Brooks, et aL 1996) and a3f31 (Yu and Stamenkovic, 1999) respectively. The 
importance of integrin association in cancer is outlined below in section 1.4 'The biological 
role of integrins.' 
The gelatinases have also been implicated in the process of embryo implantation. The 
developing embryo must invade into the uterine lining for further development and 
survival. This process can be likened to that of cancerous cells invading into surrounding· 
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tissues. The expression of:MMP-9 in mouse blastocyst outgrowth is thought to be critical 
for this event both in vitro and in vivo (Alexander et al. 1996; Das et al. 1997; Whiteside et 
al. 2001). 
Gelatinase expression has been shown in several cancers including prostate, gastric, 
colorectal and pancreatic. In gastric cancer, for example, the active form of MMP-2 is 
found in malignant tissue but not in normal tissue (Yamagata et al. 1991). In addition to 
this finding, Sato et al. (1994) showed MT1-MMP to be an important activator of MJvtP-2 
and further, MT1-MMP expression correlates with activated MMP-2 in gastric cancer 
tissues (Nomura et al. 1995). Completing the regulation ofMMP-2 mediated cell invasion, 
several studies have concluded that TIMP-2, artificially over-expressed in invasive cell 
types, reduces the cell's metastatic potential due to its inhibition of MMP-2 activity 
(Kawamata et al. 1995). 
In breast cancer, the tumour itself expresses the MMPs. In many cases the expression of 
MMP-9, in particular, is only found at the interface between the tumour and the 
surrounding stroma (Ueda et aL 1996). A pertinent study of breast tissue carcinoma 
observed, by in situ hybridisation, the localisation of MMP-9 gene expression in 
inflammatory and neoplastic cells of malignant tumours, suggesting a direct correlation 
between M.M:P-9 expression and this cell phenotype. Moreover, there is evidence for 
elevated levels of circulating MMP-9 in the plasma of breast cancer patients (Zucker et al. 
1993). Cells surrounding tumours are also found to express MMP-9, as is the case with 
colorectal adenocarcinoma and prostate carcinoma, where the surrounding macrophages 
and neutrophils express this MMP (Pyke et al. 1993; Jeziorska et aL 1994;. Nagle et al. 
1994; Gallegos et aL 1995; Zeng and Guillem, 1995). Recently, MMP-2, MMP-9 and 
MTl-MMP expression has been found in the membrane associated vesicles shed :from 
endothelial cells (Taraboletti et al. 2002), giving endothelial cells a mechanism by which 
they can. degrade the ECM for subsequent migration and formation of new blood vessels 
(angiogenesis). Thus it is clear that the metalloprotease activity of the MMPs is localised to 
the site of, and has major implications for, the process of tissue invasion. 
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1.3.4 MMPs and prostate cancer 
There is growing evidence that the MMPs are implicated in PCa, with respect to their 
expression and function. MTI-MMP expression was characterised in the PCa cell lines 
DU-145 and PC-3 (androgen insensitive cell lines), the TSU-1 cell line~ previously thought 
to be a PCa cell line but l~ter found to have originated from a bladder cancer (van 
Bokhoven et aL 2001), whilst LNCaP (androgen sensitive) showed very low levels of 
expression (Nagakawa et aL 2000). This is an interesting observation, given its role in the 
activation of MMP-2 (discussed above) and existing evidence showing MT1-MMP can 
degrade some collagens, fibronectin, laminin and vitronectin (Ohuchi et al. 1997). MMP-2 
has also been characterised in DU-145 and BPH-1 along with TIMP-2. Further, 
Macrophage Inhibitory Factor (MIF), a cytokine expressed by prostatic glandular epithelial 
cells (Meyer-Seigler, 2000), up regulated MMP-2. MMP-2, but not MMP-9 levels are also 
elevated in response to androgens in the PCa cell line LNCaP (Liao, 2003). 
The gelatinases have also been identified, by in-situ hybridisation, in prostate pre-surgery 
biopsy samples. Specimens from 40 patients were analysed and MMP-2 and -9 were found 
to be at their highest expression at the leading (invasive) edge ofthe tumour irrespective of 
the tumour grade (Kuniyasu et al. 2000). Parallel research investigated the expression of 
MTl-MMP and MMP-2 in 50 radical prostatectomy samples characteristic ofbenign and 
high-grade PIN glands. The basal cells in this case immunostained principally for MTI-
MMP in benign glands, as opposed to secretory cell staining in the case ofhigh grade PIN. 
A similar pattern was observed in the case of MMP-2 (Upadhyay et al. 1999). Another 
investigation used 42 samples from men representing both malignant and benign tumours 
and examined the mRNA expression pattern for MMP-2 and TIMP-2. Still et al. (2000), by 
quantitative analysis, concluded that with an increase in cancer severity, there was an 
increase in MMP-2 expression as compared to the expression of TIMP-2, thereby tipping 
the balance in favour ofMMP-2 proteolytic activity. 
In an in-vitro study (Inoue et al. 2000) PC-3P cells (usually poorly metastatic) were 
transfected with Interleukin-8 (IL-8) resulting in up-regulation of MMP-9 and increased 
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collagenase activity as measured by Matrigel (synthetic ECM). PC-3 cells have been 
shown to degrade mineralised and non-mineralised bone using MMP activity stimulated by 
phorbol esters (Sanchez-Sweatman et al. 1999) - not surprising considering these cells were 
originally derived from a PCa metastasis to the bone. 
MMP-7 (Matrilysin) was found to be over expressed in PCa by P~ouh et al. (1991). More 
recently, MMP-7 has been shown by quantitative RT-PCR to be up regulated by the FGF 
family in LNCaP cells whilst FGF had no effect on MMP-7 expression in the normal 
prostate cell line PrEC (Klein et ai. 1999). Additionally, EGF is also a regulator ofMMP-7 
at least in the LNCaP celHine (Sundareshan et al. 1999). Membrane vesicle associated 
uP A, an activator of the MMPs (discussed above) promotes the invasion of the poorly 
metastatic PCa cell line LNCaP and the metastatic cell line PC-3 (Angelucci et aL 2000). 
The addition of plasminogen, the substrate for uP A and a subsequent activator of the 
MMPs (discussed above), increased the adhesion to, and degradation of, collagen IV and 
Matrigel in both PC-3 and LNCaP cell cultures. Angelucci et al. (2000) also showed the 
effect of the addition of membrane vesicles collected from PC-3 cells, added to LNCaP cell 
cultures. The LNCaP cells displayed a significant amount of increased invasion through 
.Matrigel, indicating that these vesicles may have a role in increased tumorigenesis, 
presumably via MMP activation. 
1.3.5 Synthetic inhibitors of the MMPs 
Many synthetic MMP inhibitors (MMP-I) have been designed to counter the detrimental 
effects of MMP expression in cancer progression and severity. Common inhibitors include 
batimastat and marimastat of which the latter reached phase III trials for treatment of 
colorectal cancer (Sternlicht and Bergers, 2000). Rabbani et al. (2000) evaluated an MMP-
I called A-177430, previously described to block the progression of cancer (Steinman et al. 
1998) in a metastasising rat prostate modeL After injecting PCa cells into the flanks of 6 
Copenhagen rats, tumour size was measured between 8 and 16 days. A-177430 induced a 
1 O-f old decrease in tumour growth. Another compound, Alendronate, was shown to 
decrease the secretion of the gelatinases in human PC-3 ML tumours, preventing bone 
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destruction (Steams and Wang, 1998). This type of bone degrading activity was also 
suppressed using the MMP-I 1,10-phenanthroline (Sanchez-Sweatman et al. 1999). The 
drug tetracycline has also been shown to inhibit MMP secretion in PC-3 cells 
(Duivenvoorden et al. 1999). 
By 1996, over 25 pharmaceutical companies were involved in MMP-I trials (Beckett, 
1996). Common inhibitors of MMP activity, such as those mentioned above have 
undergone phase II and Ill clinical trials (Zucker et al. 2000; Coussens, et al. 2002). 
Problems associated with achieving specific .M:MP inhibition have been encountered, 
although in some cases specificity of inhibiting target MMPs has been achieved (Shalinsky 
et al. 1999). The lack of specificity has led to severe side effects in patients involved in 
clinical trials, rendering these approaches detrimental (Zucker et al. 2000; Coussens et al. 
2002). Often, if the pathological state was being treated in its early stages, it regressed 
somewhat in the first instance but the disease eventually advanced. Treatments were not 
effective once the pathological conditions were well established (Bergers et al. 2000; 
Zucker et al. 2000). A greater understanding of the underlying mechanisms of 1vi:MP action 
is required to further develop more successful drugs for the treatment of diseases such as 
cancer. Further development and refinement of these inhibitors, and a better understanding 
of the role and regulation of key MMPs for each cancer type, continues to hold promise for 
a new series of therapeutics. 
1.4 lntegrins 
Integrins are a large family of ceH membrane spanning glycoproteins capable of binding to 
structural proteins of the ECM including vitronectin, collagen, fibronectin and Iaminin 
(Hynes, 1992; Hans, 1995). Several integrins are expressed in each cell type (Hynes, 
1992). There are over twenty characterised integrins, each consisting of non-covalently 
bonded a and 13 subunits. Each a subunit is able to complex with a number of f3 subunits 
introducing a further degree of diversity (Matsumoto et al. 1995). Currently, 15 a and 9 f3 
subunits have been characterised. The a/f3 arrangement diversifies integrin functionality. 
Furthermore, splice variants of both a and f3 subunits exist (Hynes, 1992). Integrin 
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nomenclature is based on the naming of the a subunit first, followed by the f3 subunit- for 
example, a2f31 appearing in lymphocytes and allbf33, a platelet specific integrin (Hynes, 
1992). 
. · Integrins are major adhesion foci for cell-cell and cell-ECM contacts. They are also 
implicated in intracellular signal transduction via the binding of ligands. Most integrins 
have a defined recognition-binding site. Commonly, this site is recognised by a protein 
containing an RGD peptide sequence. Variations of integrin recognition sequences include 
DGEA, EILDV, GPRP and KQAGDV (Hynes,. 1992). Interestingly, more than one integrin 
can be recognised by the same ligand. An example of this is that each of the integrins 
a2f31, a3f31 and a6f31 binds the ECM protein Iaminin (Wayner et al. 1991). Also, 
individual integrins often have the capability of binding more than one ligand. Integrins 
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can be receivers or generators of signals. In both outcomes, cell adhesion characteristics 
are changed and cell-cell or cell-ECM contacts may be promoted or disrupted. 
1.4.1 The biological role of integrins 
Essentially, integrins can provide a link between cells or between cells and the ECM 
through focal adhesions. It is suggested that focal adhesions form as a result of intracellular 
signaning, possibly by protein kinase C (PKC) and the small G protein rho (Keck et al. 
1989) as well as rae and cdc42 (Horwitz and Parsons, 1999). The binding of a ligand 
stimulates intracellular events such as the tyrosine phosphorylation of paxiHins and focal 
adhesion kinase (F AK). Integrins are believed to undergo conformational changes upon the 
initial ligand binding and activation, subsequently altering their binding affinity. Therefore, 
an integrin may remain in an inactive state until its affinity is altered, conferring upon it the 
ability to bind several ligands (Gumbiner, 1996). This is exemplified by the classical major 
platelet integrin aiibf33 where, upon activation it is converted to a high affinity receptor for 
binding soluble fibrinogen, involved in the blood clot pathway (Gumbiner, 1996). At least 
seven different integrin alpha subunits contain a 200 amino acid "I" domain called the 
metal ion-dependent adhesion site (MIDAS), important for cell adhesion. MIDAS-like 
domains are also found in some beta subunits and are thought to be a type of divalent cation 
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chelator, regulating the type and abundance of particular divalent cations, which in tum, 
regulate integrin binding affinity (Gumbiner, 1996). 
An important role in cancer metastasis is that of modulating cell migration due to i:he cell 
contact characteristics described previously. It is speculated that F AK phosphorylation is 
necessary for anchorage-dependent cellular growth (Presta et al. 1989; Pepper et al. 1990) 
illustrating the concept of integrin binding leading to the correct intracellular environment 
to stimulate cell proliferation. Cells that are attached to the ECM use focal adhesions to 
which integrins are the major receptor. Focal adhesions provide a contact between the 
extracellular environment and the cell cytoskeleton or actin filaments. Ligand binding and 
signalling events regulate these types of adhesions both intracellularly and extracellularly. 
Not all integrins are in focal contact with the cytoskeleton however, for example, a5f31 is in 
focal contact whereas a.3f31 is not (Gumbiner, 1996) perhaps further diversifying the 
function of integrin binding. A study investigating the role of the integrin a.3f31 found that 
the addition of monoclonal antibodies raised to an a.3f31-tetraspanin protein complex and 
thought to biologically activate this integrin, increases the invasive potential of cells 
(Sugiura and Berditchevski, 1999). 
The importance of integrins in the metastatic process is also reflected by studies showing 
that synthetic peptides containing RGD sequences can block experimental metastasis 
(Folkman and Klagsbum, 1987). Integrins that are able to bind ECM proteins include the 
a2, a.3 and a.6 subunits, all of which bind laminin when individually bound to the (31 
subunit. Both a. Vf33 and a.5f35 are able to bind vitronectin (Felding-Habermann and 
Cheresh, 1993; Horton, 1997; Schvartz et al. 1999). This type ofbinding event in the case 
of lung carcinoma H2981 and human melanoma M21 cells, can mediate different post-
ligand binding and hence different cellular responses (Wayner et al. 1991). a5f31 is 
recognised by the RGD peptide sequences in vitronectin (Wayner et al. 1988) and IGF-BPl 
(Jones et al. 1993), which stimulates the migration of Chinese Hamster Ovary (CHO) cells 
in vitro by activating the a.5(31 cell surface integrin signalling (Jones et al. 1993). The 
binding of integrins may be imperative for the attachment of a circulating tumour cell to an 
endothelial cell before extravasation can occur. Therefore, integrin binding may be largely 
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resp~nsible for the re-establishment of a colony of primary tumour cells to a distant organ 
and the formation of a secondary tumour (Fidler and Ellis, 1994; Matsumoto et aL 1995). 
1.4.2 lntegrins and prostate cancer 
As with most highly aggressive cancers, integrin expression and function has been 
characterised in PCa. The diversity of integrin expression was illustrated by Haywood-
Reid et. al. (1997) where the a. subunits I through 6 and Vas well as the f3 subunits i 
through 5, lib and 7 were found in a cohort of PCa cells. Using PC-3 cells in a cell 
adhesion model, antibodies raised to the a.2 and f)l subunits inhibited binding to type I 
collagen. Further investigation concluded the integrin a.2f31 is a major collagen receptor 
that is up regulated by TGF f3 (Kostenuik et al. 1997). The integrin a.Ilbf33 is also 
expressed in PC-3 and DU-145 cells as well as clinical prostate tumour specimens (Trikha 
et al. 1996). When this integrin was inhibited by a monoclonal antibody in DU-145 cells, 
migration through reconstituted basement membranes was abolished. The above examples 
demonstrate the necessity of integrins for both attachment and migration. 
Other integrins involved in PCa development include the a.6 subunit (Iaminin receptor) 
which, in the case of DU-H cells (derived from DU-145 cells), complex with f)l and f34 
subunits whilst in DU-L cells, only complex with the f34 subunit. When both cell lines are 
injected into SCID (immuno-comprimised) mice DU-H cells showed a higher degree of 
invasive potential and were also 3-times more mobile on Iaminin (Rabinovitz et al. 1995). 
A recent study outlining the importance of the integrin a.6[34 showed this integrin to be 
more highly expressed in PC-3 cells when compared to LNCaP cells. Upon the 
transfection ofPC-3 cells with the androgen receptor, the expression of a.6[34 was markedly 
reduced. Further treatment of these cells with the synthetic androgen R 1881 markedly 
decreased the existing levels of a.6[34 and inhibited the attachment of these cells to laminin 
and the invasion through matrigel (Bonaccorsi et al. 2000). 
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Another comparison between LNCaP and PC-3 cell lines demonstrated the expression of 
a.Vj33 in the more metastatic PC-3 cells only. Whilst androgen-insensitive PC-3 cells 
easily adhered to, and migrated on vitronectin, androgen-sensitive LNCaP cells were only 
able to display this quality when transfected with a, Vf33 integrin. (Zheng et al. 1999). The 
same study reported F AK phosphorylation as a response to a Vf33 induction. F AK is up 
regulated in prostate carcinoma (Kornberg, 1998). These studies provide an important link 
between the loss of androgen sensitivity and a more metastatic cellular phenotype in PCa. 
The above examples are just a few pertinent studies conducted in this area of cancer 
research and outline the true functional consequences of particular integrins expressed in 
the prostate and their important contribution to metastasis. 
1.5 A Disintegrin And Metalloprotease domain (ADAMs) proteins 
ECM degradation is mediated in part by the MMPs, whilst integrin binding/dissociation is a 
key regulator of cell adhesion, both of which are important processes in metastasis. The 
ADAMs family of proteins comprise A Disintegrin And Meta1loprotease domain, acting as 
integrin binding ligands and representing metalloprotease-mediated proteolytic activity. 
Thus, the ADAMs have the potential to play major roles in tissue/cell invasion processes. 
This recently characterised group of 34 proteins, described to date (Appendix one B), are 
closely related to the reprolysins (snake venom metalloproteases). A subset of the ADAMs 
family called ADAM-TS, of which there are 12, has also been described (Appendix one B), 
differing from the ADAMs by the presence of a thrombospondin-Hke repeat that likely 
functions in binding to substrates such as those found in the ECM (Cal et aL 200 1). Like 
the reprolysins, the ADAMs are synthE?.sised as inactive zymogens, having a pro-domain 
that is proteolytically processed to yield an active enzyme. This mechanism is thought to 
function in a stepwise activation mechanism with a cysteine switch such as that described 
for the MMPs (Jia et al. 1996) (see evidence for this below). 
The ADAMs family differ from reprolysins by the addition of an EGF like domain, a 
transmembrane domain and a C-terminal cytoplasmic domain (Figure 1.3). Some members 
of the ADAMs also have a sequence homologous to viral fusion peptides (Huovila et al. 
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1996), important in cell attachment. The ADAMs proteolytic domain displays a catalytic 
motif homologous to that found in MMPs (Figure 1.4) and the disintegrin domain contains 
an integrin binding loop region with a consensus integrin-binding motif. 
As the pro-domain of the MMPs inhibits their metalloprotease activity, it has been shown, 
by expression in insect cells, the pro-domain of ADAM-17 also inhibits its meta1loprotease 
activity. Further, the cysteine-rich domain was found to be pertinent in the release of the 
pro-domain, as is the case for MMP activation. The pro-domain of ADAM-17 is thought to 
be imperative for the intracellular secretion of functional ADAM-17 from the Golgi 
apparatus (Milla et al. 1999). 
ADAM-12 is also synthesised as an inactive zymogen and there is evidence that its 
activation mechanism is via a cysteine switch mechanism. Supporting this hypothesis 
includes a study that replaced the cysteine residue in the pro-domain of.ADAM-12 with 
other residues. This yielded an active pro-form of ADAM-12 and the latency was restored 
by the replacement of a cysteine at various positions in the pro-domain (Loechel et al. 
1999). 
There is evidence that the ADAMs contain a functional furin cleavage site, raising the 
possibility of intracellular maturation, as occurs for the MT -MMPs (Schlondorff et aL 
2000). Within the ADAM family, mature proteins appear to be localised in different 
cellular compartments. ADAM-10 and -15, for example, are localised to the intracellular 
compartment as well as the cell surface, whilst ADAM-28 is on the cell surface only 
(Schlondorff et al. 2000). ADAM-12, when over-expressed in skeletal muscle cells, is 
retained in the trans-Golgi network in its unprocessed form (Kadota et al. 2000). Little 
mature ADAM-17 seems to accumulate in the intracellular compartment, although it is 
cleaved by a furin-type pro-protein convertase in the secretory pathway (Schlondorff et al. 
2000). The emerging evidence for quite similar mechanisms of regulating the 
metalloprotease activity between the ADAMs and MMP classes of the metzincin 
superfamily, suggests that these two classes may have similar biological roles in normal 
and pathological cell types. 
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Figure 1.3: A typical ADAM and its domain assembly. ss=signal sequence, 
tm=transmembrane domain (Huovila et al. 1996; Jia et aL 1996). 
The metalloprotease domain of the ADAMs contains an active site predicted to bind zinc in 
the consensus sequence HEXGHNLGXXHD (Alfandari et al. 1997). The three histidine 
residues bind a zinc ion in the same manner as the MMPs. The glydne residues allow a 
turn, reducing conformational strain, the glutamic acid is the catalytic residue and the 
aspartic acid residue is a fingerprint for all reprolysins (Wolfsberg et al. 1995). The 
similarities between the ADAM metalloprotease catalytic site and an MMP catalytic site 
(Figure 1.4) suggest the same functionality, although the structural domain components 
differ between the ADAMs and MMPs (Appendix one B) with the ADAMs having the 
additional, abovementioned disintegrin, EGF-Iike, transmembrane and cytoplasmic tail 
domains. 
Figure 1.4 The ADAMs and MMPs have strikingly similar zinc-binding catalytic motifs. 
ADAMs catalytic motif H E X G H N L G X X H D 
MMPs catalytic motif H E X G H Ll G L/ X H 
M M 
ADAMs with the metalloprotease active site sequence HEXGHXXGXXHD (across all 
known orthologues) are: ADAMs 1, 8-10, 12, 13, 15, 16, 17, 19, 20, 21, 24, 25, 26, 28, 30, 
33, and 34 (http://www.people.virginia.edu/~jw7g/Table_of_the_ADAMs.html, and 
Appendix one C). Some ADAMs are also found as soluble active metalloprotease variants, 
not unlike the MMPs. Among these, ADAM-9, -12, -17, -28 and some ofthe ADAM-TS 
family are included (outlined below). It is not yet clear as to the extracellular role these 
particular forms of the ADAMs may have. 
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1.5.1 The biological roles of the ADAMs 
The metalloprotease domain of the highly characterised reprolysins has been shown to 
contribute to the haemorrhagic response to basal lamina degradation (Kini et ai. 1992; 
Alfandari et al. 1997). Classically, the ADAMs are characterised as ceU surface sheddases, 
able to cleave and activate and/or solubilise cell surface growth factors and cytokines. The 
reader is referred to Appendix one (C) for a more comprehensive list of ADAMs and their 
characterised substrates. Of these, th~ more characterised cytokine and one of the first 
whose solubilisation was identified to be by an ADAM, is tumour necrosis factor a (TNF 
a). Pro-TNF a is a 26 kDa membrane spanning protein which has an intracellular N -
terminus. Human ADAM-10 demonstrates, along with ADAM-17 (TACE .. TNF a 
converting enzyme) the proteolytic cleavage ofproTNF a to yield soluble TNF a (Blobel, 
1997; Rosendahl et al. 1997). It is suggested that an inhibitor of TACE expression or 
metalloprotease activity would prevent its cleavage, reducing the levels of soluble 1NF a 
(Cerretti, 1999). ADAM-17 also has Growth Hormone Binding Protein (GHBP) sheddase 
activity, regulating the release ofGHBP :from the cell surface (Zhang et aL 2000). ADAM-
17, as well as ADAM-I 0, is responsible for the cleavage of the Cellular Prion Protein 
(Vincent et al. 2001) and the Amyloid Precursor Protein ((3-APP), a protein that is 
upregulated in the brain of Alzheimer patients (Buxbaum et al. 1998; Lammich et al. 1999). 
The ADAM-17 catalytic domain has been crystallised and the deduced structure yields a 
remarkable resemblance to adamalysin (a reprolysin) and to the predicted structure ofthe 
ADAM-10 catalytic domain (Maskos et al. 1998). Hence, it is not surprising that these two 
proteins have substrate specificity overlap. 
ADAM-9 (MDC9) demonstrates cleavage of peptide sequences homologous to TNF a, !3-
APP, P75 TNFR, and KL-1 as well as the MMP substrate peptide (P-Cha-G-) (Roghani et 
al. 1999). The same study also demonstrated that an array ofMMP inhibitors successfully 
inhibited ADAM-9 proteolytic activity. Further, ADAM-9 is thought to be involved in 
TPA-induced shedding of Heparin Binding EGF like growth factor (HB-EGF) via its 
metalloprotease domain and activation of its C-terminal located PKC response sites. This 
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is supported by the lack of HB-EGF cleavage upon the mutation of the metaHoprotease 
catalytic motif (Izumi et al. 1998). Additionally, ADAM-9 has recently been shown to be 
proteolytically active against fibronectin and gelatin (Schwettmann and Tschesche, 2001) 
and it is likely that the soluble form of this metalloprotease is active against the same 
substrate, likening this ADAM to a secreted MMP. 
MADM (Bovine ADAM-10) isolated from bovine kidney, has been shown to have human 
placental type IV collagenase activity (Millichip et al. 1998). ADAM-10 thus represents an 
ADAM having the same catalytic activity as MMP-2, -3, -9, -7, -10 and -11 with a similar 
membrane-spanning domain as the MT -MMPs (Nagase, 1997). ADAM-I 0 also cleaves the 
protein Ll, which has been proposed to promote cell migration via signaHing events with 
the a V~3 integrin (Mechtersheimer et al. 2001 ). 
The ADAM-TS subfamilies, which are ADAMs containing thrombospondin-Iike motifs, 
have also been characterised as active meta11oproteases. ADAM-TSI cleaves aggrecan, a 
cartilage proteoglycan (Kuno et al. 2000). This study found the C-terminal of ADAM-TSI 
to be necessary for aggrecan degradation presumably through an attachment/binding role. 
Interestingly, ADAM-TS3 and 4, also called aggrecanases, have presumed proteolytic 
activity against this substrate (Tang, 2001). ADAM-TS2 has now been identified as a pro-
collagen N proteinase whose activity is important in the cleavage of pro-collagen for the 
formation of collagen for the basement membrane and the ECM (Blelloch et al. 1999). 
1.5.2 ADAM metalloprotease activities and their regulation by TIMPs 
Recently, both ADAMs -10 and -17 have been shown to be inhibited by TIMPs. MMP 
tissue inhibitor TIMP-3 but not TIMP-1, -2 and -4 has been shown to inhibit ADAM-17 
(Amour et al. 1998}. The same group showed that TIMP-1 and TIMP-3 but not TIMP-2 
and -4 inhibited ADAM-I 0 metaiioprotease activity in vitro (Amour et al. 2000). ADAM 
12 (meltrin a.) also demonstrates metalloprotease activity as described by Loechel et al. 
(1998} using a.2 macroglobulin as a substrate. TIMP-1, -2, and -3 do not inhibit the 
metalloprotease activity of ADAM-12 (Loechel et al. 1999). ADAM-12 also exists in a 
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soluble form called ADAM-I2s. This form of ADAM-12 lacks a transmembrane domain 
and is secreted from the cell representing apotential soluble metalloprotease, not unlike the 
MN.IPs (Gilpin et al. 1998). TIMP-3 is able to inhibit the protease activity of ADAM-12s; 
no other TIMPs were examined in this study (Loechel et al. 2000). It could be inferred that 
the above TIMPs inhibit ADAM-10, -12s and -17 via the same mechanism as they inhibit 
the MMPs. Recently, the TIMPs have been shown not to inhibit the activity of ADAM-8 
and -9 (Amour et al. 2002). 
1.5.3 ADAMS and integrin binding/cell adhesion 
Because not all ADAMS are proteolytically active (Huovila et al. 1996; Jia et al. 1996; 
Blobel, 1997), it is likely that there are significant differences between the physiological 
roles of individual ADAMs. The snake venom reproiysins bind integrin a2133 and inhibit 
platelet aggregation (Kini et al. 1992; Alfandari et al. 1997). The integrin-binding domain 
of the reprolysins includes a hairpin loop with the iritegrin ligand sequence RGD (Blobel, 
1997). Although ali ADAMs contain a predicted integrin binding site, ADAM-2, -5, -7, -9, 
-11 and -15 are the only ADAMs which possess a negatively charged residue in the third 
position of the ligand binding sequence motif (Huovila et al. 1996). This characteristic has 
been conserved across species and suggests differential integrin binding potential within the 
ADAMs family. 
Perhaps the most studied ADAMs are mouse ADAM-I and -2 (fertilin a and 13 
respectively). Both ADAMs have integrin-binding activities that have major implications 
for the fundamental physiological event - the process of sperm-egg fusion in the mouse 
(Cho et al. 1996). A monoclonal antibody raised against fertilin 13 has been found to block 
sperm-egg fusion in the mouse. Also blocking this process were peptides designed against 
the predicted integrin-binding site ofFertilin (fertilin a 113 heterodirner) (Inoue et al. 1998). 
The integrin found on the egg, a6131, has been identified as a receptor for sperm, 
suggesting this integrin to in fact be the Fertilin receptor. Chen et al. (1999) further 
investigated this interaction and confirmed that the ADAM-2 disintegrin loop binds this 
integrin. In humans, ADAM-I appears to be a pseudogene. However, human ADAM-20 
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and -2I show high similarity to ADAM-I and -2 and are thought to be testis specific, 
suggesting that these ADAMs are the human homologues of mouse ADAM-I and -2 
(Hooft, 1998). 
As some ADAMs, for example, ADAM-11, only contain an active disintegrin domain and 
not an active protease domain (Huovila et aL 1996) it is possible that such ADAMs may be 
solely involved in ceii attachment. ADAMs possessing metalloprotease and integrin 
domains, ADAM-9, -12, -15 and -17, may contribute to either, or both, mechanisms. 
Additionally, ADAM-9, -11 and -15 have the conserved negatively charged peptide in the 
predicted integrin-binding domain, potentially enhancing integrin-binding affinity. Eto et 
al. (2000) have shown ROD-independent binding of human and mouse ADAM-I2 and 
mouse ADAM-15 to the integrin a9f31. Although mouse ADAM-15 does not contain an 
RGD sequence, it still possesses the negatively charged putative integrin-binding residue at 
the third position in the motif 
The specific role in attachment that ADAM-12 portrays has become increasingly evident. 
Iba et al. (2000) described the role of ADAM-12 in binding to cell surface syndecans and 
demonstrated that syndecans and the integrin f3I, respectively, support cell adhesion and 
cell spreading during the binding event. The tumour cells in this study, however, did not 
spread unless the f31 integrins were activated, via an activating monoclonal antibody. 
Another group reported similar findings with respect to the attachment of myoblast and 
fibroblast cells to the recombinant ADAM-12 cysteine-rich/disintegrin domain in a 
disulphide-bond dependent manner (Zolkiewska, 1999). Iba et al. (1999) had previously 
outlined that the cysteine-rich domain can exclusively mediate the adhesion of a number of 
cells in vitro in cell attachment assays. The same study observed that the disintegrin-like 
domain did not support adhesion of the panel of carcinoma cells tested. 
Zhang et al. (1998) found that a recombinant ADAM-15 disintegrin domain has a specific 
interaction with the integrin aVf33. Nath et al. (1999) found ADAM-15 to have specific 
binding to this integrin also, whilst Cal et al., (2000) showed ADAM-23 to have ROD-
independent binding to the same integrin. This group also demonstrated ADAM-15 
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specific binding to integrin a.5131. ADAM-9, which lacks an RGD, but has a negatively 
charged residue at the third position of the integrin-binding peptide motif, binds the 
integrins a.6131 and a.Vj35, with a similar cation dependence as needed for integrin to ECM 
interaction (Zhou et al. 2001). Within the ADAM-TS subfamily, ADAM-TSl has been 
shown to induce a tight anchorage interaction with ECM proteins, possibly through the 
same type of integrin-binding mechanisms (Kouji and Kouji, 1998). 
1.5.4 ADAMs and Cancer- &pression and Function 
ADAMs -9, -10, -II and -15 mRNA transcripts are expressed in the haematologicai 
malignant cell lines HL60, Jurkat, K562, U266B1, U937 and Cippullo (Wu et aL 1997), 
and ADAMs -10 and -17, were found to be expressed in the choriocarcinoma cell lines 
JEG-3, JAR and BeWo (Whiteside et aL unpublished data from our laboratory) as well as 
the ADAM-12 splice variants ADAM-12S (short, soluble form) and ADAM-12L (long, 
membrane-bound form) in the human tumour cell lines HU-1 (lung adenocarcinoma), 
undifferentiated RD (rhabdosarcoma) and A204 rhabdomyosarcoma (Gilpin et aL 1998). 
Furthermore, ADAM-12L appears to be up regulated in breast, colon and gastric carcinoma 
when compared to normal controls, both by PCR and IHC. Further, it was found to support 
the attachment of a.Vj33-expressing A375 melanoma cells (Iba et at 1999) in in vitro, cell 
attachment assays. Interestingly, the recombinant cysteine-rich domain but not the 
disintegrin domain was found to support cell adhesion of various tumour cells including 
breast carcinoma. This group further suggests attachment to be via cell surface heparin 
sulphate proteoglycans instead ofintegrins. ADAM-10 has been shown to cleave coHagen 
XVII (Labrousse et al. 2002), disrupting hemidesmosome complexes, which have been 
shown to be intact in the normal prostate gland but disrupted in PCa (Nagle et al. 1995). 
Also, a disintegrin-metalloprotease like protein, which was later identified as ADAM-11, 
was shown to be rearranged somatically in two primary breast cancers and has thus been 
labelled a potential tumour suppressor gene (Emi et al. 1992). 
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Our laboratory has further characterised the ADAMs in PCa showing the expression of 
ADAM-9, -10, -11, -15 and -17 mRNA in the cell lines LNCaP, ALVA-41, DU-145 and 
PC-3 (McCulloch et aL 2000). The prostatic localisation of ADAM-9 and -10 was also 
determined previously by IHC in primary tumour biopsy sections from patients with PCa 
(Akl, unpublished data and McCulloch et al. in press 2003). · Both ADAM-9 and -10 
proteins were expressed in the glandular epithelial ceUs of the prostate in all samples tested. 
Occasionally, expression was also seen in scattered stromal fibroblasts. A less intense 
signal was observed for ADAM-9 in higher-grade cancer glands compared to benign glands 
in the same section. Such a reduction in the levels of ADAM-9 as PCa progresses may 
indicate that its role is unrelated to metalloprotease degradation of the ECM, which one 
would predict to be greater in metastatic cells, but is more closely aligned with modulation 
of cell-cell or cell-ECM contacts via its disintegrin domain. A role for ADAM-9 in cell 
adhesion would be consistent with a decrease in expression in cancer cells, in vivo, as those 
cells gain a capacity to break free and dissociate from the primary tumour mass. 
ADAM-10, on the other hand, while present in the same cell types as ADAM-9, appeared 
to be unchanged or to increase slightly in cancer glands. This would be consistent with a 
role for ADAM-10 in ECM degradation and facilitation of subsequent invasion of 
metastatic cells. However, ADAM-1 0 showed marked nuclear localisation in all cancer 
glands when compared to benign glands. What role ADAM-I 0 has in the nucleus is 
unclear and requires further investigation. The co-expression but somewhat contrasting 
levels of ADAM-9 and -10 in the transition from benign glands to cancer glands may 
reflect distinct but complementary roles in regulation of tumour metastasis. 
1.5.5 The hormone/growth factor regulation of the ADAMs 
As mentioned previously, ADAM-9, -10 and -17 mRNA expression in LNCaP cells was 
found to be regulated by DHT in our laboratory (McCulloch et al. 2000). Contrary to 
ADAM-9 and -10, ADAM-17 mRNA levels were down regulated with the addition of 
DHT. Whether the declining levels of ADAM-17 have an effect on the levels of soluble 
TNF a remains to be investigated. PC-3 cells produce TNF a (McCulloch et. aL 2000) but 
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display cytotoxic effects when treated exogenously with this cytokine (Fong et al. 1992). A 
recent finding however, concluded PC-3 ceil growth, along with another androgen-
independent PCa ceii line DU-145, was not affected by treatment with TNF a (Sumitomo 
et al. 1999). In contrast, a study by Chung et al. (1999) concluded there were no detectable 
levels of TNF a in PC-3 cells or indeed any of the PCa ceil lines screened, including 
LNCaP-ATCC, LNCaP-GW and DU-145, a cohort of androgen-sensitive and androgen-
insensitive cell lines. Soluble TNF a levels have also been examined in the systemic 
circulation of patients suffering from various grades of PCa before surgery or androgen 
ablation. Adler et ai. (1999) found that TNF a levels increased with age but not with PCa 
severity or metastatic occurrence. 
The presence or absence of TNF a in PCa cell lines and their sensitivity to this important 
cytokine is clearly different in the hands of individual research groups. A defmitive role for 
TNF a in PCa however, is not clear. Its association with the ADAMs and evidence of at 
]east one link to regulation may suggest that fluctuations of TNF a, via the regulation of 
ADAM-17, can have implications in PCa progression and requires further investigation. 
Given the preliminary observation that levels of the ADAMs are regulated by DHT in PCa, 
their regulation may also be controlled by other growth factors such as IGF-1, the phorbol 
ester PMA, the androgen DHT, bFGF and EGF, which affect growth rate and cell motility, 
although there is limited data available in this respect. 
The androgen DHT is implicated in the proliferation of androgen-dependent carcinomas 
including the prostate. Tumour cells in the early stages of prostate cancer are androgen 
dependent. Tumours that become more aggressive and metastatic, are often androgen 
insensitive. Therefore, factors affecting metastasis, potentially ADAMs, may well be 
regulated by androgens in the early stages of disease development and regulated by other 
growth factors at later stages. As mentioned above, our laboratory has shown that some 
ADAM mRNA levels are regulated by DHT in the LNCaP PCa ceH line (McCulloch et al. 
2000). Alongside these observations, the expression of ADAM-7 mRNA has been shown 
to be responsive to DHT in castration studies in the mouse (Cornwall and Hsia, 1997). 
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IGF-1, a known growth promoter of the PCa cell lines LNCaP, PC-3 and DU-145 
(Iwamura et al. 1993) elevates the expression ofMMP-2 (Long et al. 1998). The prostate 
has a fully functional IGF-1 axis responsible for growth of normal and tumorigenic cell 
types (Cohen et al. 1994). Also, IGF-1 mediates cell motility regulation (Matsumoto et aL 
1995; Leventhal et al. 1997). The MtviPs have IGF-BP protease activity, processing these 
binding proteins, releasing IGF-1 and presumably increasing the bioavailability of IGF-1 
(Fowlkes et al. 1994, 1995, 1997). Kubler et al. (1998) identified an IGF-BP protease in 
human pregnancy serum with disintegrin/metalloprotease properties providing preliminary 
evidence that ADAMs may be important regulators of IGF-1 mediated activities_ More 
recently ADAM-12 has been shown to associate with IGF-BP3, partially purified ADAM-
12s was able to cleave IGF-BP3, whilst only ADAM12s and IGF-BP3 were co-precipitated 
when IGF-BP3 and -BPS was incubated with ADAM12s conditioned media (from ADAM-
12s transfected COS1 cells), suggesting no interaction with IGF-BP5 (Loechel et al. 2000) . 
. Recently, ADAM-9 was shown to cleave IGF-BP5 in a human osteoblast cell line (Mohan 
et al. 2002), potentially elevating levels of bioactive IGF-1, which may be important in 
stimulating bone deposition and resorption, processes thought to be important in PCa bone 
metastasis. 
The phorbol ester, PMA, has also demonstrated the ability to regulate MMP expression 
(Mackay et al. 1992). Additionally, PMA stimulates the expression of the integrin subunit 
[33 (Zhu, 1996). Phorbol esters are also known to activate signalling pathways through 
enzymes of the Protein Kinase C (PKC) family. Blobei (1997) suggests that at least some 
ADAMs have PKC response sites in the cytoplasmic domain. Potentially, they are 
involved in intracellular signalling. Therefore, PMA is a good candidate for regulating 
both the expression and activity of the ADAMs and has already been shown to decrease 
cell surface staining for ADAM-17, shown by immunofluorescence microscopy and cen 
surface biotinylation (Doedens and Black, 2000)~ 
Further hormonal/growth factor responsive studies are needed to better our understanding 
of how the ADAMs are regulated and the ~otential impact on their role/s in cancer. 
Because of the potentially 'dual functionality' of these proteins, the hormonal and growth 
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factor regulation of ADAMs may have major mechanistic consequences, important for 
tumorigenic cell types to metastasise. 
1.6 Conclusion 
Prostate cancer is a step-wise, progressive hormone dependent cancer, which often develop 
a highly aggressive, metastatic phenotype. The underlying molecular mechanisms of 
metastasis are unclear. However, the MM.Ps have key ECM proteolysis properties that can 
effectively assist in cell invasion through the BM and ECM. Cell migration is mediated, in 
part, by integrin activation and cell signalling events allowing tumorigenic cells to move 
through the degraded ECM. The ADAMs proteases share a functional catalytic motif 
homologous to the :MMPs and also have integrin binding activities. Hence the ADAMs are 
potential key contributors toward the successful and effective metastasis of cancer cells. 
Hormones and growth factors involved in PCa cell proliferation and survival regulate levels 
of proteins such as the MMPs. Therefore, given the similarities between the properties of 
the ADAMs and MMPs, and their key interactions with integrins, it is likely the ADAMs 
will be regulated in the same manner in PCa. Limited data is available to date, on the 
expression and regulation of ADAMs in any cancer type. There is however, a wide range 
of preliminary evidence and functional characteristics implicated, to propose that ADAMs 
have a potential hormonal/growth factor-regulated role in cancer metastasis. 
1. 7 Project Aims 
Using PCa cell lines characteristic of nonnal prostate, from low-grade, androgen sensitive 
to high-grade, androgen-insensitive PCa, and prostate tissue biopsies :from both primary 
tumours and metastatic, secondary site tumours, the overall aims ofthis study are: 
1. To characterise potential changes in the expression of both ADAM-9 and -10 
proteins in normal, low through high-grade and metastatic examples ofPCa. 
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2. To establish a PCa cell line model that over-expresses ADAM-10 by way of 
transfection with a mammalian expression construct, in anticipation of further use in 
functional in vitro assays such as cell attachment, migration and proliferation, and 
3. To examine the regulation of the levels of both AD AM-9 and -10 by the prostate 
cancer growth promoters DHT, IGF-1 and EGF in an androgen/growth factor 
responsive PCa cell model. 
Chapters 3 and 4 will examine potential differences in the levels of expression of both 
ADAM-9 and -10 proteins in a progressively metastatic PCa cell line model, the C4 series 
of cell lines. Protein expression of both ADAMs will also be examined in cellular 
compartments (cytoplasm and nucleus) between two contrasting ceH models, RWPE-1, a 
non-tumorigenic prostate cell model, and PC-3, a late-stage metastatic PCa cell model. 
Additionally, PCa bone metastases will be examined for ADAM-9 and -10 protein 
expression and localisation. These studies will build on preliminary expression data 
indicating that ADAM-9 and -10 mRNA are present in PCa cell lines and ADAM-9 and -10 
proteins are present in prostate primary tumour biopsies. 
To find a functional consequence of the expression of ADAM-10 in the prostate, Chapter 5 
will focus on the construction of a full-length human ADAM-10 construct and its 
subsequent transfection in PC-3 and RWPE-1 cells. ADAM-10 was chosen at the outset of 
this study based on the previous observations in our laboratory, discussed above, that the 
expression of this ADAM appeared elevated in high-grade PCa when compared to glands 
diagnosed with a lower Gleason grade in primary prostate tumour biopsies. Carrying out 
functional cell -based assays with cell lines over-expressing AD AM-1 0 protein is an integral 
part of elucidating the function of ADAMs such as ADAM-10 in PCa, although due to 
technical difficulties and time-constraints this aspect of the study needs further 
development. 
Lastly, Chapter 6 will extensively characterise the regulation of both ADAM-9 and -10 
mRNA and protein levels by the androgen DHT and the growth factors IGF-1 and EGF in 
the androgen/growth factor responsive cell model LNCaP. This chapter builds on our 
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laboratory's previous data, showing both ADAM-9 and -10 rnRNA levels are elevated in 
response to DHT stimulation (McCulloch et aL 2000). Additional preliminary data also 
shows that ADAM-9 protein expression is lower in high-grade PCa when compared to low-
grade and benign prostate glands. ADAM-1 0 expression, on the other hand, appears 
increased in late-stage PCa glands, and its expression is differentially localised to the ceil 
nucleus when compared to low-grade cancer glands, where it appears to be localised to the 
membrane/cytoplasm. A change in levels of ADAM protein as PCa progresses :from 
androgen-dependent through androgen-independent characteristics suggests hormones and 
growth factors, also involved in cancer progression, regulate these protein levels. 
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CHAPTER TWO 
2.0 MATERIALS AND METHODS 
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Chemicals and Reagents: All chemicals and reagents used throughout this study were of 
analytical grade and purchased from common companies such as: APS Finechem - Asia 
Pacific Speciality Chemicals Limited, Seven Hills, NSW, Australia; MERK Pty. Ltd. 
Kilsyth, Vic. Australia; Sigma RBI, Castle Hill, NSW, Australia, unless otherwise 
specified. 
1.1 Cell Culture 
1.1.1 Resuscitation of cells from liquid nitrogen (N z) storage 
Each ampoule, containing the cell line of interest, was retrieved from a liquid N2 canister, 
thawed in a 37 °C water bath, and transferred to 50 ml tissue culture medium (specific for 
the cell line undergoing resuscitation) in a Falcon tube (Becton Dickinson, Franklin Lakes, 
NJ, USA). The Falcon tube containing the medium and cells was inverted gently three 
times and centrifuged at 1 000 X G for 3 min. The medium was aspirated leaving the cell 
pellet, which was re-suspended in 5 ml medium and transferred to a standard T25 tissue 
culture flask (Nunc Nalge International, Naperville, IL, USA). Cells were allowed to attach 
to the flask and grow at 37 °C in 5 % C02 in an IR sensor incubator (Sanyo scientific, 
Bensenville, IL, USA). 
1.1.1 Routine passage of cell lines 
Once each cell line reached approximately 70 - 90 % confluency, as determined by 
visualisation under an inverted light microscope (Olympus Australia Pty. Ltd. Mount 
Waverely, Vic, Australia), the cells were washed with warm (37 °C) phosphate buffered 
saline (PBS) (tissue culture grade, Oxoid, Brisbane, Australia). The cells were treated with 
1 X trypsin/versine (Invitrogen Australia Pty. Ltd. Mount Wavereiy, Vic, Australia) (0.2 
ml for T25, 0.5 - 1 ml for T75 and I - 2 ml for Tl75 or T225 cm2 flasks) and were 
incubated for up to 5 min (depending on the cell type) at 37 °C. The culture vessels were 
gently tapped to dislodge any remaining cells from the bottom of the flask. The appropriate 
medium, which contained serum, was used to wash and re-suspend the cells for transfer 
into new culture vessels containing the appropriate amount of medium. 
36 
2.1.3 Cyropreservation of cell lines cultured 
Each cell line was harvested with trypsin/versine as described above for routine passage of 
cells. Harvested cells were pelleted by centrifugation at 1000 X G in a 15 ml Falcon tube. 
Cell pellets were resuspended in media containing 10 % Dimethyl Sulfoxide (DMSO) and 
transferred to 1.5 ml cryotubes (Nunc) in 1.0 ml aliquots. The cryovessels were put in an 
ice-cold isopropanol bath at -80 °C for at least 6 h. Each cryotube was then transferred to a 
liquidN2canister and logged in a tissue culture logbook for long-term storage. 
2.1.4 Cell counting 
The cell type of interest was cultured to -70 % confluency in either a T25 or T7 5 tissue 
culture vessel as described above, trypsin!versine treated and resuspended in either 5 ml 
(for T25) or 10 rnl (for T75) tissue culture medium. 0.2 rnl of cell suspension was 
combined with 0.2 mi 0.4% trypan blue and transferred to a haemocytometer. Viable cells 
(not stained blue) were counted in 2 X I mm2 counting chambers under an inverted light 
microscope (Olympus) under the lOX objective, ensuring that the number of cells in each 
counting square was at least 100 (for statistical viability) and that the total ceil count 
between the counting squares differed by less than 10 %. Cell number/ml was calculated 
and the appropriate dilution was made for downstream experiments requiring a_ pre-
determined cell density. 
2.2 Reverse Transcription- Polymerase Chain Reaction {RT-PCR) 
2.2.1 General RNA extraction method 
Total RNA w~ extracted from the 90% confluent, groViTt:h factor treated LNCaP cells using 
either the RNAgents Total RNA Isolation System (Promega, Annandale, NSW, Australia), 
Trizol reagent (Life Technologies, Mulgrave, Vic, Australia) or QIAGEN (Fairfield, Vic, 
Australia) column purification kit, according to the specific manufacturer's protocoL RNA 
concentrations and purity were determined using a DU 640 Beckman (La Jolla, CA) 
spectrophotometer wavelength scanning analysis from 220 nm - 320 nm or a RNA/DNA 
calculator (Arnersharn Biosciences Pty Ltd. Castle Hill, NSW, Australia). The relative 
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purity of each sample was determined by A260/ A280 ratios and was accepted as 
satisfactory in the range I .8 -:- 2.0. 
2.2.2 Reverse Transcription (RT) 
Reverse transcription (RT) was carried out using 5 f.tg of total RNA, 5 f.tg of oligodT primer 
and lU superscript II RNAse R reverse transcriptase (Invitrogen). RT was carried out at 
43 °C for 90 min. All eDNA was screened by PCR using 13-actin primers, which span a 13-
actin intron 5'-CGTGGGCCGCCCTAGGCACCA-3' (forward) and 5'-
GGGGGGACTTGGGATTCCGGTT-3' (reverse) yielding a 234 bp eDNA PCR product 
and a 330 bp gDNA PCR product, as an indicator of possible genomic DNA (gDNA) 
contamination (Telford et al., 1990). PCR was performed in a 50~~ volume containing 5 
f.tl 10 x PCR buffer (with a final reaction concentration of; 1.5 mM MgCiz, 50.0 mM KCl, 
10.0 mM Tris-HCL, pH 8.0) (Roche Diagnostics, Brisbane, QLD, Australia), 0.3 mM 
dNTP mix, 1U DNA Taq polymerase (Roche) and 1 f.tl eDNA made up to 50 ~I with sterile 
distilled water. 
2.2.3 Polymerase Chain Reaction (PCR) 
PCR was carried out on a DNA Thermal Cycler (Perkin Elmer, Brisbane, QLD, Australia) 
using the following protocol; 95 °C 5 min (initial denaturation), followed by 35 cycles at: 
95 °C 30 sec (denaturation), (annealing temperature specific for each primer used) 30 sec, 
72 °C (1 0 sec/ 100 bp PCR product) (extension) with the final cycle at 72 °C for 10 min 
(final extension). Primers were purchased from Proligo (Southern Cross University, 
Lismore, NSW, Australia). All PCR products ~nderwent electrophoresis at 100 volts for 45 
min on a 2% agarose/Tris-acetate-EDTA (TAE) gel containing 1 f.tg/ml ethidium bromide 
(EtBr). DNA molecular weight marker IX or X (Roche) was used as a guide for PCR 
product size. DNA bands were visualised under a UV lamp, photographed and excised 
from the gel with a sterile scalpel blade. Excised samples were purified using either 
Wizard PCR Preps DNA Purification System (QIAGE1\f) or Clontech Gel Purification Kit 
(Invitrogen) using the manufacturer's protocol. 
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2.2.4 Sequencing using Big Dyetm 
Automated DNA sequencing using Big Dyetm versions I through III technology was carried 
out at the Australian Genome Research Facility, (University of Queensland, Brisbane, 
Australia). 
2.3 Western Blot Analysis 
2.3.1 Protein extraction 
Whole cell lysate 
Cell pellets of the PCa cell lines from a ~70 to 90% confluent T75 tissue culture flask were 
resuspended in 500 ul Triton X-100 lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, I% 
Triton X-100, 0.1 mM PMSF, 10 mM EDTA pH 8.0, 1 tablet Roche complete protease 
inhibitor cocktail/25 ml}. The cell lysate was frozen on dry ice, thawed in ice-cold water 
then passed through a 26-gauge needle twice to shear high molecular weight gDNA. The 
cell lysate was then centrifuged at I 2000 X G for 30 min at 4 °C. The resultant supernatant 
was collected and whole cell protein was quantitated in triplicate using the BCA protein 
assay reagent (Pierce, Rockford, IL) as per the manufacturer's "microwell' protocol using 
serial dilutions of2 mg/ml Bovine Serum Albumin (BSA) as a reference standard. Yields 
between 1 and 6 11-g/111 were obtained as determined by absorbance at 545 nm on a multi-
well plate reader (Beckman). 
Nuclear I Cytoplasmic fractions 
Cellular compartmentalisation was achieved by using the NePer nuclear/cytoplasmic 
:fractionation kit (Pierce) as per manufacturer's recommendations. Briefly, cell pellets of 
LNCaP, R\VPE-1 or PC-3 cells from a ~70 to 90% confluent T25 or T75 tissue culture 
flask were resuspended in a 5 mllmg volume of buffer CERL Buffer CERII was added, 
followed by a centrifugation step, which pelleted the intact cell nuclei. By removing the 
supernatant the cytoplasmic fraction was isolated. Buffer NERI was added to the nuclear-
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membrane pellet, lysing the nuclear membrane. An additional centrifugation step pelleted 
unwanted nucleic acid, lipids, carbohydrates and cell debris. The supernatant from this step 
contained protein isolated from the cell nucleus. Each buffer was adapted to contain a final 
concentration ofO.l rnM PMSF, 10 rnM EDTA pH 8.0 and IX complete protease inhibitor 
cocktail (Roche) was added to inhibit protease activity, as recommended by the 
manufacturer. 
2.3.2 Sodium Dodecyl Sulphate- Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
10 % PAGE (29:1) Acrylamide: Bis-acrylamide (Biorad, Hercules, CA} gels (0.75 mm 
thick x 83 mm x 73 mm) were used for ali Western blot analyses, as the proteins detected 
were acceptably resolvable with this percentage of acrylamide. For the resolving gel, a 
final concentration of 0.01 % SDS, 1.5 M Tris-HCl, 10 % acrylamide, was polymerised 
with 50 ul 10. % ammonium persulfate (APS, Biorad) and 10 111 N,N,N,N-tetra-methyl-
ethylonediamine (TEMED, Biorad} at room temperature. The stacking gel contained a 
final concentration ofO.Ol % SDS, 0.5 M Tris-HCI, 3.8% acrylamide, polymerised with 30 
!ll I 0 % APS and 5 !ll TEMED at room temperature. 
Protein was loaded into each well of the stacking gel alongside a pre-stained protein 
molecular weight marker (Biorad) and electrophoresed at ~ 15 rnA per gel until the dye 
front, and hence the protein, had run into the resolving gel, at which point the current was 
boosted to ~ 20 rnA per gel. Each gel was run for 1 - 1.5 h or until the dye front was as 
close as possible to the bottom edge of the resolving geL 
2.3.3 Standard protein transfer 
After electrophoresis, each gel was equilibrated in 1 X Carbonate transfer buffer (10 mM 
NaHC03, 3 mM Na2C03, 20% Methanol, pH 9.9), pre-cooled at- 20 °C, for 1 min. The 
'blot' was built on the negative side of the Western blot transfer cassette in the following 
order: sponge, 3 X 3 sheets of blotting paper, PAGE gel, 0.2 !liD pore size nitrocellulose 
membrane (Protran, Schleicer & Schnell, Dassel, Germany) 3 X 3 sheets of blotting paper, 
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sponge. Building of the blot took place submerged in blot buffer so as to reduce possible 
air bubbles interfering with efficient transfer. Protein electro-transfer was run at~ 150 mA 
per gel for 1 h at 4 °C. The nylon membrane was removed from the gel and stained with 
Ponceau S (Biorad) (2 min) at room temperature on a bench top shaker, for protein 
visualisation so that transfer efficiency could be assessed. 
2.3.4 Standard Western blot detection 
The nitrocellulose membrane containing transferred protein was blocked for 1 - 2 h at room 
temperature in 5% Blotto (5% Skim milk powder in TBS-Tween-0.05%). The membrane 
was then incubated with the antibody of interest either overnight at 4 °C or 2 h at room 
temperature in 0.&% Blotto followed by 4 X 5 min washes in TBS-Tween (10 mM TrisHCl 
pH 8.0, 150 mM NaCl, 0.05% Tween-20) at room temperature. Next, the membrane was 
incubated with the appropriate secondary antibody (1-2 h, room temperature) followed by 
another 4 X 5 min wash in TBS-Tween. For detection of signal, the membrane was 
incubated in Femto (Pierce) chemiluminescence substrate and exposed to X-ray film for the 
appropriate amount oftime before developing on an automatic developer (Curix-60 AGFA, 
Agfa Gaveart, Australia). All films were re-aligned with the membranes and the protein 
marker was traced onto the X-ray film so that the size of the signal developed could be 
estimated. 
For the subsequent detection of additional proteins, the membrane was stripped with a first 
wash 4 X 5 min in TBS-Tween and an incubation for I 5 min at room temperature in 
Western blot stripping buffer (Pierce) followed by another 4 X 5 min wash in TBS-Tween. 
The membrane was subsequently incubated in F em to and underwent detection by X -ray 
film to ensure no signal was developed. An additional 4 X 5 min in TBS-Tween was 
carried out to remove the chemiluminescence; the primary antibody was then applied to the 
membrane. 
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1.3.5 Antibodies used in Western blotting 
For ADAM-9, two different antibodies were used throughout this study, I) ADAM-9Dis 
was raised against the recombinant disintegrin domain of ADAM-9 (Chemicon, Temecula, 
CA, USA) and 2) ADAM-9Cterm was raised against a C-terminal specific peptide (Biomol 
Plymouth Meeting, PA, USA) (See Figure 2. IA). For ADAM-I 0, two antibodies were also 
used throughout this study, I) ADAM-IOCterm was raised against a C-terminal specific 
peptide to ADAM-:10 (Chemicon) and 2) ADAM-10Met, was raised against a peptide 
sequence at the N-terrninal ofthe mature, active metaUoprotease region of ADAM-10 (see 
Figure 2.1B). For housekeeping proteins, an antibody against ~-Tubulin (Labvision-
Neomarkers, Fremont, CA, USA) was used in the case of whole cell lysate and cytoplasmic 
fractions, and an antibody against Proliferating Cell Nuclear Antigen (PCNA) (Zymed 
South San Francisco, CA, USA) was used in the case of nuclear cell fractions. 
Figure 2.1 Schematic representations of ADAM-9 and -10 antibodies used throughout this 
E 
study: 2 
A) ADAM-9 antibodies: 
I ADAM-9Dis I 
B) ADAM-10 antibodies: 
Pro-domain MetaUoproteascc lik!i domain Dismtegrin doiril!in, '.Viral fusion peptide 
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2.4 Prostate biopsy tissue section analysis 
2.4.1 Hematoxylin and Eosin (H&E) Staining 
Formalin fixed, paraffin embedded tissue sections underwent routine H&E staining for 
pathological examination . and assessment in the following protocol; Deparaffinisation 
schedule: 100 %Shellex!Xylene 3 X 5 min,. 2 X 100 %ethanol (EtOH) I min, 70 % EtOH 1 
min, distilled water (dH20) 1 min, Staining schedule: Mayers hematoxylin 4.5 min, Scotts 
water (water, pH 8.0) 1 min, 3 X dH20 30 sec, Eosin 1 min, 3 X dH20 30 sec, Dehydration 
schedule: dH20 1 min, 70 % EtOH l min, 2 X 100 % EtOH 1 min, Shellex!Xylene 3 X 5 
min fol1owed by the application of a coverslip using DEPEX, which was allowed to set for 
24 h before visualising the stained section under a light microscope. For fresh frozen tissue 
sections, the slide was introduced at the first 100 % EtOH incubation and underwent the 
subsequent steps of staining as outlined above. 
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CHAPTER THREE 
3.0 THE EXPRESSION OF ADAM-9 AND -10 PROTEASES IN PROSTATE 
CANCER 
44 
3.1 Introduction: 
The key components, which contribute to the mechanisms of successful metastasis, include 
extracellular matrix (ECM) invasion, mediated in part by matrix metalloprotease (MMP) 
proteolysis (Bergers and Coussens, 2000) and cell migration, assisted by cell surface 
molecules including the integrins (Gurnbiner, 1996). It was hypothesised that the ADAMs 
proteases were likely to be additional key mediators of this process, as they comprise A 
Disintegrin And Metalloprotease domain. These proteins exist predominantly as 
membrane bound proteases that have the potential to degrade ECM components via their 
extracellular active metalloprotease domain and to regulate cell-ceil and cell-ECM contacts 
via their integrin binding/dissociation capabilities. 
Both ADAM-9 and -10 are active metalloproteases (Skovronsky et al. 2000; Blobel 1997; 
Rosendahl et aL I 997) and are able to degrade ECM substrates in vitro, including gelatin, 
fibronectin (Schwettmann et al. 2001) and collagen type IV (MiUichip et aL 199&). 
ADAM-9 is also known to bind key integrins involved in cell-cell and cell - ECM contacts 
such as a6(31, which maintains expression throughout the various stages of PCa 
development (Rabinovitz et al. 1995). 
Previously, this laboratory has described the mRNA expression of ADAM-9, -10, -11, -15 
and -17 in PC a cell lines characteristic of androgen-sensitive disease (LNCaP and ALVA-
41) and androgen-insensitive disease (DU-145 and PC-3) (McCulloch et al. 2000). In the 
same study the regulation of three of these ADAMs (-9, -10 and -17) by the androgen 
dihydrotestosterone (DHT) was examined at the mRNA level. ADAM-9 and -I 0 mRNA 
levels were responsive to and significantly up-regulated by DHT. Given this type of 
regulat~on, it is possible that these two ADAMs will be involved in PCa development and 
progression. Indeed, closely related MMPs, for example, MMP-7 are regulated in this 
fashion in PCa (Sundareshan et aL 1999). 
In order to study this, the use of an in vitro cell model representative of PCa progression 
would be helpful. The C4 series of cell lines- C4, C4-2 and C4-2B, which were derived 
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from the co-culture of LNCaP cells with a bone cell line in athymic mice (Chung et al. 
1997; Zhau et ai. 2000) are reported to reflect changes in androgen sensitivity. The LNCaP 
and C4 cell lines are androgen sensitive and poorly metastatic whilst the C4-2 and C4-2B 
cell lines are androgen insensitive and moderately metastatic. Thus, this series of cell lines 
may represent a good model for the examination of ADAM-9 and -1 0 expression and their 
relationship to PCa progression. 
Recent studies in our laboratory have examined the expression of ADAM-9 and -10 at the 
mRNA and protein level in primary prostate tumour biopsies by in situ hybridisation (ISH) 
and immunohistochemistry (IHC) respectively (reviewed in Chapter I). This provided data 
regarding the expression and localisation patterns of these particular ADAMs in differing 
prostate diseases, from benign/hyperplastic states, to low through high-grade cancer. To 
extend those immunohistochemical studies further, several bone metastases taken from 
late-stage PCa patients at biopsy have also been examined as part of this study of ADAM-9 
and -10 expression, to determine whether these two ADAMs may have a role in these later 
stages of carcinoma. 
In the earlier more comprehensive prostate biopsy IHC studies, strong 
membrane/cytoplasmic staining was seen for ADAM-9 in the benign type of prostate gland. 
However, glands characteristic of low to high-grade cancer showed weaker staining in 
comparison. In the case of ADAM-I 0, the intensity of IHC staining was strong in the 
benign situation, apparently weaker in low-grade cancer glands but strong in high-grade 
cancer glands. The most striking observation however, was that within high-grade cancer 
glands, ADAM ... l 0 appeared to be localised to the perinuclear and/or nuclear compartment 
of the cell as compared to benign and low-grade cancer glands where membrane staining 
was more apparent. 
These novel observations led to the hypothesis that the ADAMs might have differential 
functions depending on their cellular localisation - cytoplasmic/membrane bound versus 
nuclear. To test this,. it was envisaged that there might be a nuclear-predominant expression 
of ADAM-10 in PC-3 cells, representing late-stage PCa, whereas this may not be apparent 
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in RWPE-1 cells, which represent a normal prostate cell model. In the case of ADAM-9, it 
was hypothesised that nuclear expression in one or both of these cell lines may be O>bserved, 
given the occasional perinuclear expression observed in primary prostate glands within 
prostate tissue biopsies. 
Additionally, recent studies have examined the event of membrane vesicle shedding from 
the cell surface, releasing membrane-associated proteins into the extracellular environment 
(Angelucci et al. 2000; Taraboletti et al. 2002). These studies observed MMP activity 
associated with shed membrane vesicles as well as illustrating that more tumorigenic cell 
types had a higher occurrence of shed membrane vesicles. It is therefore likely, given both 
ADAM-9 and -10 are membrane bound, that these two ADAMs are also present in shed 
membrane vesicles from PCa cell lines and their metalloprotease activity perhaps 
contributes to ECM degradation activities. 
Thus, the aims ofthis chapter were: 
1) a) To extend the RT-PCR expression data previously published (McCulloch et al. 
2000) to assess the mRNA expression of ADAM-9 and -10 in the C4 series of the 
prostate cancer cell lines: C4, C4-2, and C4-2B. 
b) To examine possible changes in the expression of ADAM-9 and -10 at the protein 
level in each ofthe LNCaP metastatic variant cell lines. 
2) To examine the protein expression pattern of ADAM-9 and -10 in prostate cancer bone 
metastases obtained at biopsy. 
3) To examine the nuclear/cytoplasmic expression patterns of ADAM-9 and -10 in 
R WPE-1 and PC-3 prostate cell lines. 
4) To examine possible membrane-vesicle associated ADAM-9 and -10 protein 
expression using the RWPE-I, LNCaP and PC-3 cell lines. 
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3.2 Materials anti Methods 
· 3.2.1 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Reverse transcription (RT) 
Total RNA was obtained from cell pellets, from each of the PCa cell lines: LNCaP, C4, C4-
2 and C4-2B and reverse transcribed as described in Chapter 2. Ali eDNA was screeDed by 
PCR using f3-actin primers (Table 3.1), which span a f3-actin intron, as an indicator of 
possible genomic DNA (gDNA) contamination. 
Polymerase Chain Reaction (PCR) 
PCR was performed as described in Chapter 2 using each of the primers and their 
corresponding annealing temperatures illustrated in Table 3.1, with 1 fll eDNA as a 
template from each ofthe cell lines LNCaP, C4, C4-2 and C4-2B in separate PCRs~ made 
up to 50 p.l with sterile distilled water. 
Table 3.1: Oligonucleotide primers for ADAM-9, -10 and ~-actin used in PCR analysis, 
and their corresponding PCR product sizes and annealing temperatures. 
mRNA Primer Sequences PCRProduct Annealing Reference ~ 
Transcript 
Size (bp) Temp.(C) 
ADAM-9 5' AGTGCAGAGGACTITGAGAA (Forward) 391 56 Wu et al. 1997 
5' TGCCGTTGTAGCAATAGGCT (Reverse) 
ADAM-10 5' TGGATTGTGGCTTCATTGGTG (Forward) 236 55 Wuetal. 1997 
5' TGCAGTTAGCGTCTCATGTGTC (Reverse) 
~-actin 5'CGTGGGCCGCCCTAGGCACCA (Forward) 234(cDNA) 55 Telford eta!. 1990 
5'GGGGGGACTTGGGATTCCGGTT (Reverse) 330(gDNA) 
3.2.2 Protein Extraction 
Protein was extracted from cell pellets lysates of the LNCaP, C4, C4-2 and C4-2B cell lines 
whilst nuclear/cytoplasmic fraction protein was extracted from cell pellets of the RWPE-1 
and PC-3 cell lines. All cell pellets were derived from ~ 70 to 90 % confluent T75 tissue 
culture flasks as described in Chapter 2. Each protein extract was quantified using the BCA 
method also described in Chapter 2. 
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Membrane Vesicle Isolation 
Serum-free media (RPMI-1640) were collected (10 ml) from RWPE-1, PC-3 and LNCaP 
confluent T75 cell cultures after 24 h incubation. The media were centrifuged at 1200 X g 
for 10 min, the resultant supernatants collected and centrifuged at 8000 X g for 20 min at 4 
0 C. The supernatant after the 2nd centrifugation should be free of any contaminating cells 
and cellular debris (Taraboletti, et al. 2002). The supernatants were then subjected to a 
high-speed ultra-centrifugation (1 00,000 X g) on an Ultracentrifuge (Beckman) using an 
SW 41.1 rotor to pellet the cell membrane vesicles as per methods outlined in Taraboletti,. et 
aL (2002). The supernatants were removed and each membrane vesicle pellet was 
resuspended in 200 !ll ofTriton X-100 protein lysis buffer (Chapter 2). 
3.1.3 Western Blot 
10 !lg of protein from each whole ceU lysate of LNCaP, C4, C4-2, and C4-2B or 5 !lg 
cytoplasmic or nuclear fractions ofRWPE-1 and PC-3 cells or 20 ~-tl of membrane vesicle 
lysate was suspended in a reducing loading buffer and boiled for 3 min prior to loading 
onto a 10 % SDS-P AGE gel, followed by a standard Western blotting procedure - outlined 
in Chapter 2. The blocked membrane (5 %Blotto) was incubated with either ADAM-9Dis, 
(0.5 J.tg/ml), ADAM-9Cterm (0.25 !lg/ml), ADAM-10Cterm (0.5 ~-tg/ml) or ADAM-IOMet 
(0.05 ~g!ml) rabbit polyclonal antibody (see Figure 2.1) or human anti-~-Tubulin, or 
_PCNA (0.2 Jlg/ml) mouse monoclonal antibody, in 0.8 % Blotto: TBS/Tween-20 (0.05 %) 
at 4 °C overnight. The primary antibody was collected and re-used up to three times 
without loss of efficiency. The membrane was incubated for 2 h at room temperature in 
anti-rabbit HRP (DAKO, Carpintera, CA), 0.2 Jlg/ml or anti-mouse POD (Roche), 0.2 
Jlg/ml in 0.83% Blotto: TBS/Tween-20 (0.05%). For detection, the membrane was 
incubated in 2 ml Femto (Pierce). The resultant signal was detected on X-ray film by 
autoradiography and developed on an automatic developer (Curix-60 AGF A, Agfa-
Gaveart, Australia). 
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3.1.4 Immunohistochemistry (IHC) & Immunocytochemistry (ICC) 
Bone metastasis tissue samples (IHC) 
Paraffin embedded, EDTA-decalcified~ prostate bone metastasis tissue blocks with 
embedded tissue acquired from men with high-grade, metastatic PCa at biopsy were 
obtained from the Bernard O'Brien Institute of Microsurgery (BOBIM), St. Vincent's 
Hospital, Melbourne, Vic. via collaborations undertaken with Dr. Elizabeth Williams 
(Senior Research Scientist). 
Cell line culture (ICC) 
The normal but transformed, non-tumorigenic prostate cell line RWPE-1 and the metastatic 
PCa cell line PC-3 were cultured in standard T25 tissue culture vessels to 70 % confluency 
and harvested with trypsin/versine as described in Chapter 2. The ceHs were counted on a 
haemocytometer and seeded onto a 12 well tissue culture microscope slide at a 
concentration of 5000 cells/well and allowed to grow overnight. 
Fixation and processing 
For IHC, the tissue blocks were sectioned at 4-5 ~m thickness on a standard bench-top 
microtome and the sections were mounted on APES (3-aminopropyl triethoxysilane) coated 
slides and dried at 37 °C overnight. _The sections were then dewaxed and rehydrated as 
described in Chapter 2. H&E - as described in Chapter 2 was used for routine histological 
examination. For ADAM-10, antigen retrieval was necessary, the tissue sections were 
immersed in 0.1 M citrate buffer, enclosed in a microwave proof pressure cooker and 
heated on high setting (650 Watt microwave) 2 X 4 min. The pressure cooker was cooled 
on ice for 20 min and the slides allowed to cool in Citrate buffer to room temperature. For 
ICC, the medium was aspirated and the ceHs were washed with warm (3 7 °C) Phosphate 
Buffered Saline (PBS) and fixed by immersion in ice-cold methanol at -20 °C for 5 min. 
The fixed sections/cells were incubated in 10% methanolic peroxide, 2 X 20min or 2 X 15 
min (IHC and ICC respectively) at room temperature to block any endogenous peroxidase 
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activity, which may be present in the samples. Non-specific antigenic sites were blocked 
by incubation with 5% BLOTTO for 1 hour (IHC) or 30 min (ICC) at room temperature. 
The optimal antibody dilution for IHC (ADAM-1 OCterm: 5 f.!g/mi, ADAM-9Dis: 4 f.!g/ml) 
or ICC (ADAM-9Dis & ADAM-lOCterm: 10 f.!g/ml) or Prostate Specific Antigen (PSA) 
(pre-optimised immune rabbit anti-sera - DAKO), in the case of IHC, was applied and 
incubated overnight at 4 °C. 
The slides were washed for 3 X 5 min in TBS-Tween. The signal was detected using the 
DAKO Envision plus detection kit which involves a 30 min incubation with a HRP-
conjugate antisera followed by a 3 X 5 min wash in TBS-Tween and detection using 
diaminobenzine (DAB) chromogenic substrate, which was monitored for optimal 
incubation time (I- 10 min) under a light microscope. The DAB was inactivated by a dH20 
bath. The nuclei were counterstained with Hematoxylin (5 min) followed by several washes 
in tap water and dehydration through graded ethanol (70 % and 100 %) and cleared in 
Xylene, cover-slipped using DEPEX and allowed to dry overnight in a fume hood before 
microscopic examination. The mounted slides were viewed under a light microscope and 
with the use of a digital camera (Kodak) images could be directly downloaded and saved as 
a Tagged Image File Format (TIFF) picture file. 
As a positive control for IHC, paraffin embedded prostate tissue blocks from men with 
BPH, non-malignant conditions and various stages (Gleason scores) of cancerous prostate 
tissues were obtained via collaboration with Dr. Hema Samaratunga from the Pathology 
Department, Royal Brisbane Hospital, Australia. As a negative control for the 
irnrnunostaining, the primary antiserum (either ADAM-9 or ADAM-10) was omitted from 
the staining schedule. ADAM-I 0 primary antibody was also pre-absorbed with a purified 
blocking peptide (Chemicon) to detect non-specific binding. No blocking peptide~ or its 
precise sequence was commercially available for the ADAM-9 primary antibodies. The 
PSA negative control (non-immune rabbit serum) was supplied as a pre-optimised solution 
by DAKO. As a negative control for the ICC, the primary anti-serum was omitted from the 
staining schedule. 
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3.3Results 
J.3.1 The expression of ADAM-9 and -10 mRNA and protein in the LNCaP metastatic 
variants 01, C4-2 and C4-2B 
mRNA expression by RT-PCR 
Expression of PCR products, the expected size for ADAM-9 and -10 were found in eDNA 
from each ofthe LNCaP PCa ceU line metastatic variants C4, C4-2 and C4-2B (Figure 3.1). 
As the PCR protocol was not quantitative no comparison of expression levels is possible in 
this case. The LNCaP cell line was used as a positive control in aU steps as ADAM-9 and-
10 mRNA was previously identified in this cell line (McCulloch et al. 2000) and it is the 
parent cell line of the subsequent metastatic variants analysed. Each cell line eDNA was 
free of gDNA contamination as determined by f)-Actin primers. 
Protein expression by Western blot 
A qualitative measure of protein expression was undertaken by Western blot analysis and 
showed ADAM-9 and -10 protein expression in the LNCaP, C4, C4-2 and C4-2B whole 
cell lysate (Figure 3.2). ADAM-9 was detected in all of the PCa cell lines tested with a 
single band at ~84 kDa (Figure 3.2A). the anticipated size of the inactive pro-form of 
ADAM-9. Very faint bands at ~60 kDa were occasionally observed (too faint to be shown) 
and may indicate the mature active form of ADAM-9 protein. ADAM-10 protein bands 
were visualised at ~100 kDa representing the unprocessed, pro-form of ADAM-10 and ~60 
kDa, the expected size ofthe mature, catalyticaHy active form of ADAM-10 (Figure 3.2B). 
A positive control (as recommended by Chemicon), using JURKAT (Human Acute T-cell 
leukaemia) whole cell lysate run alongside LNCaP cell protein, showed bands of the same 
size for unprocessed and processed ADAM-10 forms (Figure 3.2C). 
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Figure 3.1: RT-PCR of ADAM-9 and -10 mRNA transcripts in the increasingly metastatic 
prostate cancer cell lines LNCaP, C4, C4-2 and C4-2B 
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Each cell line was cultured to 70 - 90 % confluency, harvested, and their total RNA 
extracted of which 5 11g was reversed transcribed as described in Materials and Methods. 
ADAM-9 and -10 gene specific primers (Table 3. I) were used in subsequent PCR analysis. 
The size of the PCR product was determined by direct comparison of molecular weight 
marker IX (Roche- not shown) run alongside each PCR product on a 2 % agarose gel 
containing 1 ~-tg/ml EtBr. The PCR product was visualised under a UV lamp. !3-Actin 
primers, which span an intron, were used to ensure the eDNA in each cell line was free of 
gDNA contamination. The LNCaP cell line, known to express both ADAM-9 and -10 
rnRNA transcripts was used as a positive RT -PCR control whilst a PCR with no eDNA 
template was used as the negative control. Identical results were found for three separate 
RNA preparations of each C4 series cell line. 
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Figure 3.2: Western blot analysis of ADAM-9 and -10 protein m the increasingly 
metastatic prostate cancer cell lines LNC(lP, C4, C4-2 and C4-2B 
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Each cell line was cultured to 70 - 90 % confluency, harvested, and their total protein 
extracted with protein extraction lysis buffer. 10 flg of protein was loaded onto a 10 % 
PAGE gel followed by standard Western blot procedure (Chapter 2). The size of each 
ADAM product was determined by comparison ofBiorad pre-stained protein marker run on 
the same PAGE gel (not shown). The housekeeping gene 13-Tubulin was used in a 
subsequent Western blot on the same membrane to visualise protein loading variability 
between cell lines. Similar results were found in three separate whole cell lysate protein 
preparations for each C4 series cell line. As a positive control for ADAM-1 0, LNCaP 
whole cell lysate was run alongside the JURKA T cell line whole cell lysate. 
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33.2 The expression of ADAM-9 and -10 in bone metastases obtained at biopsy from 
prostate cancer patients 
Immunohistochemistry (IHC) 
ADAM-9 and -10 protein expression was observed by lliC in prostate tissue taken from 
patients undergoing bone metastasis biopsies. Expression of both AD AM-9 and -10 
proteins was dearly detected in the epithelial cells of prostate origin within each biopsy 
(Figure 3.3 A - ADAM-9 & Figure 3.3 B - ADAM-10) with little or no bone or bone 
fibroblast cell staining. In the case of both ADAM-9 and -10, levels comparable to those in 
primary prostate tumours (eg. Figure 3 E & F) were detected in the cytoplasm and on the 
ceil membrane with expression also seen in the perinuc1ear/nuclear region. As a positive 
control, PSA was detected using immune rabbit anti-sera (DAKO), in the same type of cells 
of prostate origin in which ADAM-9 and -10 were detected~ in serial sections (Figure 3.3 
G). H & E (Chapter 2) stained serial sections were reviewed by a pathologist and the 
different cell types within each bone metastasis section were identified. Negative controls 
for both ADAM-9 and -10 included the omission of each primary antibody (Fig. 3.3 E). 
Positive controls included the detection of ADAM-9 (Figure 3.3 G) and ADAM-10 (Figure 
3.3F) and PSA (Figure 3.3G) in primary prostate tumours taken from PCa patients at 
biopsy, performed in the same IHC experiment. Negative controls for primary prostate 
tumours for ADAM-9, -10 and PSA included the omission ofthe primary antibody (Fig. 
3.3 H). These observations were the same in at least five independent patient bone 
metastasis biopsies. 
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Figure 3.3: Immunohistochemistry for ADAM-9, -10 and PSA on bone metastases, obtained 
from prostate cancer patients at biopsy 
A)ADAM-9 B)ADAM-10 
Immunohistochemistry for ADAM-9, -10 and PSA on bone metastases, obtained from prostate 
cancer patients at biopsy: ADAM-9Dis and ADAM-10Cterm antibodies show staining in 
prostate cancer cells in bone metastases. ADAM-9 (A) and ADAM-10 (B) are predominantly 
expressed in the cell cytoplasm, cell membrane and occasionally in the cell nucleus. PSA was 
detected in the same cell types in adjacent bone sections from the same bone metastases (C). In 
the case of ADAM-9 and -10, both antibodies were omitted to serve as the same negative 
control (D) Legend: M- Metastasis, B- Bone, BF- Bone Fibroblast, C- Cytoplasmic staining, 
N - Nuclear staining. 
Figure 3.3cont: Immunohistochemistry for ADAM-9, -10 and PSA (positive controls), for 
primary prostate tissue obtained from prostate cancer patients at biopsy 
G)PSA H) Negative Control 
Immunohistochemistry for ADAM-9, -10 and PSA on prostate primary tumours, obtained from 
prostate cancer patients at biopsy: ADAM-9 (E), ADAM-10 (F) and PSA (G) were detected in 
the same lliC run as the bone metastases (Fig. 3A, B, C & D - previous page). In the case of 
ADAM-9 and -10, both antibodies were omitted to serve as the same negative control, for PSA, 
non-immune primary rabbit antisera (DAKO) was used (H). Legend: C- Cytoplasmic staining, N 
-Nuclear staining, F- Fibroblast, PG- Prostate Gland . 
33.3 The nuclear and cytoplasmic expression of ADAM-9 and -10 in the prostate cell 
lines RWPE-1 and PC-3 
Nuclear localisation signal (NLS) 
Previous observations in this laboratory using IHC showed strong nuclear expression for 
ADAM-10 in high-grade PCa and occasional nuclear/perinuclear expression for ADAM-9 
throughout aU stages of PCa (discussed in Chapter 1 ). This, along with the apparent 
nuclear expression of both these ADAMS in bone metastases (shown above) provides a 
good rationale for further investigation of this phenomenon. An active transport 
mechanism is required to import larger molecular weight proteins, such as ADAM-9 and-
10 into the nucleus of a ceiL The mechanisms often depend on the presence of a consensus 
nuclear localisation signal (NLS). Therefore, the primary amino acid sequence of the 
coding region of ADAM-9 and -10, Genbank (NCB I, NIH) accession numbers NP _ 003816 
and NP _ 001110 respectively, were imported into the World Wide Web based search engine 
PSORT and analysed for likely NLS consensus sequences. Table 3.2 shows the numerous 
NLSs found in both ADAM-9 and -10, which are consensus sequences for the a/~ Importin 
active nuclear transport system (Catimel et al. 2001). 
Immunocytochemistry 
Similar observations regarding cellular localisation were made for both ADAM-9 and -10 
in both the R WPE-1 and PC-3 cell lines. ADAM-9 was expressed in the cytoplasm, on the 
cell membrane and in the nucleus in both PC-3 (Figure 3.4 A & B) and RWPE-1 cell lines 
(Figure 3.4 D & E). In the case of ADAM-10, cytoplasmic and membrane staining was 
•. 
observed in both the PC-3 (Figure 3.4 G & H) and RWPE-1 (Figure 3.4 J & K) along with 
strong perinuclear/nuclear staining in both cell types. No staining was visualised in the 
case of each negative control (primary antibody omitted) for ADAM-9 (Figure 3.4 C & F) 
and ADAM-I 0 (Figure 3.4 I & L ). 
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Table 3.2: Consensus Nuclear Localisation Sequences (NLSs) found in the primary amino 
acid sequence of ADAM-9 and -10. 
Sequence Pattern Consensus Motif ADAM 9 Sequences ADAM 10 Sequences 
(Origin) 
Pat4 4 basic amino acids - K orR RRRR (residues 202-) RKKR (residues210-) 
(SV 40 Large T antigen) (or 3 basic aa plus H or P) RRRH(295-) KRRR (721-) 
RKKR(729-) RRRP(722-) 
Pat7 PXl-3 plus 3(KJR) out of next PELLRKK (206-) 
(SV40 Large T antigen) 4residues PEGRKCK (490-) 
PLARLKK (653-) 
PGTLKRR (717-) 
Bi-Partite 2 basic residues, 1 0 residue RR RPPQPIQQPQ RQRPR 
(Xenopus) spacer, 3 basic in next 5 (722-) 
residues 2 KIRXl 0(3/5 KIR) 
The primary amino acid sequences of ADAM-9 and -10 were analysed in PSORT for the 
consensus NLS for the a/~ importin system. Several NLS were identified in the case of 
ADAM-9 and more so in ADAM-10. 
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Figure 3.4: Immunocytochemistry analysis of ADAM-9 & ADAM-I 0 in RWPE-1 and PC-
3 cells 
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Immunocytochemistry using ADAM-9Dis and ADAM-I OCterm antibodies. ADAM-9 
(A & B- PC-3, D & E- RWPE-1), -10 (G & H- PC-3, J & K- RWPE-1) was shown in 
the cytoplasm and nucleus of each cell line. Negative controls: omission of each 
primary antibody (ADAM-9- PC-3, C & RWPE-1, F) (ADAM-10- PC-3, I & RWPE-
1, L). Legend: N =Nucleus, C =Cytoplasm. 
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Western blot analysis 
For the ADAM-9Dis antibody, a band at the predicted size ofthe unprocessed pro-form, 
~84 kDa was expressed across aU cellular fractions and whole cell lysate in both RWPE-1 
and PC-3 cell lines (Figure 3.5). A lower band ~60 kDa, the predicted active form of 
ADAM-9, was expressed highly in RWPE-1, but weakly in PC-3 cell lines to the point that 
it was not detectable when 5 p.g ofwhole cell lysate was analysed by Western blot (Figure 
3.5 A). Further, this potentially mature active form of ADAM-9 could be seen in whole 
cell lysate_and nuclear fractions but only faintly in the cytoplasmic :fraction of the RWPE-1 
cell line. A smaller doublet of ~34 kDa of unknown identity but previously detected in 
other studies with antibodies raised to similar regions of ADAM-9 (Weskamp et al. 1996) 
was detected in the cytoplasmic fractions ofRWPE-1 and PC-3 cells but not in the nuclear 
:fractions. As a control for the efficiency of subcellular fractionation, _the cytoplasmic 
specific protein ~-Tubulin (54 kDa) and the nuclear specific protein Proliferating Cell 
Nuclear Antigen (PCNA) (34 kDa) was detected by Western blot in each cell line fraction 
(Figure 3.5 B - Tubulin & 3.5 C - PCNA). Although slight cross-contamination was 
observed, ~ 10 % as expected and stated by the manufacturer of the subcellular fractionation 
kit (NePer- Pierce), the subcellular fractionation was found to be sufficient and acceptable 
for the purposes of analysis in this study using these particular markers. The cross-
contamination observed in this case was indicative of each subsequent sub-cellular 
:fractionation carried out for replication purposes of each ADAM-9 and -10 protein 
expression experimental data. 
For ADAM-10, the ADAM-lOCterm antibody detected a ~100 kDa band (unprocessed 
form) in RWPE-1 cells, whilst weak expression of this band was occasionaiiy seen in PC-3 
cells (Figure 3.6 A). Two lower bands, ~54 and ~56 kDa, likely representing mature active 
forms, were expressed in both RWPE-1 and PC-3 cells (Figure 3.6 A). Examination of 
cellular fractions showed, with the ADAM-1 OCterm antibody, the higher ~56 kDa band 
was expressed in the cytoplasmic :fraction of each cell line whilst the lower ~54 kDa band 
was present only in the nuclear fraction ofRWPE and PC-3 cells. These lower molecular 
weight bands were also detected by the ADAM-IOMet antibody, which was raised to the 
N-terminal of the processed, mature catalytically active form of ADAM-10 (Figure 3.6 B), 
61 
indicating the presence ofthe N-terminal of the active ADAM-10 protein sequence in each 
ofthese isoforms. In the case of Figure 3.6 B, both the 54 kDa and 56 kDa bands were 
detected in the nuclear fraction of both of the cell lines, unlike the previous analysis using 
the ADAM-I OCterm antibody, which detected the clear differential localisation described 
above. It is possible that, given the ADAM-I OMet antibody is raised to the N-termina1 
sequence of mature ADAM-1 0; its affinity for processed ADAM-10 might be stronger than 
that of the ADAM-IOCterm antibody. Hence, lower levels of ADAM-10 protein present, 
possibly, but not necessarily due to cross-contamination might be easily detected. 
Nonetheless, the lower 54 kDa band still appears to be exclusively expressed in the nuclear 
:fraction of each of the R WPE-1 and PC-3 cell lines. The expression of the unprocessed 
form of ADAM-10 was not readily detected with the ADAM-IOMet antibody in this case, 
which again reflects the possibility of the differing binding preferences/affinities of this 
antibody between the ADAM-I 0 processed and unprocessed fonns. 
3.3.4 The expression of ADAM -9 and -10 in isolated membrane vesicles from the 
prostate eel/lines RWPE-1, LNCaP and PC-3 
For ADAM-9, a qualitative membrane vesicle protein content from the normal prostate ceH 
line R WPE-1 and the PCa ceil lines LNCaP and PC-3 was analysed by Western blot with 
the ADAM-9Dis and the ADAM-9Cterm antibody. The ADAM-9Dis antibody detected a 
band in RWPE-1 (60 kDa) and LNCaP (60 kDa) vesicles but not in the PC-3 cell vesicles 
(Figure 3.7), whilst the ADAM-9Cterm antibody detected bands in the LNCaP cell vesicies 
(84 kDa and 60 kDa) whilst no bands were detected in the PC-3 or the RWPE-1 cell 
vesicles (Figure 3. 7). A higher band ~ 100 kDa of unknown identity was, in this case, also 
detected with the ADAM-9Dis but not the ADAM-9Cterm antibody in the LNCaP whole 
cell lysate preparation, as wen as the expected 84 kDa and 60 kDa bands (positive control) 
along with the additional 34 kDa band ofunknown identity, as found previously in RWPE-
1 and PC-3 cell extracts described above. 
For the qualitative assessment of ADAM-1 0 membrane vesicle protein content, the 
ADAM-lOMet antibody detected an intense signal at ~60 to ~80 kDa in PC-3, whilst for 
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RWPE-1 a less intense signal was detected at approximately the same size (Figure 3.8). 
For LNCaP, two major bands (~100 k:Da and ~60 k:Da) were detected :in close vicinity to 
the bands detected in the LNCaP whole cell lysate (positive control) run on the same gel 
(Figure 3.8) and may represent unprocessed and processed, catalytically active proteins 
respectively. 
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Figure 3.5: Western blot analysis of ADAM-9 in the nuclear and cytoplasmic fractions of 
the normal but transformed prostate cell line RWPE-1 and the metastatic prostate cancer 
cell line PC-3 
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A) Cell pellets ofRWPE-1 and PC-3 cells were collected from a ~70- 90% confluent T75 
tissue culture flask and subcellular fractionation was subsequently carried out. 5 ~g of 
protein from each nuclear (N), cytoplasmic (C) cell fraction or whole cell (WC) lysate was 
run on an SDS-PAGE followed by standard Western blot procedure as described in Chapter 
2. P-Tubulin (cytoplasmic specific) (B) and PCNA (nuclear specific) (C) were detected by 
standard Western blot procedure as controls for the efficiency of subcellular fractionation. 
Similar observations were observed in three separate ceiiular fractionation preparations. 
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Figure 3.6: Western blot analysis of ADAM-10 in the nuclear and cytoplasmic fractions of 
the normal but transformed prostate cell line RWPE-1 and the metastatic prostate cancer 
cell line PC-3 
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Cell pellets ofRWPE-1 and PC-3 cells were collected from a ~70- 90 % confluent T75 
tissue culture flask and subcellular fractionation was subsequently carried out. 5 !lg of 
protein from each nuclear (N), cytoplasmic (C) cell fraction or whole cell (WC) lysate was 
run on an SDS-PAGE followed by standard Western blot procedure as described in Chapter 
2. A) The ADAM-lOCterrn antibody detected a differential expression pattern for the 
predicted active form, whilst the unprocessed form was not readily detected in the whole 
cell lysate of PC-3 cells and may indicate a higher level of expression of this form in the 
nuclear protein fraction of this cell line. In the case ofthe ADAM-lOMet antibody (B), 
both bands were detected in each fraction, confirming the presence of the active N-terminal 
metalloprotease sequence. The lower 54 kDa band was exclusively confined to the nuclear 
compartment in both cases, in both cell lines. This was indicative of results seen between 
more than three separate nuclear/cytoplasmic fractions of each cell line. 
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Figure 3.7: Western blot analysis of ADAM-9 in the membrane vesicle fractions of the 
normal but transformed prostate cell line RWPE-1, and the prostate cancer cell lines 
LNCaP and PC-3 
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Qualitative Western blot analysis of protein isolated from membrane vesicles released into 
the media of each ofthe cell cultures PC-3, RWPE-1 and LNCaP. LNCaP whole cell lysate 
was run alongside the membrane vesicle protein lysate as a positive control, with the 
expected 84 kDa and 60 kDa bands being detected with each antibody. These results are 
indicative of one preliminary membrane vesicle isolation experiment, which now needs to 
be confirmed. 
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Figure 3.8: Western blot analysis of ADAM-10 in the membrane vesicle fractions of the 
normal but transformed prostate cell line R WPE-1, and the prostate cancer cell lines 
LNCaP and PC-3 
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Qualitative Western blot analysis of protein isolated from membrane vesicles released into 
the media of each of the cell cultures PC-3, RWPE-1 and LNCaP. The ADAM-IOMet 
antibody was used for this experiment. LNCaP whole cell lysate was run alongside the 
membrane vesicle protein lysate as a positive control, and showed the expected I 00 kDa 
and 60 kDa bands. These results are indicative of one preliminary membrane vesicle 
isolation experiment, which now needs to be confirmed. 
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3.4 Discussion 
The development and progression of prostate cancer (PCa) involves a plethora of molecular 
events, which seemingly act in synergy, eventually enabling metastasis to occur. PCa 
commonly metastasises to the lymph node and bone where the colonisation of prostate 
secretory epithelial cells takes place. The process of PCa metastasis, specifically to the 
bone is poorly understood. However, it is thought that tumour cells are attracted to bone by 
growth factors and cytokines activated or released upon osteoclast bone reabsorption, from 
bone marrow and stroma (Roodman, 2001). The processes of ECM and bone matrix 
degradation, and cell migration are key mechanisms for establishing secondary site 
metastatic tumours. 
ADAM-9 and. -l 0 are potential candidates for assisting the type of activity required for 
metastasis - firstly, via their active extracellular metaUoprotease domains and s~condly by 
the ability, in the case of ADAM-9, to interact with integrins, potentially regulating ceH-ceH 
and cell-ECM contact and adhesive capabilities. 
The expression of ADAM-9 and -10 was examined in an in vitro metastatic ceil line model 
(the C4 series), derived from the PCa cell line LNCaP, which was originally isolated from a 
lymph node metastasis. The C4 cell line was derived from the primary tumour and C4-2 
cell line from the lymph node metastasis resulting from the LNCaP cell line being co-
cultured with the human bone fibroblast ceH line (MS) in male athymic mice (Wu et aL 
1994) whilst the C4-2B cell line is a bone metastasis derivative from the C4-2 cell line 
(Chung et al. 1997), again established by passage in male athymic mice. The LNCaP and 
C4 cell lines are proliferatively responsive to androgen stimulation, whilst the latter C4-2 
and C4-2B cell lines are not, giving these derivatives the characteristics of PCa progression 
and providing a good theoretical model to characterise the expression of potential mediators 
of metastasis to the lymph node and more so, given the co-culture conditions with bone 
fibroblast cells, to the bone. 
Expression of both ADAM-9 and -l 0 proteins was found in the parent LNCaP cell line and 
its metastatic derivatives: C4, C4-2 and C4-2B cell lines. The Western blots revealed an 
ADAM-9 band at ~84 kDa under reducing conditions, a size which agrees with that of 
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latent pro-forms of ADAM-9 expression in rodent kidney-derived extracts (Weskamp et aL, 
1996) and with recombinant expression in COS-7 cells (Mahimkar et al., 2000). Faint 
bands were occasionally seen at about ~60 kDa (too faint to be shown) suggesting that 
mature ADAM-9 is present at very low levels in these PCa cell lines. For ADAM-1 0, two 
distinct bands were observed at ~ 100 kDa and ~60 kDa. The larger band likely represents 
the unprocessed pro-form of ADAM-10, whilst the ~60 kDa band corresponds to that found 
in plasma membrane preparations from bone MG-63 cells (Dallas et aL, 1999) and is 
believed to represent the mature, active form of ADAM-10. The predicted sizes of each 
ADAM-9 and -10 protein from their primary amino acid sequence is illustrated in Figure 
3.9 A & B respectively. The observed Mr of ADAM-9 and -10 protein by Western blot was 
a close match to that of the predicted size, although the ADAM-I 0 pro-form ranged 18 kDa 
higher than the predicted 82 kDa most likely due to post-translational modification such as 
N-or 0-glycosylation (Coiciaghi et al. 2002). 
Despite no obvious changes in levels of either ADAM, when compared to the levels of the 
housekeeping gene f3-Tubulin, detection of endogenous levels of the active form of 
ADAM-10 (~60 kDa) indicates a potentially intrinsic role for ADAM-10 in each of these 
cell lines. ADAM-9, on the other hand, was not routinely detected in its predicted active 
fonn (~60kDa), although the parent latent form could be readily detected in each ofthe cell 
lines tested. Western blots are at best semi-quantitative, suffering from a limited dynamic 
range. With the use of recently developed, commercially available, recombinant ADAM-9 
and -10 (R & D systems), Western blot efficiency of each of the antibodies used in this 
study could be assessed as a measure of linearity for a more efficient quantitative 
assessment. 
To further these observations, the possibility of finding the expression of ADAM-9 and -10 
outside of the cell in the extracellular environment was explored by way of isolating ceU 
membrane vesicles. Previous studies have found. that for some cell types the cell membrane 
tends to constitutively 'bud' and shed parts of its membrane and cellular/membrane bound 
protein content into the extracellular environment (Angelucci et al. 2000; Taraboletti et al. 
2002). 
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Figure 3.9: Schematic representation of ADAM-9 and -10 showing the predicted molecular 
weights of the unprocessed and processed forms as determined from their primary amino 
acid sequence 
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It has also been previously observed that cell lines of a tumorigenic nature undergo more 
frequent membrane budding (Angelucci et al. 2000) and ECM proteases such as the MMPs 
have been found in these membrane vesicles (Taraboletti et al. 2002). Furthermore, these 
vesicles have been found to facilitate cell migration of other cell types, when added in cell 
culture media in in vitro cell migration assays (Angelucci et al. 2000). These observations 
suggest an important potential role for membrane vesicles in the early stages of metastasis. 
The presence of ADAM-9 and -1 0 in these vesicles suggests that they might also be 
involved in this activity. 
The expression of the presumably active ADAM-9 and -10 was found in isolated 
membrane vesicles from LNCaP and PC-3 cell lines, and ADAM-I 0 was also found in the 
RWPE-1 cell line. Interestingly, the active form of ADAM-9 was readily detected in shed 
membrane vesicles of the LNCaP cell line as opposed to not routinely being detected in 
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LNCaP whole-cell lysate, this observation needs to be explored further to assess absolute 
amounts of ADAM-9 (and -10) within and between cell types varying from normal to a 
metastatic phenotype. These data give evidence that ADAM-9 and -10, as pootentially 
active ECM proteases, may exert their activity extracellularly. 
Although earlier studies from this laboratory have examined ADAM-9 and -10 protein 
expression in primary tumour biopsies from the prostate (McCulloch et ai. in press, 2003, 
see Chapter 1 ), nothing was known about their expression in secondary tumours or 
metastasis. Thus, the present study extended these observations by characterising the 
expression of both ADAM-9 and -10 protein by IHC, in bone metastases donated by PCa 
patients at biopsy. Levels of expression comparable to the expression levels in primary 
tumours were detected, for ADAM-9 and -10 in colonised tumorigenic prostate cel1s within 
the bone, which were also found to co-express PSA, confirming their origin as prostate-
derived. Both ADAM-9 and -10 were predominantly expressed in the cytoplasm and on 
the cell membrane and in some cases, the nucleus. These data suggest the ADAMs 
continue to have roles late in the process of metastasis, perhaps important in the 
colonisation process involving bone matrix degradation, cell migration and proliferation. 
This and our previously described data outlining the presence ofboth ADAM-9 and -10 in 
normal through hyperplastic and low to high-grade cancer glands, and their apparent 
differential cellular localisation - membrane-bound, cytoplasmic and nuclear - suggests that 
ADAM-9 and -10 have important intrinsic, perhaps varied roles, in the various stages of 
PCa development. 
The nuclear presence of ADAMs -9 and -10 was particularly interesting - raising questions 
about how it gets there and what it does. To gain some further insight as to how ADAM-9 
and -10 might enter the nucleus the primary amino acid sequence of ADAM-9 and -10 was 
analysed in PSORT, a World Wide Web based analytical search engine which analyses 
·primary protein sequences for consensus motifs of interest, to look for possible nuclear 
localisation signals (NLS). The 1\o'LS consensus sequences identified are homologous to 
those sequences implicated in the nuclear import pathway mediated by the Importin a/f3 
heterodimer (Gorlich, 1998). This pathway is strongly implicated in the post-translational 
nuclear import/translocation of many proteins, each containing such NLSs (Catimel et ai. 
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2001). Hence, this is a possible nuclear import mechanism for the nuclear translocation of 
ADAM-9 and -10. The perinuclear/nuclear localisation of ADAM-10 has been previously 
reported in human articular cartilage (Dallas et al. 1999) whilst closely related ADAM-17, 
has also been reported to be localised to perinuclear regions in other cell types, although 
these were not tumorigenic in origin (Roghani et aL 1999; Schlondorff et aL 2000). 
Given the strong evidence that points to both ADAMs -9 and -10 being nuclear localised in 
clinical prostate tumour samples, their cellular localisation was further investigated in two 
prostate cell lines; by immunocytochemistry (ICC), and secondly by subcellular 
fractionation and Western blot analysis. Both RWPE-1, which is a normal but transformed 
prostate ceil line and PC-3, which is a high-grade, androgen-insensitive PCa cell line 
derived from a PCa metastasis to the bone, were utilised as cell line models to differentiate 
potential changes in expression patterns between a normal prostate situation and a high-
grade metastatic PCa ceiL 
For ICC, strong cytoplasmic/membrane and nuclear/perinuclear expression was found for 
both ADAM-9 and -10 in both RVlPE-1 and PC-3 cell lines. For subcellular fractionation, 
the processed, ~60 kDa mature form of ADAM-9 was expressed in both the cytoplasmic 
and nuclear fractions of RWPE-1 and PC-3 cells, although the lower 60 kDa form is not 
apparent in PC-3 cells when lower amounts of protein are loaded and detected by Western 
blot. These observations strengthen the data obtained by ICC with respect to observed 
nuclear expression. 
For ADAM-10 expression, the ~100 kDa pro-form was not as frequently observed across 
different PC-3 cell lysate preparations as it was in RVlPE-1 cell lysate. The subcellular 
fractionation revealed quite a distinct pattern of the mature isoform expression between the 
cytoplasm and the nucleus. The smaller form (~54 kDa) was exclusively localised in the 
cell nucleus in both cell types whilst the slightly larger (~56 kDa) form appeared initially to 
be cytoplasmic/cell membrane specific, although further analysis with a second ADAM-10 
antibody showed expression of this form in the nuclear fractions of each of the two ceiJ 
lines. Whether this observation is a result of cytoplasmic fraction contamination in the 
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nuclear fraction remains to be investigated. Therefore, at this point in time it cannot be 
fully concluded that the 56 kDa form of ADAM-10 is specifically localised to the cell 
cytoplasrn!membrane. The presence of ADAM-I 0 in the nucleus raises new questions as to 
what possible role the ADAMs, and in particular ADAM-1 0, might have in PCa. Further, it 
led to the new hypothesis that as PCa progresses, the nuclear localisation observed by IHC, 
might be attributed to the smaller ~54 kDa isoform of mature ADAM-10 as well as the 
unprocessed form of ADAM-I 0. 
For both ADAM-9 and -10 protein expression, their unprocessed higher molecular weight 
forms were universally expressed across each of the cell :fractions and in the whole cell 
lysate of each cell line. However, their processed, presumably catalytically active lower 
molecular weight forms appeared differentially expressed as described above. This 
observation suggests the possibility that, after these ADAMs are processed through the 
Golgi apparatus, they are differentially transported to either the cell membrane or the 
nucleus. Presumably, a pool of ADAM protein might be available after processing and a 
portion of this pool of ADAM protein, depending on its location, might be bound by the 
a/!3-importin protein complex via their NLS (discussed above, Table 3.2), and actively 
transported into the nucleus. 
In the case of ADAM-9, the mature processed form appears to be the same molecular 
weight whether appearing in the cell cytoplasm or in the nucleus. ADAM-10 processed 
mature form, on the other hand, appears to be a different size in different locations within 
the cell. A contributing factor to differential molecular weight analysis is often 
glycosylation. In this study, differentially glycosylated ADAM-10 might as a consequence 
be transp.orted to different cellular locations if, for example, such glycosylation determined 
specific nuclear import system recognition, or where ADAM-10 is secreted :from the Golgi 
apparatus, to a potential docking rendezvous with nuclear import systems. The 
unprocessed form of ADAM-10 would also be indicative of a slightly higher or Iower 
molecular weight, depending on its extent of glycosylation. As this may be the case, data 
generated to date in this study has not uniformly depicted definitive sizes of unprocessed 
ADAM-I 0 across separate cellular :fractions. Both N- and 0- sugar linkages have been 
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characterised on the mature, catalytically active region of ADAM-1 0 (Colciaghi et al. 
2002), see Figure 5.1 for putative glycosylation sites on the ADAM-1 0 primary amino acid 
sequence. Attempts in our laboratory have been made to N-deglycosylate proteins within 
each cellular fraction. However, no changes in molecular weight of either of the isofonns in 
question were seen in subsequent Western blot analysis (data not shown), although these 
experiments need further investigation, as they were not conclusive. 
Another possible explanation for the differences in molecular weights of each ADAM-I 0 
isofonn might be due to differential splicing events, whereby one or more exons might be 
spliced during translation. As the ~54 kDa and ~56 kDa forms are smaiier than the 
predicted Mr of processed ADAM-10 (60 kDa- Figure 3.9 B) this may well be the case. 
Examination of the exon arrangement of ADAM-10 gDNA shows that some exons are in 
the correct reading frame that, if removed, the primary amino acid sequence would not be 
altered down-stream and both the ADAM-I OMet and ADAM-I OCterm antibodies would 
still efficiently detect potential splice variants. 
The observations made across the RWPE-1 and PC-3 cell line models, whilst novel, are 
limited with respect to extrapolating the data generated to the 'in tissue' observations made 
with prostate tissue biopsies. RWPE-1, although derived from normal prostate tissue has 
undergone the usual 'crisis' event involved in the cell immortalisation process. Hence its 
genome consists of greater than 50 chromosomes (Bello et aL 1997), it is an infinite ceiJ 
line in terms of population doublings and its population displays a mixed genotype when 
karyotyping is carried out (Bello et al. 1997). Despite this, RWPE-1 is non-tumorigenic 
when seeded into NUDE mouse models (Bello et aL 1997), unlike PC-3 which forms 
primary tumours (Kim et aL, 2003) setting these two cell types apart sufficiently for the 
purposes of these studies. Given this information, the presence of ADAM-1 0 in the 
nucleus of R WPE-1 may not truly be a reflection of the localisation pattern seen in normal 
prostate epithelial secretory cells as the nuclear expression of this ADAM is less commonly 
seen in normal/hyperplastic prostate glands by IHC. 
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For the first time the expression of ADAM-9 and -10 at the protein level has been shown in 
prostate cell lines indicative of normal (R.WPE-1), androgen sensitive PCa (LNCaP, C4) 
and androgen-insensitive PCa (C4-2, C4-2B and PC-3). These studies also extended our 
previous data pertaining to the expression of ADAM-9 and 10 in primary prostate tumours 
to prostate cancer bone metastases. Furthermore, the cellular localisation of ADAIM-9 and 
-10 in vitro in the contrasting cell line models RWPE-1 and PC-3 has been characterised; 
the potential active forms of both ADAMs are present in the nuclear compartment of both 
of these cell lines. These data suggest both ADAMs to have intrinsic and varied roles in 
normal and pathological states of-the prostate. Further investigation is required to identify 
and correlate the molecular size of each ADAM found in vitro to the prostate gland 
secretory epithelial cells in vivo. 
75 
CHAPTER FOUR: 
4.0 THE DETECTION OF ADAM-9 AND -10 mRNA AND PROTEIN IN CELLS 
ISOLATED BY LASER CAPTURE MICRODISSECTION FROM PROSTATE 
• GLANDSOBTAJJ\TEDATBIOPSY 
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4.1 Introduction 
Laser Capture Microdissection (LCM) is a state of the art technique useful for the isolation 
of a homogeneous cell population from a heterogeneous tissue sample. LCM enables the 
user to scrutinise gene expression within and between individual cell types from tissue 
sections 5 to 8 !lM in thickness (Rubin, 2001). In the case of PCa, which is co:mmonly 
found in small foci in the prostate, the glands within a tissue sample obtained at biopsy may 
be classified by a pathologist as containing normal, hyperplastic and/or tumorigenic 
cells/glands. However, as not every gland within that particular tissue sample will be of a 
common diagnosis, this introduces variability when downstream molecular screening of the 
presence, abundance and different potential alternative transcripts of mRNA, and isoforms 
of proteins of interest is carried out. With the use of LCM, one can isolate individual 
glands of each type for subsequent analysis of their pattern of specific proteins, in this case 
ADAM expression - and minimize the error that cellular/ glandular heterogeneity may 
contribute in this type of study. 
The basic principle ofLCM, illustrated in Figure 4.1, involves placing a Synthetic Transfer 
Polymer (STP), made of Ethylene Vinyl Acetate, in direct contact, overlaying the tissue 
section. With the aid of an appropriate cytological stain, for example, Hematoxylin, the 
epithelial cells of each type of gland can be viewed on a monitor attached to a laser-fitted, 
inverted light microscope. The user is able to guide the laser around each single gland. 
Each time the laser is pulsed, the STP is activated and the cells on the tissue section adhere 
to the polymer. Once the polymer is lifted from the tissue section only the 
activated/adhered region of the tissue, that is, the cells of the gland type of interest, are 
removed. The polymer/adhered cells can then be placed in an eppendorf tube and the 
downstream application of choice (RNA, DNA or protein extraction) can be carried out. 
Previously, ADAM-9 and -10 expression has been examined, firstly by RT-PCR and 
Western blot in nonnal prostate and prostate cancer (PCa) cell lines (Chapter 3) and 
secondly, by Immunohistochemistry (IHC) in prostate tissue (Reviewed in Chapter 1) and 
bone metastases obtained from PCa patients at biopsy (Chapter 3). 
77 
Figure 4.1: Schematic representation of the principle ofLaser Capture Microdissection 
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In the case of the prostate cell lines, readily detectable levels of unprocessed and processed, 
presumably catalytically active, forms of ADAM-9 and -10 were found in cells 
representing normal prostate, androgen-sensitive and late stage androgen-insensitive PCa. 
Examination of expression in tissue sections by IHC suggested that for ADAM-9 a 
decrease in protein levels could be seen as a general trend from prostate glands of the 
benign state to low, through to high-grade carcinoma. In contrast, for ADAM-10, the same 
or increasing levels of protein could be seen from low through to high-grade PCa. 
Furthermore, along with the changes in staining intensity, ADAM-10 showed specific 
nuclear localisation in high grade PCa. Further examination of the expression of both 
ADAM-9 and -10 in prostate secretory epithelial cells might provide more specific 
information as to exactly which isoforms of each ADAM found in prostate cell lines in 
vitro may be present in a prostate gland of a normal, benign, PIN or low to high-grade 
malignant state. 
It was primarily hypothesised that the nuclear expression of ADAM-I 0, seen in high-grade 
prostate cancer by IHC, is the same ADAM-10 isoform (54 kDa) as that seen in the nuclear 
fractions ofboth RWPE-1 and PC-3 cell lines, whilst the benign cells ofthe prostate gland 
might express the isoform found in the cytoplasmic fraction (56 kDa) ofthese two cell lines 
(Chapter 3). A secondary hypothesis was that the two forms of ADAM-9 previously 
detected in prostate cell lines, would also be present in clinical PCa samples. Using LCM 
followed by Western blot analysis, one could elucidate the molecular size of both ADAMs 
- to date only observed in vitro - in tissue from PCa patient biopsies. Further, with respect 
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to our existing IHC data, the particular isoform of each ADAM, to date only observed by 
immunostaining in prostate tissue, may be resolved. 
Therefore, the aims of this chapter were: 
I) To optimise a system using LCM technology to isolate both hyperplastic and 
malignant prostate cells :from patients who underwent radical prostatectomy or 
TURP biopsy, suitable for subsequent protein analysis by Western immunoblotting 
and mRNA analysis by RT-PCR, and 
2) To determine whether ADAM-9 and -10 mRNA and/or protein was detectable in 
material captured from the optimised LCM assays and to examine the molecular 
weight of the subsequently detected protein from homogeneous LCM samples. 
4.2 Methodology and Results 
4.2.1 The optimisation of processing and frxation of prostate tissue obtained at biopsy for 
LCM analysis. 
Processing of prostate tissue obtained at biopsy 
Prostate tissue obtained at biopsy was either formalin-fixed and paraffin embedded and 
stored at ambient room temperature or snap-frozen in Optimal Cutting Temperature (OCT) 
compound, in liquid N2 and stored at -80 °C. A board-certified pathologist assessed each 
biopsy as a particular percentage of benign, PIN or a particular Gleason score of cancer 
(outlined in Chapter 1). The paraffin-embedded prostate tissue was cut into 8 f.!ID sections 
on a microtome and mounted on uncoated microscope slides, dried overnight at 60 °C and 
stored at room temperature to be used for further analysis. 
The OCT embedded frozen tissue was sectioned on a cryotome as follows; Each specimen 
was kept on dry ice until it was transferred into the cryotome cold chamber (-20 °C); the 
cutting temperature of the specimen block was set at -15 °C. Up to 10 sections (8 !lM 
thick) were cut from any given prostate specimen. The sections were transferred and 
adhered to uncoated microscope slides, returned to a slide box embedded and pre-cooled in 
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dry ice. All of the mounted tissue sections coHected were transferred to -80 °C to await 
further processing. Mounted specimens were not used after 7 days of mounting to ensure 
the specimen did not 'over-adhere' to the slide due to dehydration, rendering it not useful 
for LCM applications. 
Western blot analysis of ADAM-9 and -10 from 8 ,aM tissue sections 
To ensure it was possible to detect the small amounts of protein contained in 8 11M sections 
of tissue by Western blot, an initial 'Whole Section Scrape' (WSS} was performed by 
scraping an 8 11M frozen section off its slide with the sterile edge of another microscope 
slide, into a 1.5 ml eppendorftube. 60 111 of protein lysis buffer (50 mM Tris pH 7.5, 150 
mM NaCl, 1% Triton X-100, 0.1 mM PMSF, 10 mM EDTA pH 8.0, I tablet Roche 
complete EDT A-free protease inhibitor cocktail/25 ml) was added to the eppendorf tube 
and the tissue was homogenised by pipette and vortexed vigorously creating a crude 
extract. 20 !ll of the crude extract was combined with 5 11I of 5X Western blot reducing 
loading buffer, boiled for 5 min and loaded on a 10% PAGE gel followed by standard 
Western blot procedure for both ADAM-9 and -10 as outlined in Chapter 2. Figure 4.2A & 
B shows that bands representing ADAM-9 (50 and 70 kDa) and -10 (50 and 82 kDa) are 
readily detectable from an 8 !lffi WSS, with the preliminary observation that each of the 
ADAM-9 and -10 isoforms is present in heterogeneous clinical PCa specimen tissue. 
Fixing and re-hydration of fixed prostate tissue 
The usefulness of formalin-fixed, paraffin embedded tissue for the analysis of ADAM-9 
and -1 0 protein was assessed by testing two conditions. Two tissue sections were de-waxed 
with Shellex, 2 X 5 min, followed by dehydration, 100 % EtOH for 2 min. One of the 
sections underwent further rehydration in 70 % EtOH, 1 min and water. Both sections 
underwent a WSS and were resuspended in lysis buffer. No bands were detected for either 
ADAM-9 or ADAM-10 in subsequent Western blot analysis (Figure 4.2 C&D) 
80 
For :fresh :frozen prostate tissue, each section was fixed for 5 min in ice-cold acetone. One 
was subjected to the re-hydration sche~ule through to water, as descn"bed above, whilst a 
second section was immediately homogenised in protein lysis buffer. Each of these 
procedures was performed in duplicate so that both ADAM-9 and -10 could be examined 
on separate membranes by subsequent Western blotting (Figure 4.2 C&D). 
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Figure 4.2: The detection of ADAM-9 and -10 by Western immunoblot and the subsequent 
effect of fixation and rehydration schedules from formalin fixed and fresh frozen prostate 
tissue sections 
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A) & C) The detection of ADAM-9, ~70 & 50 kDa (using the ADAM-9Dis antibody) and 
B) & D) the detection of ADAM-10, ~54, 56 and 100 kDa (using the ADAM-IOCterm 
antibody) on protein from a whole section scrape (WSS) of a fresh frozen prostate tissue 
section foJlowed by Western blot analysis, described previously. For A) & B), no fixative 
was used, whilst for C) and D), fresh frozen tissue was fixed in ice-cold acetone, whilst 
paraffin embedded tissue was dewaxed in Shellex. Both tissues underwent differential 
rehydrating schedules as described previously. No signal was detected for either ADAM-9 
or -10 from the paraffin embedded prostate tissue sections. 
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4.2.2 The optimisation of histological staining of fixed prostate tissue sections obt'ained at 
biopsy for LCM analysis. 
Subsequently, only ADAM-10 was used for optimisation of Western blot protocols as the 
previous data showed both ADAM-9 and -10 to be comparably detectable from fresh 
frozen prostate tissue sections. 
Although acetone was a successful fixative on :fresh frozen tissue for subsequent Western 
blot analysis, ice cold ethanol (EtOH) fixation was subsequently chosen as the preferred 
method, as this is more commonly used for LCM and it was anticipated that it would give a 
better histological resolution with subsequent staining protocols. A fresh frozen tissue 
section was fixed in 70 %ice cold EtOH, 15 sec followed by a WSS and Western blot 
analysis. Figure 4.3A shows that ADAM-I 0 was detectable after EtOH fixation and further 
staining schedules using this type of fixation were therefore carried out. 
In order to optimise the staining of ethanol fixed fresh frozen tissue sections several 
different staining schedules were examined, including the following stains: Methylene blue, 
H&E and Histogene, a commercial stain available from Arcturis Engineering. 
Methylene blue & H&E staining 
EtOH fixed fresh-frozen sections (described above) were subjected to staining with 
Methylene blue dye according to the following schedule 70 % EtOH, 15 sec, sterile 
distilled water (SDW), 15 sec, 1 % Methylene blue, 30 sec, 70 % EtOH, 15 sec, 90 % 
EtOH, 15 sec, 100% EtOH, 15 sec. 
The above Methylene blue staining schedule was performed alongside a rapid H&E stain 
whereby the following protocol for H&E staining was performed; 15 second steps were 
used for all of the following reagents in the order, 70% EtOH, SDW, Mayers Hematoxylin, 
SDW, Scotts water (dH20, pH 8.0), SDW, Eosin, SDW, 70% EtOH, 90% EtOH, 100% 
EtOH. 
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Figure 4.3: Detection of ADAM-I 0 protein from fresh frozen prostate tissue sections, 
which underwent differential histological staining treatments 
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Western blot analysis of ADAM-10 (ADAM-lOCterm antibody) on protein from fresh 
frozen prostate tissue sections fixed in ice-cold ethanol (A) or Methylene blue, in 
comparison with H&E staining schedule (B). The Methylene blue staining schedule, as 
described above, was found to be the optimal stain for ADAM-10 detection as clearer 
bands could be detected than those after H&E staining (B). 
84 
One section was processed through the whole H&E protocol, whilst one omitted the 
Hematoxylin step and another omitted the Eosin step. One slide was cover-slipped 
(DEPEX) for visualisation under the light microscope whilst the other slides were subjected 
to a WSS and Western blot analysis (Figure 4.3 B). AH of the solutions used for Methylene 
blue and H&E staining contained 50 mM EDTA, 0.1 mM PMSF and IX EDTA free 
complete protease cocktail inhibitor (Roche). 
Histogene 
Histogene (Arcturis Engineering), a commercially available stain of which the contents are 
a trade secret, was purchased. Histogene was designed for the application of rapid staining 
for LCM applications, specifically for subsequent RNA extraction. The foilowing 
Histogene staining schedule was carried out; all steps had an incubation time of 30 sec 
except for the Histogene stain, which was 20 sec: 75 % EtOH, SDW, Histogene, SDW, 75 
% EtOH, 95 % EtOH, I 00 % EtOH followed by WSS and Western blot analysis (Figure 
4.4 A). Slides were mounted with DEPEX and cover-slipped for pathologist review. 
Introducing a 'quick-dip' method whereby all of the above reagents were used except the 
SDW, which was omitted in both cases, optimised the Histogene stain further. The fresh 
frozen specimen was immersed and immediately removed from each solution. In the case 
of the Histogene stain, 20 to 100 ul (depending on the size ofthe section) was applied by 
pipette directly onto the tissue section, incubated at room temperature for 5 to 30 seconds 
before the slide was passed to the next solution. AH solutions contained 0.1 mM PMSF, 10 
mM EDTA pH 8.0 and I X Roche complete EDT A-free protease inhibitor cocktail. 
Having established that both the Methylene blue and Histogene stains gave similar, 
acceptable levels ofthe detection of ADAM-10 by Western blot (see Figure 4.3 & Figure 
4.4), each of these two staining schedules were repeated, and the stained sections were 
coverslipped with DEPEX and reviewed by a pathologist. Dr. Kennith Opeskin 
(Department of Pathology, St. Vincent's Hospital, Melbourne) deemed the Methylene blue 
stained prostate tissue section unacceptable to successfully determine prostate pathology, 
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whilst the Histogene stained section was found to be satisfactory (Figure 4.4B) and was 
consequently used in the subsequent experiments in this study. 
4.2.3LCM 
A fresh frozen tissue section was removed from -80 °C and immediately processed through 
the rapid Histogene staining protocol described above, followed by 2 X 5 min incubation in 
Xylene. The slide was allowed to air dry in a fume hood for ~5 min before being 
transported in a closed container to the LCM station. 
The LCM microscope (PixCell® II), manufactured by Arcturus Engineering (California, 
USA), consists of an inverted microscope (Olympus IX-50 Binocular), a class IIIB variable 
output laser (0 - 100 m W), a video imaging camera (High Resolution Panasonic GP-
KR222) and monitor (High Resolution Sony, PVM-1350}. An inbuilt vacuum assists in 
holding the slide in place on the microscope stage and a stage joystick enables the stage, 
and hence, the slide to be easily manoeuvred in an X-Y plane. 
The Histogene stained, slide-mounted prostate tissue section was placed on the microscope 
stage and the vacuum was activated. A 'Capsure' (see Figure 4.1) was placed over, and 
lowered onto, the tissue section with a mechanical arm so that handling of the STP could be 
avoided. Once the prostate glands of the tissue were focussed on the monitor the laser was 
switched to the on position. Three settings: spot size (diameter of the laser fired), 
amplitude (milliwatts) and pulse width (milliseconds) were optimised according to which 
combination of settings gave the best 'wetting' effect (Figure 4.5). Wetting is best 
described in terms of refractive index where, before the transfer polymer is activated, the 
light passing through the specimen is slightly distorted by the transfer polymer giving a 
well resolvable but not optimal image. Once the laser is fired, the polymer is activated and 
it adheres to the cells on the specimen improving the refractive index (amount of light 
distorted) closer to 1.0 (no distortion oflight). The image where 
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Figure 4.4: Morphological examination of Histogene stained fresh frozen prostate tissue 
sections and subsequent Western blot analysis of ADAM-10 from protein extracted from a 
similarly stained tissue section 
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A) The detection of ADAM-10 by Western blot from an EtOH fixed, Histogene- stained, 
fresh-frozen prostate tissue section. B) Morphological examination of fresh frozen, ethanol 
fixed, Histochioce-stained prostate tissue section deemed acceptable by a pathologist to 
assess the pathological state of the prostate glands within. 
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the polymer is activated becomes sharp and crisp and appears 'wet' in contrast to areas not 
activated by the laser. The optimum setting was determined to be: 60 !liD spot size, 
amplitude 40 miniwatts and the pulse width ll 0 milliseconds. 
Once the area of interest, in this case, the epithelial cells around a given prostate gland, 
were adhered to the STP, the Capsure was simpiy lifted off the tissue section with the 
mechanical arm. The cells from the prostate gland were removed from the tissue section 
(Figure 4.6 A & B) with a lifting motion. The STP was briefly placed on the sterile, sticky 
back of an adhesive paper (as recommended by Arcturis Engineering) to remove any non-
specific stromal adhesion (Figure 4.6 B). 
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Figure 4.5: The 'wetting effect' is indicative of optimised LCM settings 
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A photomicrograph of a fresh-frozen tissue, Ethanol fixed and Histogene stained as 
described previously, depicting cancerous glands of the prostate, as determined by a 
pathologist. Note the 'wetting effect', which was achieved by firing overlapping laser spots 
and activating the STP to give a well-resolvable image. 
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Figure 4.6: Photomicrographs of prostate gland secretory epithelial cells before and after 
removal by LCM 
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Photomicrographs of A) Gleason Grade 3 prostate glands, as determined by a pathologist 
before LCM and B) after the secretory cells of the prostate glands were removed by LCM. 
The lumen of the prostate glands and their surrounding stroma remain on the tissue section 
illustrating the capturing of a homogeneous cell population from a heterogeneous tissue 
sample. Stroma that adhered to the polymer non-specifically (B) was removed with a 
sterile sticky back adhesive paper before the specifically adhered tissue underwent 
downstream processing. Diagrammatic representation of the captured PCa glands and the 
non-specific adhesion of stromal tissue are depicted beside each photomicrograph. 
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4~2.4 The cryotomy and LCM of prostate samples obtained at biopsy. 
Prostate tissue biopsies 
Fresh frozen prostate tissue biopsies were obtained from the Bernard O'Brien Institute of 
Microsurgery (BOBIM), St. Vincent's Hospital, Melbourne, Vic. tissue bank or from Dr. 
RA (Frank) Gardiner, Royal Brisbane Hospital, Brisbane Qid. The following table is a 
summary oftissues obtained for LCM studies. 
Table 4.1: A summary of prostate tissue obtained at biopsy. 
SampleiD Pathologists Location and Volume If 
Opinion Indicated In Pathology Report ' 
of Cancer in Prostate Gland 
02R4 Gleason 3+3=6 Approximately 8 % volume of 
the left lateral lobe 
02R6 Gleason 3+4=7 Up to 35 % of the total prostate 
gland 
02R9 Gleason 3+3=6 Left lateral lobe 
02R12 Gleason 3+4=7 15 % right lateral lobe, 10 % left 
lateral lobe 
02R13 Gleason 4+ 3=7 15 %right lateral lobe, 10% left , 
lateral lobe 
RC4-00 Gleason 4+ 3=7 Up to 30% of the total prostate 
gland 
RC9-00 Gleason 4+5=9 Poorly differentiated 
adenocarcinoma through entire 
core 
RC9-99 , Gleason 3+ 3=6 Moderately differentiated 
carcinoma in 5 % 
Table 4.1 indicates each of the fresh frozen tissue samples used in this study, the grade of 
cancer diagnosed, the anatomical location, and the predicted % volume of cancer within the 
prostate. 
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Cryotome sectioning and routine H&E staining of fresh frozen prostate tissue 
The appropriate prostate lobe (if indicated) for each tissue outlined in Table 4.1 was 
subjected to cryotome sectioning as described previously. 25 sections were cut in series, 
mounted on non-coated microscope slides and stored at -80 "C. The first and last section 
from each serial was fixed in ice cold 75 % EtOH, 1 min and underwent routine H&E 
staining as described in Chapter 2. The slides were cover-slipped and mounted using 
DEPEX and examined by a pathologist. Table 4.2 is a summary of the pathologists' 
opinion pertaining to the glands within the initial sectioning of each tissue. 
Table 4.2: The pathologist's histological examination of 8 urn sections initially cut from 
fresh, frozen tissue. 
. SampleiD Pathologists Opinion 
02R4 Hyperplasia 
02R6 . Hyperplasia 
02R9 Gleason 3+ 3=6 
02R12 Seminal Vesical 
02RJ3 Hyperplasia 
RC4-00 Hyperplasia 
RC9-00 Artefact - Diathermic 
RC9-99 Hyperplasia 
As illustrated in Table 4.2, only the 02R9 sample had cancerous glands within the tissue 
section, all the other samples contained hyperplastic glands, contrary to the previously 
reported presence of high grade cancer illustrated in Table 4.1. The RC9-00 sample was 
artefactual due to incorrect temperature processing at biopsy (in the pathologists opinion). 
Each lobe of interest except 02R9 was subjected to further cryotomy using the opposite side 
of the tissue as the cutting template, than was used previously. Again, 25 more sections 
were cut in serial from each tissue of which the first and last section was EtOH fixed and 
underwent routine H&E staining followed by examination by a pathologist. Table 4.3 
summarises the pathologist's second report. 
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Table 4.3: The pathologist's histological examination of 8 !liD sections subsequently cut 
from fresh, frozen tissue. 
SampleiD Patholo2ists Opinion 
02R4 Hyperplasia 
02R6 Hyperplasia 
02R9 Gleason 3+3=6 
02R12 Gleason Grade 3+ 3=6 
02R13 Hyperplasia 
RC4-00 Hyperplasia 
RC9-99 Hyperplasia 
As shown in Table 4.3, cancer glands were present in an additional sample 02R12, and still 
present in 02R9, whilst the glands in the rest of the samples remained diagnosed as 
hyperplastic. 
Further cryotomy was performed on biopsies from both the same and opposite lateral lobes 
for samples 02R4, 02R6 and 02RI3. Although additional tissue for RC4-00 and RC9-99 
was not available, the remaining tissue was sectioned through to completion. Surprisingly, 
no cancer glands were subsequently found in any of the lobes subjected to further 
examination. These observations are indicative of the very small foci in which PC a glands 
are located within the prostate tissue as a whole. Only a small amount of the available 
biopsy material actually contained prostate glands tumorigenic in nature. This result was 
somewhat surprising and limited this particular study. In this particular archive, ~40% of 
samples taken from the whole prostate are found to contain PCa by the pathology 
department (Personal Communication, Dr. Elizabeth Williams, Senior Scientist, BOBIM). 
Although it was now not plausible to anticipate a sound comparison of expression analysis 
of either ADAM-9 or -10 between prostate glands of differing pathological states, 
important information regarding the molecu]ar size of both ADAMs in a homogeneous 
population of secretory epithelial cells from prostate glands could still be obtained. 
93 
4.2.5 LC~ protein and RNA extraction from cryosectioned prostate tissue 
Isolation of protein from tissue sections by Laser Capture Microdissection 
Tissue sections from each of the samples represented in Table 4.3 underwemt rapid 
Histogene staining as described above, followed by subsequent LCM processing. Before 
and after photomicrographs were taken of the process of capturing and removing the 
secretory epithelial cells from the prostate glands of interest in each section. This enabled 
the assessment of efficiency of the removal of these ceUs from each microdissected tissue 
section as well as reference photographs for a pathologists review at a later date. Once the 
STP was lifted from the tissue section, the mechanical arm was swung on a hinge to a 'via] 
capping station' where a 0.5 ml eppendorftube containing 40 111 of protein lysis buffer was 
loaded. The Capsure was clipped into the top of the eppendorf tube creating an airtight 
seal, inverted so that the lysis buffer was in direct contact with the captured cells on the 
STP and placed immediately on ice. The whole procedure, from Histogene staining to 
placing the captured ceHs on ice, took approximately 1 h. The eppendorf tube was stored 
on ice for up to 3 hours to await further processing whilst subsequent tissue underwent 
LCM. Initially the eppendorf tube containing the Capsure was vortexed vigorously for 5 
min followed by centrifugation at 10 000 X G for I 0 min. 
Examination of the Capsure under a light microscope revealed that a high percentage of 
tissue remained adhered to the transfer film. Therefore, an additional sonication step (high 
frequency water bath sonication) by the submersion of the Capsure/eppendorf tube, 2 min 
was performed at room temperature, followed by vigorous vortexing, 2 min and a 30 min 
centrifugation (1 0 000 X G), 4 °C. Examination of the Capsure under the light microscope 
showed that 100 % of the captured cells had been removed from the transfer film by this 
method. Once the Capsure was removed from the eppendorf tube, the captured ceHs were 
briefly homogenised by pipette. The resultant protein extract was stored at -80 °C to await 
further analysis. 
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Isolation of RNA from tissue sections by Laser Capture Microdissection 
The prostate samples 02R9 and 02Rl2 were processed through rapid Histogene staining as 
described above and subjected to LCM, with benign and cancer glands from the same tissue 
section being isolated in two separate LCM runs. Two paraffin embedded, formaiin fixed 
tissue sections were de-waxed in xylene 2 X 5 min and also rapid stained with Histogene 
and subjected to the same kind of LCM processing. Upon isolation of each prostate 
gland/cell type, the Capsure was placed into a 0.5 ml eppendorf tube containing RNA 
extraction buffer (XB) (PicoPure Isolation Kit, Arcturus Engineering). Total RNA was 
extracted as per the manufacturer's protocoL Briefly, the eppendorftube was inverted so 
that the XB covered the transfer film and incubated at 42 °C for 30 min. A centrifugation 
step collected the XB containing the LCM material from the transfer film into the bottom of 
the eppendorf tube. Ethanol was added to the RNA extract and the solution was applied to a 
spin column, provided by the manufacturer. The column containing bound RNA was 
washed 3 times by centrifugation with provided wash buffers and eluted into a separate 
eppendorftube by centrifugation, 2 times each with II 111 of elution buffer, collected in the 
same eppendorftube (total volume= 22 !ll) and stored at -80 °C to await further analysis. 
Protein and RNA material available for downstream LCM analysis 
The small number and amount of initial sample available from this study, followed by the 
clear absence of cancer in many of the available lobes of the prostate tissue, infringed on 
solid outcomes of this study. Nonetheless Table 4.4 summarises the samples that were 
obtained from LCM. These samples were used for optimisation and examination in the 
appropriate downstream processing (Western blot analysis or RT -PCR) described above. 
Enough material was available to carry out pilot experiments for Western blot and RT-PCR 
analysis of ADAM-9 and -10. Availability was however, limited and as this experiment 
was performed in a collaborative laboratory, geographically distant from QUT, time did not 
permit the collection and analysis of further prostate tissue biopsies. 
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Table 4.4: Samples obtained from LCM for use in downstream applications. 
SampleiD # Benign # Cancer #Benign RNA # Cancer RNA 
Protein Protein Samples Samples 
Samples Samples 
02R4 4 .. .. .. 
02R6 2 .. .. .. 
02R9 1 4 1 1 
02Rl2 4 2 2 2 
02Rl3 )2 .. .. .. 
RC4.00 1 .. .. -
RC9.99 4 .. - -
Wax - .. 1 1 
Embedded A 
Wax .. .. 1 1 
EmbeddedB 
Table 4.4 represents the material collected from LCM experiments performed at BOBIM, 
Melbourne, Vic. Australia. 
The material outlined in Table 4.4 was, however, enough to determine the possibility of 
detecting each ADAM of interest in LCM acquired material and to make preliminary 
observations as to the corresponding molecular weight of ADAM-9 and -10 in a 
homogeneous cell population of prostate glands. 
4.2. 6 Downstream processing of protein and RNA isolated from prostate tissue samples 
byLCM. 
Western blot analysis of ADAM-9 and -10 
20 f.!l of protein extract isolated from each sample described above was combined with 5 [.tl 
5 X Western blot reducing loading buffer and boiled for 3 min, loaded onto an SDS-PAGE 
gel followed by standard Western blot procedure (Chapter 2). ADAM-9Cterm (0.025 
[.tg/ml), ADAM-9Dis (0.5 [.tg/ml) and ADAM-IOMet (0.05 f.!g/ml) or ADAM-lOCterm (0.5 
[.tg/mi) was used as primary antibody. Each blot was incubated with primary antibody 
overnight at 4 °C, followed by 4 X 5 min washes in TBS Tween20 (0.05%). Anti-rabbit 
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HRP (Dako) was used at the concentration of 0.2 11g/ml in a 2 h incubation at room 
temperature, followed by a further 4 X 5 min wash in TBS Tween20 (0.05%}. FEMTO 
(Pierce) chemiluminescent substrate was used to detect signal by autoradiography on an X 
ray film. RWPE-1 or PC-3 prostate cell lines were run on each Western blot to serve as a 
positive controL A pre-stained protein marker (Biorad) was used to determine molecular 
weight by direct comparison of migration distances. 
Reverse Transcription- Polymerase Chain Reaction (RT-PCR) of fJ-actin, ADAM-9 and-
10 expression from LCM RNA samples 
9 ~-tl of each RNA extraction sample, described above, was reversed transcribed with 
Superscript II (Invitrogen) using random decamers and oligodT priming. 5 flg of LNCaP 
total RNA was used as a positive RT controL Reverse transcription was carried out at 43 °C 
for 2.5 h. PCR was carried out using f)-actin, ADAM-9 or ADAM-10 primers (McCulloch 
et al. 2000) in a standard PCR reaction (Chapter 2) increasing the amount of cycles to 60 
and using 2 11I of eDNA as a template. The PCR product was run on a 2 % agarose EtBr 
gel and visualised under a UV lamp. The size of the PCR product was determined by 
comparison to molecular weight marker IX (Roche) run alongside the PCR products on the 
same geL 
4.1. 7 Western blot analysis of ADAM:...9 and -10 
ADAM-9 and -10 proteins were both detected in protein samples obtained by LCM. For 
ADAM-9, bands at ~70 kDa and ~50 kDa were detected in the 02R9 (cancer) sample with 
the ADAM-9Cterm antibody (Figure 4.7 A) which correspond to some of the bands 
detected in the R WPE-I whole cell lysate (positive control), whilst higher molecular weight 
bands ~85 - 90 kDa were detected in RC4.00 and 02R4 (benign) samples (Figure 4.7 B) 
using the ADAM-9Dis antibody. Unlike the previous ADAM-9 Western blots performed 
with the ADAM-9Dis antibody in the previous chapter, the ADAM-9Cterm antibody 
showed additional higher molecular weight bands in the R WPE-1 whole ceil lysate 
preparation used in this experiment. The identity of these bands is not yet known. 
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For the ADAM-lOMet antibody, clear bands were detected at ~54 kDa and ~56 kDa in the 
02R12 and 02R4 (benign) samples (Figure 4.7 C) and the 02R9 cancer sample (not shown-
too faint), which correspond to bands detected in the RWPE-1 positive control cell line, as 
well as bands detected in WSS specimens run alongside the LCM protein extracts. 
Additional lower molecular weight bands ~30 kDa could also be seen in each WSS and 
may represent smaller processed ADAM-I 0 fragments possibly found in the stroma but not 
in the epithelial cells ofthe prostate gland. Higher molecular weight bands ~100 kD·a were 
also detected, although very faintly (Figure 4.7 C). The ADAM-I OCterm antibody detected 
bands of similar size in RC4.00 and 02R12 (benign protein samples) (Figure 4.7 D). 
4.2.8 RT-PCR analysis of [3-Actin, ADAM-9 and ADAM-10 
Using i)-Actin primers, which span an intron, clear PCR products were detected in 02Rl2 
(benign), 02R9 (benign) and 02R9 (cancer) samples, however, no PCR product was 
visualised from RNA extracted from formalin fixed, paraffin wax embedded prostate tissue 
or from 02Rl2 (cancer) (Figure 4.8 A). The eDNA was free of genomic DNA (gDNA) 
contamination as determined by the absence of a higher molecular weight band, which 
would otherwise represent an intronic sequence in the !3-Actin gene. PCR products of the 
expected size for both ADAM-9 and -10 (Figure 4.8 A & B) were successfully detected in 
the same samples as the [3-Actin PCR products, using primers described previously 
(McCulloch et al. 2000). 
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Figure 4.7: Western Immunoblot ofLCM acquired protein for ADAM-9 and -10 
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Western blot analysis for LCM samples (Table 4.4) for ADAM-9: A) bands were detected 
~50 to ~70 kDa with the ADAM-9Ctenn antibody and B) ~85 to ~90 kDa with the ADAM-
9Dis antibody. RWPE-1 was used as a positive controL For ADAM-10: C) bands were 
detected ~54 kDa and ~56 kDa and 100 kDa with the ADAM-IOMet antibody and D) 
bands of similar sizes were detected with the ADAM-IOCterm antibody. Corresponding 
WSS were run alongside the LCM material as well as the positive control cell line RWPE-
1. 
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Figure 4.8: RT-PCR showing !3-Actin, ADAM-9 and ADAM-10 eDNA transcripts from 
LCM acquired RNA 
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Figure 4.8: All PCR products for !3-Actin (A), ADAM-9 (B) and ADAM-10 (C) were 
successfully detected in eDNA from LCM processed fresh-frozen tissue except 02R12 
(Cancer). No PCR products could be detected from eDNA from LCM processed formalin 
fixed, paraffin embedded tissue. The size of the PCR product was determined by molecular 
weight marker IX (Roche) run alongside each PCR product on a 2% agarose EtBr gel and 
visualised under a UV lamp. Each eDNA sample positive for !3-Actin was free of gDNA 
contamination as determined by the !3-Actin primers that cross an intron. LNCaP cell total 
RNA was used as a positive RT-PCR control in which all three genes were also 
successfully detected. 
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4.3 Discussion 
Laser Capture Microdissection (LCM) enables the isolation and enrichment of specific cell 
types within a heterogeneous tissue sample. This approach has been previously used 
successfully to identify differences in gene expression pro:fiJes between hyperplastic and 
cancer glands from the prostate (Paweletz et al. 2001). These studies used subsequent 
downstream analysis such as 2-D PAGE gel analysis, SELDI- and MALDI-TOF (protein 
molecular weight spectra analysis), mRNA expression by real time PCR and Microarray 
analysis (Xu et al. 2002; Rubin et al. 2001). Despite the abovementioned protein analytical 
approaches, the application of the Western blot used in conjunction with LCM, is relatively 
uncommon, despite the information this type of analysis may add to studies such as these. 
Just two studies, by a single research group, have used LCM in this fashion to examine the 
detectability of the well-characterised PCa marker Prostate Specific Antigen (Ornstein et al. 
2000). The current study represents the first demonstration of ADAM family members at 
both the mRNA and protein level, in LCM-derived prostate epithelial glands. 
PCa glands are commonly present in small, defined foci within prostate tissue. At the time 
of biopsy, several tissue samples are taken from anatomically different locations within the 
prostate so as to increase the chances of the successful detection of any PCa, which may or 
may not be confined within the prostate. The extensive cryotome sectioning of the prostate 
tissue obtained at biopsy in this study, reinforced the difficulty of locating cancerous glands 
within the prostate. Despite having available several tissue samples from each of the left 
and right lateral lobes of the prostate, which were initially diagnosed with the presence of 
high-grade PCa glands, cancer could be found in only two out of an initial eight biopsies. 
A requirement for this type of study is the analysis of carefully defined specific regions 
within the diseased prostate. Nonetheless, eight separate biopsies provided a good source 
of normal/hyperplastic prostate glands, and on occasion, cancerous glands, sufficient to 
develop a suitable approach for analysing gene expression by LCM in the secretory 
epithelial cells of prostate glands. 
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A LCM protocol was developed which enabled the isolation of both protein and RNA from 
homogeneous ceil types in PCa glands :from prostate tissue characteristic of the benign and 
malignant disease. Further, it was demonstrated that mRNA could be detected at suitable 
levels for subsequent real time PCR analysis. Importantly, the detection of ADAM-9 and-
I 0 protein from LCM samples by Western blot analysis was also effectively achieved, 
although the molecular weights of the bands detected in some cases, outlined below, varied 
somewhat :from those molecular weights detected in cell lines previously studied in Chapter 
3 and may represent prqcessing that has occurred throughout the LCM procedure. 
To this stage, this particular study has not had access to enough individual fresh frozen 
prostate patient specimens, nor sufficient material to allow for adequate replicates to 
provide a valid comparison of ADAM-9 or -10 between benign and malignant states of the 
prostate. However, preliminary data obtained clearly indicates that the protocol developed 
will be suitable to extend this study further. The current data obtained by Western 
immunoblot analysis, however, do provide information as to the molecular size of each 
ADAM present in homogeneous ceil populations of the prostate gland and warrants a short 
!liscussion. 
for ADAM-9, a clear band was detected, firstly with the ADAM-9Cterm antibody at -60 
tmd -70 kDa and subsequently with the ADAM-9Dis antibody at -85 to -90 kDa. Each of 
these bands corresponded to bands detected in the RWPE-1 prostate. cell line. The larger 
molecular weight bands may represent the m:-processed, inactive form of ADAM-9 whilst 
the intermediate and lower molecular weight bands may represent partly processed and 
fully processed mature active forms of ADAM-9 respectively. 
No specific role for ADAM-9 has been determined as yet, although it has been shown to be 
an active membrane-bound metalloprotease, as well in being secreted as a soluble form. As 
outlined in Chapter 1, ADAM-9 is able to cleave peptide sequences mimicking cell surface 
protein cleavage sites such as those in p75 TNFR, TNF a and ~-Amyloid Precursor Protein 
(P-APP) (Roghani et al. 1999). However, in vivo data has not yet been obtained in respect 
to this proposed role. ADAM-9 is also able to degrade gelatin and fibronectin 
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(extracellular matrix substrates) in vitro (Schwettmann and Tschesche, 2001). Additionally, 
its disintegrin domain is able to bind particular integrins involved in cell-cell and cell-ECM 
interactions such as a6!H (Zhou et al. 2001). It is therefore entirely possible that ADAM-9 
and other ADAMs, due to their multifunctional domain composition, may perform a variety 
of roles in PCa cells and that those roles may differ during the multiple stages of PCa 
progression. 
In the case of ADAM-10, the ADAM-IOMet antibody detected clear bands at ~54 and ~56 
kDa, which corresponded to the size of ADAM-1 0 found in nuclear and cytoplasmic 
fractions, respectively, ofboth RWPE-1 and PC-3 prostate cell lines (Chapter 3). Larger 
molecular weight bands up to ~100 kDa were also detected with both the ADAM-lOCterm 
and ADAM-lOMet antibodies possibly representing unprocessed, partly processed or 
different isoforms ofunprocessed ADAM-10. 
Active ADAM-10 is known to carry out the defmitive but shared task in vivo (with ADAM-
17), of solubilising pro TNF a; (Blobel, 1997; Rosendahl et aL 1997) and the cleavage of ~­
APP (Buxbaum et al. 1998; Lammich et al. 1999). Another study has shown that bovine 
ADAM-10 can cleave collagen type IV (a basement membrane and extracellular matrix 
protein) (MiHichip et al. 199&). Each of these roles, and others outlined in Chapter 1, has so 
far focussed on metalloprotease activity on the cell surface. 
It was found by LCM that the secretory epithelial cells of prostate glands express what 
appear to be cytoplasmic and nuclear specific isoforms of ADAM-I 0, as detected in 
previous subcellular fractionation studies (Chapter 3). These isoforms each contain the N-
terminal domain of the mature, catalytically active protein, as determined by a site-specific 
antibody. A new question has now arisen as to what roles active ADAM-10 may have in 
the cell nucleus. Given the consistent observation by IHC that ADAM-10 re-iocalises to 
the nucleus in high-grade cancer, when compared to benign and low-grade cancer glands in 
the same tissue section (See Chapter I), it is likely that, as discussed for ADAM-9, ADAM-
10 may have differential roles through the stages ofPCa development. 
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LCM has enabled us to directly compare observations from prostate cell lines in vitro to 
homogeneous cell populations from glands of the prostate in clinical specimens. Also, 
especially with respect to ADAM-I 0, LCM has allowed us to correlate data acquired by 
IHC and sub-cellular fractionation and its apparent nuclear ADAM-I 0 localisation, to the 
molecular size ofthe ADAM-10 protein found in the secretory cells of the prostate glands. 
Further studies using a larger population set and more replicates are required, so that any 
difference in the pattern of expression for both ADAM-9 and -I 0 mRNA and protein can be 
properly examined between homogeneous populations of normal, hyperplastic and 
cancerous secretory cells of the prostate gland. 
LCM is a powerful tool, which gives rise to important information with respect to gene 
profiling between differing normal and pathological states of glands within tissues and 
organs. Although the optimisation of such assays is a lengthy process and the mRNA or 
protein yield can be very limiting, the investment in time is worth the acquisition of novel 
data, such as those acquired by this technique in this particular study. With more sensitive 
and effective methods of molecular analysis emerging,. LCM has sound applications in 
downstream processing and gene profiling experiments and perhaps the diagnosis of 
pathological disease states. 
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CHAPTER FIVE: 
5.0 THE CLONING AND OVER EXPRESSION OF FULL LENGTH ADAM-10 IN 
PROSTATE CELL LINES 
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5.1 Introduction 
The previous two chapters have established the expression status of both ADAM-9 amd -10 
in a range of normal prostate and prostate cancer (PCa) cell lines, prostate tissues and bone 
metastases. Both ADAM-9 and -10 were expressed at readily detectable levels in PCa cen 
line models that mirror characteristic of androgen-sensitive and androgen insensitive 
prostate cancer. The processed forms corresponding to the molecular weight of 
catalytically active ADAM-9 and -1 0 were detected by Western blot analysis in both the 
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normal prostate and PCa cell lines and were also found to be variously localised in the cell 
nucleus; cytoplasm/membrane and in extracellular, plasma membrane vesicles. These 
observations provide significant but as yet poorly studied opportunities for both ADAMs to 
display many potential functions within and outside the cell. 
As reviewed in Chapter 1, the functions of ADAM-10 that have been described to date, 
include "sheddase" activity at the ceH surface, whereby ADAM-I 0 can cleave the 
ectodomains of membrane-bound proteins such as TNF a and f3APP (Blobel, 1997; 
Rosendahl et al. 1997; Lammich et al. 1999). Given that we have described the localisation 
of both ADAM-9 and -I 0 in the ce1I nucleus and in extracellular membrane vesicles, it is 
likely that these ADAMs have additional but distinct functional roles, beyond cell surface 
sheddase activities. The presence of metalloprotease activity, essentially as a soluble 
protease in the case of membrane vesicle expression, gives rise to potential ECM 
degradation activity, which may impact on cell invasive and migratory properties. This is 
especially pertinent with respect to ADAM-9 and -10, which, as reviewed in Chapter I, can 
degrade fibronectin and coHagen respectively, in vitro (Schwettmann and Tschesche, 2001; 
Millichip et al. 1998). With ;respect to the nuclear localisation, the function of ADAM-9 or 
-I 0 proteins is not yet known. 
A common and accepted approach for showing the functional consequences of proteins 
with respect to cellular behaviour is to under - or over-express them in suitable, relevant 
cell models. In the case of the prostate, the normal (RWPE-I) and the metastatic (PC-3) 
prostate cell lines, in which we have already described both ADAM-9 and -10 localisation 
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to the nucleus, cytoplasm/membrane and shed membrane vesicles, provide good in vitro 
models to examine the function ofboth of these ADAMs. 
ADAM-1 0 was chosen in this particular study because of the previous observations that 
ADAM-I 0 appears to show increased expression in high-grade cancer glands. Further to 
this, a clear shift in localisation from the cell membrane to the nucleus of prostate tumour 
cells suggests that ADAM-10 has roles in late-stage cancer that may be related to 
transcriptional events, which may lead to abnormal cellular behaviour. Full-length ADAM-
I 0 mammalian expression constructs should provide good molecular tools for stimulating 
cell lines to express elevated levels of this protein. Over-expression of active AD AM-I 0 in 
differing non-tumorigenic and tumorigenic PCa cell lines win provide information about 
the function of these proteins in PCa through the use of subsequent functional assays such 
as cell invasion, adhesion and migration, as well as micro-array analysis. 
The aims of this chapter were 
I) To clone full length ADAM-10 eDNA into non-inducible and inducible mammalian 
expression vectors, and 
2) To test each full length clone's efficiency, with respect to its ability to be over 
expressed in prostate cell lines by means of transient transfection. 
A number of technically challenging problems were encountered at the onset of, and 
throughout, this part of the overall study. Such problems included, initially, difficulty in 
obtaining enough ADAM-I 0 PCR product for subsequent cloning activities, followed by 
the failure of several different cloning strategies, which were attempted numerous times. 
Through a logical approach to these problems, two ADAM-IO full-length mammalian 
expression vector constructs were eventually created. These were used to test for ADAM-
10 over-expression in prostate cell lines by way of transient transfection. Hence, this 
chapter describes the optimisation activities carried out for the successful attainment of 
each aim. Due to time constraints the studies could not be extended to the ultimate 
intended goal - of carrying out ADAM-I 0 functional studies in cell invasion, adhesion and 
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migration assays. Information obtained from the current studies does however, set a basis 
fo~ future studies to be carried out in this area. 
5.2 Methodology and Results 
5.2.1 The design of ADAM-10 primers for full length eDNA amplification and 
sequencing 
The primary mRNA sequence for ADAM-10 was retrieved from Genbank (accession 
number NM _ 00 Ill 0) and subjected to restriction enzyme site analysis {WEB AN GIS) to 
determine which common restriction enzyme sites did and did not fall within its primary 
sequence. The restriction enzymes Hindiii and Xhol were chosen for the forward and 
reverse primers respectively, as they did not cut full length ADAM-10 and were matched to 
the multiple cloning sites (MCS) of the chosen mammalian expression vectors pcDNA3.1 
and pMEP4 (Appendix Two). The forward (sense) primer for ADAM-10 was designed 5' 
to the naturaUy occurring Kozak sequence of ADAM-10 (GAAAGaugG); and the reverse 
primer (antisense) encompassing the upstream natural 3' stop codon. The appropriate 
restriction enzyme sites were incorporated in each primer by mutating the minimum 
number ofbases in the primary mRNA sequence of ADAM-10 (Figure 5.1). Forward and 
reverse sequencing primers were also designed every 300 bp along the full-length ADAM-
10 primary sequence for subsequent PCR and sequencing analysis (Figure 5.1). 
5.2.2 ADAM-I 0 full-length transcript PCR 
Initially, 5 11g of mRNA from PC-3 cells was reversed transcribed with 500 ng oligodT or 
SOOng gene specific (ADAM-IOXhoR) priming. The oligodT primed RT was screened for 
gDNA contamination as described in Chapter 2. A lambda prostate library was also 
purchased (Promega). To check for the attainment of amplifiable full-length eDNA, 
platinum Taq DNA polymerase (Life Technologies) was used initially, with the 
understanding that once the PCR was optimised, a proof reading system would be 
employed. Each of the two templates (PC-3 eDNA and the prostate library) was used in 
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the following PCR protocol: 95 °C (5 min), 40 cycles: 95 °C (30 sec), 50 °C (30 sec), 72 °C 
(3 min), with a final incubation of 72 °C (1 0 min) with the final magnesium concentration 
of 1, 2, 3 or 4 rnM with 200 nM forward and reverse primer. No bands were seen for either 
of the templates PC-3 eDNA (Figure 5.2), or the lambda prostate eDNA library (Figure 
5.3). 
5.2.3 ADAM-I 0 eDNA cloning 
The result from Table 5.1 and Figure 5.4, allowed the reasonable assumption that a) both 
AlOHindlllF and AlOXhoR efficiently bound to the full length ADAM-10 transcript and b) 
internal sequences of ADAM-10 are present in each of the templates tested. It was a 
surprise however, that full length ADAM-10 could not be amplified from either of the 
templates. Given this information, a variety of templates were tested from mRNA 
extracted from other PCa cell lines including: LNCaP, ALVA-41 and DU-145 eDNA by 
the PCR protocol described above. 
For the PCa cDNAs outlined above, a faint band was seen in AL V A-41 eDNA (too faint to 
be shown). Are-amplification of this PCR product- ALVA-41 (a) was carried out using 
that particular PCR product as a template in one reaction, and the original eDNA, using 4 
(ll instead of 1 !ll in a separate PCR reaction. A band at the expected molecular weight, 2.4 
Kb was clearly visualised in the AL V A-41 (a) PCR product re-amplification and only 
faintly visualised in the original ALVA-41 (a) eDNA (Figure 5.5 A). Each band was 
subsequently gel purified (Life Technologies). The gel-purified products were subjected to 
a nested PCR to confirm the authenticity of the transcript. The nested PCR from internal 
ADAM-10 primers was successful (Figure 5.4 B). Although these bands could be gel 
purified for nested PCR., not enough DNA could be recovered from the gel to be 
successfully quantitated by spectrophotometric analysis, for subsequent cloning activities. 
We did not pursue a re-amplification step as this would greatly increase the risk of 
introducing errors into the eDNA sequence given existing sequence had already been 
amplified through at least 40 cycles. 
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Figure 5.1 Primary sequence of full length ADAM-10 (Genbank accession number 
NM_OOlliO) showing the position offorward and reverse fuU length and sequencing 
primers 
TSS 
-------ADAM-~OHindF------7 M V L L R 
1 TCCCTCCGGATCGATGTGCTGCTGTTAACCCGTGAGGAGGCGGCGGCGGCGGCAGCGGCAGCGGAAGAii'GGTGTTGCTGAGA 
AGGGAGGCCTAGCTACACGACGACAATTGGGCACTCCTCCGCCGCCGCCGCCGTCGCCGTCGCCTTCTACCACAACGACTCT 
V L I L L L S W A A G M G G Q Y G N P L N K Y I R H Y 
B3 GTGTTAATTCTGCTCCTCTCCTGGGCGGCGGGGATGGGAGGTCAGTATGGGAATCCTTTAAATAAATATATCAGACATTATG 
CACAATTAAGACGAGGAGAGGACCCGCCGCCCCTACCCTCCAGTCATACCCTTAGGAAATTTATTTATATAGTCTGTAATAC 
E G L S Y N V D S L H Q K H Q R A K R A V S H E D Q F L 
165 AAGGATTATCTTACAATGTGGATTCATTACACCAAAAACACCAGCGTGCCAAAAGAGCAGTCTCACATGAAGACC.AATTTTT 
TTCCTAATAGAATGTTACACCTAAGTAATGTGGTTTTTGTGGTCGCACGGTTTTCTCGTCAGAGT'GTACTTCTGGTTAAAAA 
·R L D FHA H G R H F N L R M K R D T S L F S DE F K 
247 ACGTCTAGATTTCCATGCCCATGGAAGACATTTCAACCTACGAATGAAGAGGGACACTTCCCTTTTCAGTGATGA.ATTTAAl'. 
TGCAGATCTAAAGGTACGGGTACCTTCTGTAAAGTTGGATGCTTACTTCTCCCTGTGAAGGGAAAAGTCACTACTTAAATTT 
V E T S N K V L D Y D T S H I Y T G H I Y G E E G S F 
329 GTAGAAACATCAAl'.TAAAGTACTTGATTATGATl'.CCTCTCATATTTACACTGGACATATTTATGGTGAAGAAGGA.AGTTTTA 
CATCTTTGTAGTTTATTTCATGAACTA)l.TACTATGGAGAGTATAAATGTGACCTGTATAAATACCACTTCTTCCTTCAAAAT 
~-ADAM-10 
S H G S V I D G R F E G F I Q T R G G T F Y V E P A E R 
411 ----ADAM-lOSeqFl-'7 
GCCATGGGTCTGTTATTGATGGAAGkTTTGAAGGATTCATCCAGACTCGTGGTGGCACATTTTATGTTGAGCCAGCAGAGAG 
CGGTACCCAGACAATAACTACCTTCTAAACTTCCTAAGTAGGTCTGAGCACCACCGTGTAAAATACllACTCGGTCGTCTCTC 
SeqRS---
·Y I K DR T L P F H S VI Y HEDDI NY PH K Y G P 
493 ATATATTAAAGACCGAACTCTGCCAT'l'TCACTCTGTCATTTATCATGAAGATGATATTAACTl'.TCCCCATAAATACGGTCCT 
TATATAATTTCTGGCTTGAGACGGTA."ili:GTGAGACAGTAl'ATAGTACTTCTACTATAATTGATAGGGGTATTTATGCCAGGl'. 
Q G G C A D H S V F E R M R K Y Q M T G V E E V T Q I 
575 CAGGGGGGCTGTGCAGATCATTCAGTATTTGAAAGAATGAGGAAATACCAGATGACTGGTGTAGAGGAAGTAACACAGATAC 
GTCCCCCCGACACGTCTAGTAAGTCATAAACTTTCTTACTCCTTTATGGTCTACTGACCACATCTCCTTCl'.TTGTGTCTATG 
Site of Maturation 
P Q E E H A A N G P E L L R ' ~ S A E K N T C Q L 
657 CTCAAGAAGAACATGCTGCTA.ATGGTCCAGAACTTCTGAGGAAAAAACGTACAACTTCAGCTGAl'.Al'_"ili.ATACTTGTCAGCT' 
GAGTTCTTCTTGTACGACGATTACCAGGTCTTGAAGACTCCTTTTTTGCATGTTGA.AGTCGACTTTTTTTATGA.ACAGTCGA 
· Y I Q T D H L F F K Y Y G T R E A V I A Q I S S H V K 
739 TTATATTCAGACTGATCATTTGTTCTTTAAATATTACGG.l'.ACACGAGA..I>.GCTGTGATTGCCCAGATATCCAGTCA.TGTTAAA 
A.ATATAAGTCTGACTAGTAAACAAGA.AATTTATAATGCCTTGTGCTCTTCGACACTAACGGGTCTATAGGTCAGTACA.ATTT 
~--ADAM-10Se.qR4' Glyc. 
A I D T I Y Q T T D F S G I R Ni'· y· t?: F M V K R I R I N' 
---ADAM-10SeqF2--> 
B21 GCGATTGATACAATTTACCAGACCACAGACTTCTCCGGAATCCGTAACATCAGTTTCATGGTGAAACGCATAAGAATCAATA 
CGCTAACTATGTTA.l'\A:TGGTCTGGTGTCTGAAGAGGCCTTAGGCATTGTAGTCA.AAGTACCACTTTGCGTATTCTTAGTTAT 
Glyc. 
T .· 'if. A D E K D P T N P F R F P N I G V E K F L E 1 N S E 
9{)3 CAACTGCTGATGAGAAGGACCCTACAAATCCTTTCCGTTTCCCA.Al'.TATTGGTGT'GGAGAAGTTTCTGGAATTGA.ATT'CTGA 
GTTGACGACTACTCTTCCTGGGATGTTTAGGAAAGGCAl'JIGGGTTTATA.ACCACACCTCTTCAAAGACCTTAACT'I'AAGACT 
· Q N H D D Y C L A Y V F T D R D F D D G V L G L A. W V 
9B5 GCAGA.ATCATGATGACTACTGTTTGGCCTATGTCTTCACAGACCGAGATTTTGATGATGGCGTACT'I'GGTCTGGCTTGGGTT 
CGTCTTAGTACTACTGATGAC~.AACCGGATACAGAAGTGTCTGGCTCT~~CTACTACCGCATGA.ACCAGACCGA.ACCCl'.A 
G A P S G S S G G I C E K S K L Y S D G K K K S L N T 
1067 GGAGCACCTTCAGGAAGCTCTGGAGGAATl'.TGTGAAAAAAGTAAACTCTATTCl'.GATGGTAAGAAGAAGTCCTTAA.~C.~CTG 
CCTCGTGGAAGTCCTTCGAGACCTCCTTATACACTTTTTTCATTTGAGF.TAAGTCTACC.l'.T'I'CTTCTTCAGGAATTTGTGAC 
G I I T V Q N Y G S H V P P K V S H I T F A H E V G H N 
1149 GA.ATTATTACTGTTCAGAACTl'.TGGGTCTCATGTACCTCCCA.AAGTCTCTCACATTACTTTTGCTCACGA.~GTTGGACATAA 
CTTAATAATGACAAGTCTTGATACCCAGAGTACATGGAGGGTTTCAGAGAGTGTA.ATGA.AAACGAGTGCTTCAACCTGTATT 
~--ADAM-10SeqR3-
. F G S P H D S G T E C T P G E S K N L G Q K E N G N Y 
---ADAM-10SeqF3---7 
IIO 
1231 CTTTGGATCCCCACATGATTCTGGAACAGAG"..'GCACACCAGGAGAATCTAAGAATTTGGGTCAAAAAGAAAATGGCAATTAC 
GAAACCTAGGGGTGTACTAAGACCTTGTCTCACGTGTGGTCCTCTTAGATTCTTAAACCCAGTTTTTCTTTTACCGTTAATG 
G~yc. 
I M Y A R A T S G If K L N N N K F S L C S I R i)l. ';" ·s, Q 
1313 ATCATGTATGCAAGAGCAACATCTGGGGACAAACTTAACAACAATAAJ..TTCTCfi.CTCTGTAGTATTAGAAfi.TATAAGCCAAG 
TAGTACATACGTTCTCGTTGTAGACCCCTGTTTGAATTGTTGTTATTTAAGAGTGAGACATCATAATCTTTATAT'l'CGGTTC 
V L E K K R N N C F V E S G Q P I C G N G M V E Q G E E 
1395 TTCTTGAGAAGAAGAGAAACAACTGTTTTGTTGAATCTGGCCAACCTATTTGTGGAAATGGAATGGTAGAACAAGGTGAAGfl. 
AAGAACTCTTCTTCTCTTTGTTGACAAAACAACTTAGACCGGTTGGATAAACACCTTTACCTTACCATCTTGTTCCACTTCT 
·CDC G Y S D Q C K DEC C FDA N Q PEG R K C K L 
14 7 7 ATGTGATTGTGGCTATAGTGACCAGTGTAfi.AGATGAATGCTGCTTCGATGCA.l\ATCAACCAGAGGGAAGA.l\AATGCAfi.ACTG 
TACACTAACACCGATATCACTGGTCACATTTCTACTTACGACGAAGCTACGTTTAGTTGGTCTCCCTTCTTTTACGTTTGAC 
~--ADAM-10SeqR2--
K P G K Q C S P S Q G P C C T A Q C A F K S K S E K C 
1559 AAACCTGGGAAACAGTGCAGTCCAAGTCAAGGTCCTTGTTGTACAGCACAGTGTGCATTCAAGTCAAAGTCTGAGAAGTGTC 
TTTGGACCCTTTGTCACGTCAGGTTCAGTTCCAGGAACAACATGTCGTGTCACACGTAAGTTCAGTTTCAGACTC'l'TCACAG 
Glyc. 
R D D S D C A R E G I C N G F T A L C P A S D P K P N F 
---ADAM-10SeqF4-~ 
1641 GGGATGATTCAGACTGTGCAAGGGAAGGAATATGTAATGGCTTCACAGCTCTCTGCCCAGCATCTGACCCTAAACCAAACTT 
CCCTACTAAGTCTGACACGTTCCCTTCCTTATACATTACCGAAGTGTCGAGAGACGGGTCGTAGACTGGGATTTGGTTTGAA 
~~ D C N R H T Q V C I N G Q C A G S I C E K Y G L E E 
17 23 CACAGACTGTAATAGGCATACACAAGTGTGCATTAATGGGCAATGT'GCAGGTTCTATCTGTGAGAAATATGGCTT AGAGGAG 
GTGTCTGACfi.TTATCCGTATGTGTTCACACGTAATTACCCGTTACACGTCCAAGATAGACACTCTTTATACCGAATCTCCTC 
C T C A S S D G K D D K E L C H V C C M K K M D P S T 
18 05 TGTACGTGTGCCAGTTCTGATGGCl'.Afi.GATGATAAAGAATTATGCCATGTATGCTGTATGAAGAAAA TGGACCCA TCAACTT 
ACATGCACACGGTCAAGACTACCGTTTCTACTATTTCTTAATACGGTACATACGACATACTTCTTTTACCTGGGTAGTTGAA 
C A S T G S V Q W S R H F S G R T I T L Q P G S P C N D 
1887 GTGCCAGTACAGGGTCTGTGCAGTGGAGTAGGCACTTCAGTGGTCGAACCATCACCCTGCAACCTGGATCCCCTTGCAACGA 
CACGGTO.TGTCCCAGACACGTCACCTCATCCGTGAAGTCACCAGCTTGGTAGTGGGACGTTGGACCTAGGGGAACGTTGCT 
~--ADAM-lOSeqRl-
·F R G Y CD V F M R C R LV DAD G P LA R L K K A I 
--ADAM-
10 
1969 TTTTAGAGGTTACTGTGATGTTTTCATGCGGTGCAGATTAGTAGATGCTGATGGTCCTCTAGCTAGGCTTAAAAAAGCAATT 
AAAATCTCCAATGACACTACAAAAGTACGCCACGTCTAATCATCTACGACTACCAGGAGATCGATCCGAATTTTTTCGTTAA 
F S P E L Y E N I A E W I V A H W W A V L L M G I A L 
SeqF5---~ 
2051 T'l'TAGTCCAGAGCTCTATGAAAACATTGCTGAATGGATTGTGGCTCATTGGTGGGCAGTATTACTTATGGGAATTGCTCTGA 
AAATCAGGTCTCGAGATACTTTTGTAACGACTTACCTAACACCGAGTAACCACCCGTCATAATGAATACCCTTAACGAGACT 
I M L M A G F I K I C S V H T P S S N P K L P P P K P L 
2133 TCATGCTfi.ATGGCTGGATTTATTAAGATATGCAGTGTTCATACTCCAAGTAGTAATCCAAAGTTGCCTCCTCCTAAACCACT 
AGTACGATTACCGACCTA.l\ATAATTCTATACGTCACAAGTATGAGGTTCATCATTAGGTTTCAACGGAGGAGGATTTGGTGA 
·P G T L K R R R P P Q PI Q Q P Q R Q R PRES Y Q M 
2215 TCCAGGCACTTTAAAGAGGAGGAGACCTCCACAGCCCATTCAGCAACCCCAGCGTCAGCGGCCCCGAGAGAGTTATCA.l\ATG 
AGGTCCGTGAAATTTCTCCTCCTCTGGAGGTGTCGGGTAAGTCGTTGGGGTCGCAGTCGCCGGGGCTCTCTCAATAGTTTAC 
G H M R R * 
2297 GGACACATGAGACGCTAACTGCAGCTTTTGCCTTGGTTCTTCCTAGTGCCTACAATGGGfi.AAACTTCACTCCAAAGAGAAAC 
CCTGTGTACTCTGCGATTGACGTCGAAAACGGAACCAAGAAGGATCACGGATGTTACCCTTTTGAAGTGAGGTTTCTCTTTG 
~----ADAM-10XhoR----------­
~--------ADAM-10HindR------
2379 CTATTAAGTCATCATCTCCAAACTAAACCCTCACk~GTAACAGTTGfi_~GAAAAAATGGCAAGAGATCATATCCTCAGACCAG 
Gfi.TAATTCAGTAGTAGfi.GGTTTGATTTGGGAGTGTTCATTGTCAACTTCTTTTTTACCGTTCTCTfi.GTA.TAGGAGTCTGGTC 
Ill 
Primer 
AJOHindF 
AJOSeqFl 
A10SeqF2 
AJOSeqF3 
A10SeqF4 
A10SeqF5 
AIOSeqRl 
A10SeqR2 
AlOSeqR3 
AIOSeqR4 
AIOSeqR5 
AlOXhoR 
AlOHindR 
Sequence 
5' ATCGATAAGCTTCTGTTAACCCGTGA 3' 
5'TGATGGAAGATTTGAAGG3' 
5'GGAATCCGTAACATCAGT3' 
5' GAGTGCACACCAGGAGAA 3' 
5'GGAAGGAATATGTAATGG3' 
5' AAGCAA TTTTTAGTCCAG 3' 
5' CCCATGGCTAAAACTTCC 3' 
5'TTCTCGTGTTCCGTAATA3' 
5'CTGTAGCAAAAGTAATGT3' 
5' TTCTTC CCTCTGGTTGAT 3' 
. 5' TTGCAGGGTGATGGTTCG 3' 
5' GGTITCTCGAGGGAGTGAAGTTTTCCCAT 3' 
5' CTCTTTGGAGTGAAGCTTTCCCATTGTAG 3' 
ADAM-1 0 forward and reverse primers designed for the full-length amplification of 
ADAM-10 eDNA together with internal primers along the full-length sequence for 
subsequent nested PCR and sequencing analysis. The restriction enzyme sites are indicated 
in bold/italic in each AI OHindiiiF and Al OXhoR primer sequence. Glyc. indicates putative 
glycosylation sites. The site of maturation is a furin-recognition cleavage site at which 
ADAM-I 0 is processed. 
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Figure 5.2: Effects of magnesium titration on PCR amplification of full length ADAM-I 0 
in PC-3 cells 
3Kb 
2Kb 
lKb 
O.SKb 
0.3Kb 
[lmM 
1
2mM !3mM !4mM 
ABCABCABCABC 
PC-3cDNA 
No bands were obtained for full length ADAM-10 at any of the final magnesium 
concentrations of 1, 2, 3 or 4 rnM. Each lane represents A (PC-3 eDNA by oligodT 
priming), B (PC-3 eDNA by gene-specific reverse priming with ADAM-lOXhoR) and C 
(no template- negative control). See Figure 5.3 for positive control detecting the presence 
of internal sequence of ADAM-10 in PC-3 eDNA. 
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Figure 5.3: Full length ADAM-1 0 amplification using a Lambda prostate library as a 
template 
517bp --Jit-
396bp __ .,. 
A 
Lambda DNA 
B 
236bp 
PC-3 
No PCR product was obtained from the Lambda prostate library for full length ADAM-10 
(A). Positive controls included internal ADAM-10 primers used previously (Table 3.1) in 
the same PCR (B) in which clear PCR products were seen in both the Lambda prostate 
eDNA library and in PC-3 eDNA at the expected 236 bp, indicating the presence of 
ADAM-I 0 transcript in both templates used. 
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The efficiency ofhybridisation ofthe two restriction enzyme incorporated primers ADAM-
lOHindF and ADAMlOXhoR used for ADAM-10 full length amplification was tes:ted by 
combining each with sequencing primers oUtlined in Figure 5.1. Table 5.1 (below) 
summarises each primer set used, their expected size in base pairs and a summary of the 
results obtained and illustrated in Figure 5.4. 
Table 5.1: ADAM-10 full-length forward and reverse primer binding efficiency by PCR 
Forward Primer Reverse Expected Size PC-3 Lambda Prostate 
(ADAM-10) Primer (Base Pairs) Template Library 
(ADAM-10) Template 
AlOHindF Al0SeqR1 . 380 
..J X 
A10SeqF5 A10XhoR 338 
..J .J 
, AIOISeqFl A10SeqR5 1522 
.J ? .J ? 
Table 5.1: --J indicates that a clear PCR product was visualised at the expected molecular 
weight, X indicates no PCR product, and ? indicates that non-specific binding was seen. 
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Figure 5.4 PCR of internal sequences of ADAM-I 0 full-length transcript in each of the 
Lambda prostate library and PC-3 templates 
1 2 3 
3Kb 
2Kb ... 
I Kb 1522 bp 
517 bp .. 
396bp 380bp 
338bp 
A B C A B C A B C 
Bands of expected size for each of the templates A (negative control), B (PC-3) and C 
(Lambda prostate library) for the primer sets outlined in Table 5.1 were visualised. The 
expected PCR products were seen in I (1522 bp, templates B & C), 2 (338 bp, templates B 
& C) and 3 (380 bp, template B only). 
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Figure 5.5: PCR of full length ADAM-10 using ALVA-41 and DU-145 eDNA as a 
template 
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Full length ADAM-10 (A) by PCR could be obtained from one of two separate RT-PCR 
preparations ofthe ALVA-41 (a and b) prostate cancer cell line eDNA (ALVA-41 a) but 
not the ALVA-41 b or DU-145 prostate cancer cell line. The bands shown at ~2.4 Kb (A) 
were gel purified and analysed by subsequent nested primers (B), AlOSeqlF and 
Al0Seq4R confirming the identity of the ~2.4 Kb transcript as ADAM-10. For negative 
controls, no template was added to the PCR. 
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Next the EST database (Genbank) was searched and an EST that contained the full-length 
ADAM-10 sequence (Genbank accession number AI 680390,. I.M.A.G.E clone LD number 
2264325) was found and subsequently purchased from Insight Genoinics (St. Louis, USA). 
The proof reading enzyme system, EXPANDtm (Roche), was initially tested using the 
following PCR protocol: Two separate master mixes were made, the first containing 700 
f!M dNTP, 200 nM each 5' ADAM-lOHindF and 3' ADAM-10XhoR full length transcript 
primers, 56 ng template (EST) in a final volume of 25 f.!l per reaction. The second master 
mix contained 5 f!l 1 OX Buffer (supplied by the manufacturer), 0.75 f!l Expand enzyme in a 
final volume of25 f!l per reaction. Each master mix was combined and the following PCR 
protocol was run: 94 °C 3 min, 35 cycles; 94 °C 30 sec, 55 °C 30 sec, 68 °C 3 min followed 
by 68 °C 10 min. 
The PCR product (2.4 Kb) (Figure 5.6 A) was column purified (QlAGEN) and ligated into 
pGEMTEasy (Pro mega) (Appendix 2) as per the manufacturer's protocol (no A-tailing was 
necessary as the EXPAND system incorporates an A-tailing polymerase). 1 ml of 
competent JM-109 cells (Life Technologies) was transformed with the resultant ligation; 43 
°C for 50 sec, and incubated at 37 °C I 2500 rpm on a table-top shaker, for 2 hours 
(recovery) followed by plating out onto XGAL!IPTG LB-Ampicillin (I f!g/ml) blue/white 
selective agar. White colonies were se]ected and cultured in 6 ml LB-AmpiciHin 37 °C, on 
a platform shaker, 2500 rpm for 16 h. Subsequent cultures were mini-prepped (QIAGEN 
miniprep columns) and the concentration determined on a DNA/RNA calculator 
(Pharmacia). Yields between 100 and 200 Jlg/ml were obtained. To check for the efficient 
introduction of each restriction enzyme site incorporated in the forward and reverse 
primers, lflg of each mini-prepped clone was subjected to a Hind!II/Xhol (lU each) double 
digest in a final volume of 20 111 at 37 °C, 2 h. Clone#4, one of the successfully digested 
clones (Figure 5.6 B) was selected and its full length ADAM-10 insert was sequenced using 
each of the forward and reverse sequencing primers in Figure 5. I. 
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Figure 5.6: Full length ADAM-10 PCR product from an ADAM-10 EST template and the 
restriction digest of this product once cloned into pGEMTeasy 
A) 
B) 
3Kb --•• 
2Kb --.-• 
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ADAM-10 
A) Full length ADAM-10 amplified from an ADAM-10 EST using the proofreading 
enzyme system EXP ANDtm and B) Hindiii!Xho I double restriction enzyme digest of one 
pGEMTeasy clone#4 containing the ADAM-10 full-length insert. Bands at the expected 
size of linear pGEMTeasy (3 Kb) and full length ADAM-10 (2.4 Kb) were clearly seen, 
indicating the successful cloning ofthe full length ADAM-10 insert. 
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5.2.4 Sub-cloning of full length ADAM-10 
Full length sequencing data was analysed using Seqman (DNA Star Software). A single 
contig was constructed from each of the sequences generated by the forward and reverse 
sequencing primers (Figure 5.1) and aligned with the full-length ADAM-10 eDNA 
sequence imported from Genbank. A point mutation was found in the cloned ADAM-I 0 
primary DNA sequence. Co-incidentally, the Met-Ala mutation occurred at a point in the 
primary amino acid sequence, which is crucial for a Met-turn (Va1434-Met435-Tyr436) that 
aligns the substrate-binding pocket with the catalytic centre in all metalloproteases. Hence, 
this site was crucial for catalytic function (Gall et al. 2001). Attempts to sub-clone this 
insert into the mammalian expression vectors pcDNA3.1 and p:MEP4 were made as it was 
anticipated that a one base mutation could be corrected by site directed mutagenesis. This 
clone also provided, by chance, a potentiaHy non-functional mutant. 
Construction of an ADAM~ I 0 DIG-labelled probe 
A DIG-labelled ADAM-10 probe was constructed using the ADAM-10 EST as a template 
with the sequencing primers A10SeqlF and A10Seq5R, by incorporating DIG-labelled 
UTP into the PCR reaction (annealing temperature 50 °C), extension time I min 30 sec 
with platinum Taq DNA polymerase. The DIG labelled probe was gel purified and 
quantitated by dot-blot alongside a known amount ofDIG-IabeUed DNA. A concentration 
of 100 pg/pJ was calculated. This probe was intended for use in a colony blot fashion for 
the colonies that grew as a result ofthe sub-cloning activities. Full length ADAM-10 was 
used as the positive control whilst the vector pcDNA3 .1 was used as a negative control-in 
each dot-blot. 
Sub-cloning of ADAM-I OpGElv.f.T#4 
Double digests (HindJJIIXhoi) of AlOpGEMTeasy#4 (Figure 5.6B), pcDNA3.1 and 
pMEP4 were performed as described above. The purified, digested products were column 
purified. Each vector was either treated with Calfintestinai Phosphatase (CIP) (1 U/50pmol 
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vector free ends for 2 hat 37 °C to remove free phosphates from the digested ends) or not. 
The. CIP treated and non-treated vectors underwent a further column purification 
(QIAGEN) to remove any free CIP and/or restriction enzymes from the solution. A ligation· 
schedule was set up using three different insert:vector ratios, 5: 1, 3: 1 and 1:1 ng DNA with 
T4 ligase at 4 °C for 16 h. JM109 E.coli cells were transformed as described above. The 
resultant colonies were screened both by PCR and by colony dot-blot analysis, positive 
colonies were picked, cultured overnight and subsequently mini-prepped, followed by 
double digestion with HindiiJ!XJJ.o 1 as described above and analysed by full length PCR. 
Each of these methods, plus further sequencing analysis, confirmed the vectors did not 
contain inserts, confirming that this cloning method was not suitable. Other competent 
E.coli cells used included ToplO, in which no results were obtained and, previous DH5 a 
competent E.coli preparations (supplied courtesy of Dr. Dirnitro Odorico) showed,. when 
transformed with pGEMTeasy containing full-length ADAM-10, that this strain of E.coli 
cells inserted a transposon into the ADAM-10 insert. 
Sub-cloning of ADAM-1 0 full-length PCR product 
Several attempts were made to clone the full-length ADAM-10 PCR product not contained 
within a vector, 'directionally' into pcDNA3.1 and pMEP4. ADAM-10 was amplified 
from the EST using the ADAM-I OHindiJIF and ADAM-I OXhoR full-length primers with 
the PCR protocol describe above (EXP ANDtm) followed by column purification. The 
concentrations ofDNA obtained were between 2.7- 11.3 f!g/ml. 
To test restriction enzyme efficiency, 1 f!g of pcDNA3.1 was digested with IU Hindiii or 
Xhol (there were enough base pair overhangs on either side ofthe restriction site ofthe 
full-length PCR product as recommended for these restriction digest enzymes) at 37 °C for 
2 hours. The subsequent digest was run on a 1% agarose gel containing EtBr. Linear 
vector was visualised at the expected size in each case confirming the efficacy of each 
restriction digest. 1 f!g ofpcDNA3.1 orpMEP4 or ~400 ng of purified full length ADAM-
10 was double digested with HindJII andXhol overnight at 37 °C. 
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Each restriction digest was column purified (QIAGEN) and quantitated. Digested 
pcDNA3.1 and pMEP4 were treated with or without CIP IU/50 pmol vector for 2 hat 37 
°C to remove the free phosphates from the digested ends. Double digested/CIP treated or 
non-treated expression vectors were again column purified and quantitated. Three different 
ligation schedules were set up for each vector using 50 ng, I 00 ng and 200 ng of vector 
with ratios of vector:insert I :1 and 3:1 in each case. T4 ligase was used in an overnight 
ligation reaction at 4 °C. JM-109 E.coli were transformed by heat shock (43 °C, 50 sec) 
with the resultant overnight ligation reaction. The cells were suspended in I ml LB-broth 
and left to recover on a shaker at 37 °C for 2 h. Each transformed E.coli culture was: plated 
out on LB-agar containing lug/ml ampicillin and cultured for 16 hat 37 °C. 
Typically, ~30 colonies were screened by PCR using ADAM-10 nested primers. Clones 
that screened positive (Figure 5.1 A, for example) appeared to yield the correct PCR 
product size. Each of these colonies was picked and cultured for 16 h in 5 ml 
LB/Ampicillin broth at 37 °C on a shaker and subsequently mini-prepped (QIAGEN). I 1-fg 
of the vector was double-digested and run on an agarose gel; only linear vector at the 
expected size ofthe empty vector could be seen (Figure 5.7 B). Other additional colonies 
were screened with different sets of ADAM-I 0 nested primers. Those that screened 
positive had the same process repeated, with the same negative result. Similar results were 
seen in each of the cases of pMEP4 and pcDNA3.1. 
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Figure 5.7: PCR screens of potential pcDNA3.1/ADAM-10 clones and their subsequent 
mini-prep digests 
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A) A representative PCR screen of colonies which were transformed with potential 
pcDNA3.1/ Al 0 ligation products. Each colony which screened positive was miniprepped 
and underwent a subsequent Hindiii/Xho I double digest. Each potential clone was also 
sequenced. B) No ADAM-10 insert was present (C =Cut or digested with HindJJI and 
Xhol, U= uncut or not digested). Similar results were obtained for the vector/ligation 
carried out with pMEP4/ADAM-10. 
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Cloning with one restriction enzyme site 
Having established the directional Cloning strategy to be sub-optimal either by sub-cloning 
or directly from amplified PCR product, an ADAM-10 full length PCR was carried out 
using the new proofreading enzyme P.fx (as a mutation was previously encountered with the 
use of the EXPAND system), primers ADAM-IOHindF (Figure 5.1) and a new ADAM-
IOHindR(Figure 5.1) and the ADAM-10 EST as a template was carried out. The purified 
PCR product was A-tailed using Taq DNA polymerase (Roche) and ligated into 
pGEMTEasy. JM109 competent cells were transformed and taken through to the miniprep 
stage as described above. Full length sequencing of resultant clones in both the forward and 
reverse direction revealed no errors in the full-length transcript insert when analysed by the 
DNAStar software as described above. 
The insert was digested from the pGEMTEasy vector with 1 U Hindlll, alongside a Hindiii 
digest of each of the expression vectors pcDNA3 .l and pMEP4. Each vector was CIP 
treated as described above, column purified and subsequently ligated with the ADAM-I 0 
HindiJI digested insert. Colonies that screened positive by PCR on LB-Ampicillin agar 
plates were picked and cultured. Subsequent minipreps were screened for the selection of 
clones with the ADAM-10 insert in the forward direction (the ADAM-10 5' Kozak 
sequence closest to the vector promoter) by restriction digest mapping. Four clones were 
chosen for further use in the laboratory: pcDNA3.1#6.2, pcDNA3.1#6.4, pMEP4 #4.1 and 
pMEP4 #4.2 (Figure 5.8). Each clone was fully sequenced to confirm the insert orientation 
and an error free primary DNA sequence. 
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Figure 5.8: Hind!Jl digest ofpcDNA3.1/A10 and pMEP4/A10 
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Representative restriction enzyme digest using Hindiii for AI) pcDNA3.1 without ADAM-
10 insert and A2) with ADAM-10 insert and Bl) pMEP4 without ADAM-10 insert and 
with ADAM-1 0 insert (B2), D = Digested, U = Undigested. These vectors were used for 
subsequent transient transfection studies. 
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5.2.5 Transient transfection of prostate cell lines with pcDNA3.1 and pMEP4 
mammalian expression vectors containing full length ADAM-I 0 
Cell culture 
The prostate cell lines PC-3 and RWPE-1 were resuscitated from liquid N2 and grown to 90 
% confluency in a T75 standard tissue culture flask as described in Chapter 2. The PC-3 
cells were harvested with trypsin!versine and counted on a haemocytometer using trypan 
blue as described in Chapter 2. 36 wells of 2 X 24 well plates were seeded with 100,000 
cells/well in RPMI1640/l 0 % FBS and allowed to attach and grow to ~90 % confluency. 
Transient transfection 
Each of the vectors illustrated in Table 5.2 were transiently transfected into PC-3 cells 
using the following Vector: Lipofectamine ratios respectively: 0.9 f.Lg:2 f.ll, 1 f.Lg:3 f.Ll and 
1.2 f.Lg:3 .6 f.LL These ratios were recommended by the manufacturer of the transfection 
reagent Lipofectamine 2000 (Invitrogen) and were shown previously, to give a greater than 
60% transfection efficiency for GFP expressing vectors in PC-3 cell cultures (courtesy of 
Dr. Dimitri Odorico ). The following transfection protocol was used. Each vector was 
diluted in 50 f.ll Opti-:MEM media (Life Technologies), mixed gently by pipette and 
allowed to incubate for 5 min at room temperature. Alongside this, Lipofectamine 2000, as 
per manufacturers recommendations, was also diluted into a separate tube (See amounts in 
Table 5.3) in a final volume of 50 Ill Opti-MEM. Both 50 ul aliquots of Opti-MEM (one 
containing the vector, the other containing Lipofectamine 2000) were combined, mixed 
gently by pipette and allowed to incubate at room temperature for a further 20 min. 
The PC-3 cells plated in the 24 well plates as described above, were washed twice with 
warm PBS just before the 100 J.!l aliquots containing both vector and lipofectamine were 
added to duplicate wells. The volume in each well was made up to 1 ml with antibiotic free 
RPMI-1640/1 0 % FBS. 
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Table 5.2: Transient transfection protocol for full-length ADAM-I 0 mammalian 
expression vector constructs 
Vector/Clone Insert and Direction pi Lipofectamine/ pi Lipofectaminef 1 11g pi! Lipofectamine/ 
0.9 11g vector vector 1.2ug vector 
pMEP44.1 ADAM-10 Forward 2 " 3.6 ::> 
pMEP44.2 ADAM-10 Forward' 2 3 3.6 
pcDNA3.1 6.1 ADAM-10 Forward 2 "' 3.6 ::> 
pcDNA3.1 6.2 ADAM-10 Forward 2 " 3.6 ::> 
pMEP4 No Insert Control 2 3 3.6 
pcDNA3.1 No Insert Control 2 3 3.6 
The PC-3 cells were incubated for 18 hat 37 °C and the medium was aspirated, the cells 
were then washed twice with warm PBS. For the inducible vector, pMEP4 transients, 
RPMI-1640/10 % FBS containing 5 f.!M of the metallothionine promoter activator CdC}z 
(as per previous studies- Kazmi et al. 1996) was added (1 mllwell) whilst media without 
CdCh was added to the pcDNA3 .1 vectors. The cells underwent further 16 h incubation at 
37°C. 
Western blot analysis 
Each cell population was washed twice with warm PBS and harvested with 200 ul ice cold 
cell lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1 mM PMSF, 10 
mM EDTA pH 8.0, I tablet Roche complete EDT A-free protease inhibitor cocktail/25 ml). 
The crude cell extract was quantitated using the BCA assay 'micro-well protocol' (Pierce). 
Equal amounts of protein for each vector containing ADAM-10 insert and its appropriate 
control (each vector without the ADAM-10 insert) were loaded onto a 10% PAGE gel, 
followed by standard Western blot procedure (Chapter 2) using 0.5 f.!g/ml ADAM-lOMet 
antibody. After the detection of ADAM-10 by X-ray autoradiography, using Femto 
(Pierce) chemiluminescence, the membrane was stripped as described in Chapter 2 and the 
levels ofthe housekeeping gene tubulin-!3 (0.2 f.!g/mi, Neomarkers) were detected to allow 
normalisation for any differences in protein loading. Figure 5.9 shows clearly, that little or 
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no increase in ADAM-10 protein levels could be seen in any of the cases tested by Western 
blot analysis. 
It was then decided to 'scale up' our cell population number and test for transient 
transfection efficiency in RWPE-1 and PC-3 cells in T25 tissue culture flasks. Both cell 
lines were cultured to 90% confluency, at which point transient transfection was carried 
out as described above. For pMEP4, differing incubation times with 5 !!M CdCh were also 
tested with 4 f.tg vector: 10 f.tl Lipofectamine-2000 ratio in the hope that we might optimise 
the induction of expression (Figure 5.10). Previous optimisation activities found that> 5 
!lM CdCh induced cell death within 8 h. Further, differing amounts of each expression 
vector, were introduced in several transient transfection attempts in each prostate cell line 
(Figure 5.11). Again, it was previously determined the upper Iimit ofDNA concentration 
that did not result in cell death 16 h post transfection in each of the cases ofRWPE-1 (9000 
ng) and PC-3 (5000 ng). 1000 ng lower than that determined to induce cell death was used. 
In no cases were significant increases in ADAM-1 0 protein levels seen. 
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Figure 5.9: Transient transfection of pcDNA3J and pMEP4 containing a full length 
ADAM-I 0 insert in PC-3 cells 
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PC-3 cells were transiently transfected with the two separate full-length ADAM-IO clones 
ofpcDNA3.I or pMEP4 with increasing amounts of vector DNA: A) 900 ng, B) 1000 ng 
and C) I200 ng. pcDNA3.1 transients were harvested 34 h post transfection, whilst for 
pMEP4 clones: 18 h post transfection, 5 11M CdClz was added and cells were incubated for 
a further 16 h prior to harvesting. No significant increase in ADAM-I 0 expression could 
be seen in any of the transfection conditions tested when compared to levels of the 
housekeeping gene (3-Tubulin. Negative controls included transfection of PC-3 cells with 
the respective vectors, which do not contain the ADAM-10 insert. These particular blots 
only revealed signal for mature ADAM-I 0, possibly due to the lower levels of protein 
having to be loaded onto the PAGE gel (2 - 3 Jlg), a result of a low protein yield, due to a 
small population of cells from one well, in a 24-well plate. 
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Fignre 5.10: Transient transfection of pMEP4 containing a full length ADAM-I 0 insert in 
PC-3 cells 
PC-3 
0 30min 2h 4h 8b 
112 kDa + UnprocessedADAM-16 
90 kDa ..,_ 
;+Mature 
52 kDa ·~ ADAM-10 
'ij 
;~ 
~ ~· -" --I+ 13-Tnbulin 
~ M M M M 
"'!' ~ ~ ~ ~ 
"'!' 
=t.f: 
"'!' =t.f: =t.f: =t.f: =t.f: "'!' 
""!!' "'!' "'!' "'!' ""!!' "'!' "'!' ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~. ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ c.. c.. c.. c.. c.. c.. c.. c.. c.. c.. 
PC-3 cells were transiently transfected with 4000 ng of pMEP4/ ADAM-I 0#4.2 clones. 18 
h post transfection 5 11M CdCh was added and cells were incubated for each of the times 
outlined above, prior to harvesting. No significant increase in ADAM-10 expression could 
be seen in any of the transfection conditions tested when compared to the levels of the 
housekeeping gene f3-Tubulin. Negative controls included the transfection of PC-3 cells 
with the same amount ofp:tv1EP4 empty vector, which did not contain the ADAM-I 0 insert. 
Each time point was determined in anticipation that functional cell assays would be 
performed within or close to this range of times. 
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Figure 5.11: Transient transfection ofpcDNA3.1 containing a full length ADAM-I() insert 
in RWPE-1 and PC-3 cells 
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RWPE-1 or PC-3 cells were transiently transfected with A) 2000 ng or 4000 ng 
pcDNA3.1#6.2 for PC-3, or B) 2000 ng or 8000 ng pcDNA3.1#6.2 for RWPE-1. Cells 
were harvested 40 h. post transfection. No significant increase in ADAM-IO expression 
could be seen in any of the transfection conditions tested when compared to the levels of 
the housekeeping gene ~-Tubulin. Negative controls included the transfection of both 
RWPE-1 and PC-3 cells with the same amount ofpcDNA3.1 empty vector, which did not 
contain the ADAM-I 0 insert. 
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5.3 Discussion 
At the commencement ofthis part of the thesis, such a tool as an ADAM-10 mammalian 
expression construct containing human ADAM-I 0 was unavailable despite exhaustive 
efforts including personal communication with international laboratories that study 
ADAM-10. It was decided to attempt to clone full-length human ADAM-10 (hADAM-10) 
eDNA by PCR amplification and insertion into each of the mammalian expression vectors 
pcDNA3.1 and pMEP4. The pcDNA3.I mammalian expression vector contains a CMV 
viral promoter element upstream of the Kozak sequence and the translation start site 
included in the full-length hADAM-10 insert for potential efficient transcription. The 
pMEP4 mammalian expression vector is an inducible vector that has a metallothionine 
promoter element upstream of the hAD AM-I 0 Kozak sequence. Its activity is induced by 
the introduction of CdCb into the cell system (Kazmi et ai. 1996). 
Initially, obtaining full-length hADAM-10 by PCR from eDNA of several PCa cell lines 
proved unrewarding. The presence of an EST, which contained the full-length sequence, 
provided a more suitable template. However, the directional cloning strategy of the fuH-
length hAD AM-I 0 PCR product, or the sub-cloning of this product directionally, from the 
intermediate vector pGEMTeasy, was not successful. Therefore, a new strategy using a 
single restriction enzyme site, where an error free insert could be ligated in either the 
forward or the reverse direction, was used. This method led to successful sub-cloning from 
pGEMTeasy into each of the vectors pcDNA3.1 and pMEP4. Subsequently, forward 
direction clones were screened and selected by restriction digest mapping and confinned by 
sequencing. 
Once full-length clones were established, the efficiency ofthe vector/ADAM-10 clones to 
induce levels ofhADAM-10 in a transient transfection system was tested. By Western blot 
analysis in the prostate cell line PC-3, neither the pcDNA3.I clone, nor the inducible 
pMEP4 clone, led to enhanced hADAM-1 0 protein production. A similar result was 
obtained in the non-tumorigenic prostate cell Iine RWPE-1. A separate study in this 
laboratory has cloned the same full-length transcript in-frame in a Green Fluorescent 
132 
Protein (GFP) expression vector. Like the results presented in this study, the GFP clone did 
not fluoresce, as one would have expected, in a transient transfection system in the PCa cell 
lines LNCaP and PC-3 (data not shown). 
Given that in three different vectors the same lack of expression was shown, it was 
hypothesised that the natural Kozak sequence, which is: encompassed by the forward primer 
binding sites chosen in this study, may not be strong enough to promote any significant 
translation. We chose to use the natural Kozak sequence as the bases known to be crucial 
within a Kozak sequence for strong promotion of translation (A at -3, and Gat +4) (Kozak, 
1997) were indeed conserved in human ADAM-10, suggesting this to be a 'strong' Kozak 
sequence. 
A study recently published (Anders et aL 2001) cloned full length bovine ADAM-10 
(MADM) into pcDNA-HA, a vector which post-dates pcDNA3.1, with a Hemagglutinin 
(HA) tag, and selected stably transfected HEK293 cells. This study demonstrated the 
expression of AD AM-1 0-HA by affinity chromatography using an anti-HA antibody and 
further demonstrated an increase in ~-APP processing in this ceH system by measuring the 
levels of secreted ~-APP. As seen in Table 5.3 (below) the Kozak sequence for MADM 
varies slightly from that of hADAM-10. This may be functionally relevant and may, in 
part, explain the inability of our mammalian expression constructs to stimulate ADAM-10 
expression in prostate cell lines. Interestingly, this study only showed over-expression by 
using the HA-tag antibody in Western irnmunoblots and no indication of a foJd increase of 
overall (endogenous plus HA-tagged) ADAM-10 production within the cell system was 
presented. In our cell system, translation of ADAM-I 0 from our vector templates may weH 
have taken place. However, a tagged vector was not used, so the introduced ADAM-10 
protein could not be distinguished from endogenous ADAM-10 protein, as it was in the 
above study using MADM. 
Another recent study (Y an et al. 2002) showed, by transfection, that ADAM-10 but not 
ADAM-9 or -17 was able to mediate the transactivation of the EGFR. This study used an 
expression construct with full-length mouse ADAM-10,. which as illustrated below (Table 
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5.3) has a Kozak sequence almost identical to MADM. Yet another group showed ihat the 
introduction of ADAM-9 and -10 expression vectors to a keratinocyte cell line, lead to the 
enhanced cleavage of CoHagen XVII (Franzke et al. 2002). In Franzke's study, human 
ADAM-9 was used, but in the case of ADAM-I 0, the bovine orthologue MADM was again 
used for these purposes. 
Table 5.3 ADAM-10 ortho1ogue Kozak sequences 
Consensus Kozak c c 4 c c A u G G G Kozak, 1984 
hADAM-10 Kozak G A 4 A G A u G G G Genbank Accession # 
NM_001110 
MADMKozak G G 4 A G A u G G G Genbank Accession # 
NM_l74496 
Genbank Accession # 
; 
Mouse ADAM-10 G G A A G A u G G T 
NM_007399 
Table 5.3 illustrates the differences in the Kozak sequence of human ADAM-10 (hADAM-10), bovine 
ADAM-10 (MADM), mouse ADAM-10 and the consensus Kozak sequence (Kozak, 1984). 
Given that studies such as these have chosen to use MADM or mouse ADAM-1 0 rather 
than human ADAM-10, to generate functional data in human cell lines, it is likely that 
these and other groups may have also experienced the same technical difficulties, with 
respect to the generation of functional hADAM-10 mammalian expression vectors. 
Because the transient transfections were unsuccessful in stimulating ADAM-I 0 production 
it was decided, due to time constraints, not to pursue this part of the study further at this 
time, since the next stages anticipated were to 1) to make stably transfected over-expressing 
ADAM-1 0 prostate cell lines and 2) to perfonn functional assays including cell migration, 
attachment and invasion on both transiently transfected and stably transfected prostate and 
PCa cell lines. 
To progress this study, which is intrinsically important, firstly, a strategy whereby primers 
are designed against a small Y untranslated sequence of each pcDNA3.1 or pMEP4 vector 
sequence, between the promoter region and the ADAM-I 0 gene, followed by PCR analysis 
should be carried out. This approach, which was not carried out in this study, might 
confirm the expression or otherwise of exogenously produced ADAM-10. Failing this, a 
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new Kozak sequence should be introduced, which exactly matches the consensus Kozak 
sequence CCACCaugG (Kozak, 1984) or that ofMADM and mouse ADAM-10 primary 
DNA Kozak sequence (Table 5.3). Recently developed mammalian expression systems, 
with detectable tags, as well as the existing two used (pcDNA3.1 and pMEP4) in this 
particular study would be used. Additionally, the use of a cell line that does not express 
ADAM-I 0 would also be advantageous in distinguishing exogenously expressed protein. 
Although no such cell line was available in this study, such a cell line could easily be 
derived from an ADAM-1 0 knockout mouse, for example. No full-length human ADAM-
1 0 mammalian expression vector, to date, to our knowledge, is available for this kind of 
research. With the added knowledge this study has provided, key areas have been 
identified, which require attention when attempting to establish such a hADAM-1 0 over-
expressing system. 
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CHAPTER SIX: 
6.0 THE REGULATION OF ADAM-9 AND -10 mRNA AND PROTEIN 
EXPRESSION BY THE PROSTATE GROWTH PROMOTERS DHT, IGF-1 AND 
EGF IN THE LNCaP PROSTATE CANCER CELL LINE 
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6.1/ntroduction 
As reviewed in Chapter 1 prostate cancer (PCa) occurs in two distinct stages, 'early' and 
'late'. In the early stages, ceH growth and proliferation is sensitive to androgen stimulation 
(Lee, 1996). IGF-1 and EGF are thought to help maintain cell survival and growth during 
this earJy stage of PCa development (Lee, 1996). As the cancer progresses into a more 
aggressive, metastatic phenotype (late stage), cell proliferation becomes insensitive to 
androgens. IGF-1 and EGF and other growth factors/cytokines, such as IL-6 are thought to 
act in an autocrine and paracrine manner to maintain the cancer ceHs survival and 
progression (Russell et al. 1998). 
Normal prostate and PCa cell models are widely used to characterise the growth factor 
responsiveness and expression profile of candidate genes, which are potential contributors 
to PCa progression. The LNCaP cell line, previously used in our earlier expression studies 
(McCulloch et al. 2000), is a particularly good model as its proliferation can be stimulated 
by androgens such as DHT, synthetic androgens, for example, Rl881, and other growth 
factors, including IGF-1 and EGF (Iwamura et aL 1993; Culig et aL 1994; Russeii et al. 
1998), enabling the effective assessment of the growth factor responsiveness of ADAM 
protein levels. 
The extensive ADAM expression profiling outlined in Chapters 3 and 4 showed the 
presence and localisation of both ADAM-9 and -10 throughout the stages of PCa 
development. Additionally, preliminary data suggested that the LNCaP cell line, like the 
RWPE-1 and PC-3 cell lines used in Chapter 3, expressed both ADAM-9 and -10 in the 
nuclear compartment. Given the readily detectable levels of ADAM-9 and -10 in ceH 
models of normal, androgen-dependent and androgen-independent PCa, and in primary and 
secondary/metastatic tumours, and the previous observation that AD AM-9, -10 and -17 
mRNA levels are regulated by DHT (McCulloch et al. 2000), it is reasonable to hypothesise 
that the expression of ADAM-9 and -10 mRNA and protein may be regulated by a cohort 
of other hormones, growth factors and cytokines which stimulate PCa cell growth, 
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proliferation, invasion and migration. This provides a rational basis for the further 
characterisation of the growth factor and hormonal regulation of these particular ADAMs. 
The three pertinent and extensively studied hormone/growth factors DHT, IGF-1 and EGF 
were chosen for this study. This set of hormone/growth factors are already implicated in 
the regulation of PCa cancer development and the induction of specific enzyme expression 
in the prostate, including the well characterised serine protease Prostate Specific Antigen 
(PSA) and the Matrix MetaUoproteases (MMPs), in particular MMP-7 and -2 (Montgomery 
et aL 1992; Sundareshan et al. 1999; Liao, 2003). 
Thus, the aims of this chapter were: 
1) To assess the responsiveness of ADAM-9 and -10 mRNA levels to DHT,. IGF-1, 
DHT plus IGF-1 and EGF alone in LNCaP cells. 
2) To assess the responsiveness of ADAM-9 and -10 proteins levels in the whole cell 
lysate ofLNCaP cells by DHT, IGF-1, DHT plus IGF-1 and EGF alone. 
3) To assess the responsiveness of ADAM-9 and -10 protein levels in the nucleus of 
LNCaP cells to EGF. 
This chapter builds on work previously published from this laboratory (McCulloch et al., 
2000), which found ADAM-9 and -10 mRNA to be significantly up regulated by varying 
levels ofDHT in the LNCaP PCa cell modeL It is important to examine whether the levels 
of these potentially active proteases fluctuate in response to hormone/growth factor 
regulation in order to understand the roles the ADAMs may have throughout the 
progressive stages of PC a. 
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6.2 Materials and Methods 
6.2.1 Cell culture 
For characterisation of ADAM-9 and -10 mRNA and protein expression 
The PCa cell line LNCaP was obtained from A TCC (RockVille, MD) and cultured in 
standard T75 culture flasks to ~60-70% confluency, as described in Chapter 2. The cells 
were transferred into serum-free (SF) RP:Ml-1640/ 0.01% Bovine Serum Albumin 
(BSA)/50 U/ml Penicillin/50 f.!g/ml Streptomycin sulphate for 24 h. TeSt medium was then 
added to the cells after a warm wash (37 °C) with Phosphate Buffered Saline (PBS) (tissue 
culture grade; Oxoid, West Heidelberg, Australia). To test for androgen regulation 5a-
dihydrotestosterone (DHT) (Sigma, St Louis, MO} was added at concentrations of 0 
(control), 0.1, 1.0 or 10 nM. For IGF-1 regulation, human recombinant IGF-I (Gropep, 
Adelaide, Australia) was added at concentrations of 0 (control), 10 or 50 ng/ml in the 
presence or absence of 10 nM DHT in SF-RPMI-1640/Phenol Red (PR) free/0.01% BSA/ 
Peniciiiin/Streptornycin. A maximal dose of 10 nM DHT was chosen based on previous 
ADAM-9 and -10 mRNA regulation data (McCulloch et al. 2000) so that any additional 
regulatory effects could be attributed to IGF-1 acting in synergy with DHT. For EGF 
regulation, human recombinant EGF (Gropep) was added at concentrations ofO (control) or 
50 ng/ml. In a preliminary experiment, ADAM-10's responsiveness to EGF was tested at 
concentrations of5, 10, 50 and 100 ng/ml (data not shown), 50 ng/ml was found to have the 
maximal stimulatory effect with ADAM-IO protein levels declining at 100 ng/ml. Hence, 
50 ng/ml EGF was chosen for subsequent mRNA and protein reguiation experiments. The 
cells were cultured for a further 48 h under test conditions, with a change of medium to 
replenish the appropriate growth factors after 24 h. Cells were harvested with ice-cold PBS 
and a cell scraper, pelleted by centrifugation at 175g· (1000 rpm, CS-6R Centrifuge, 
Beckman) for 3 min and stored at -80 °C until further processing. 
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Cell proliferation assay using the M1T dye method 
A 90% confluent cell culture of LNCaP was trypsin/versine treated and seeded into a 96-
well tissue culture plate (Medos) at a pre-determined optimal density of 10 000 cells/wen 
(as determined on a haemocytometer- Chapter 2) in 200 fll RPMI-1640/10% HI-FBS/PR 
free/Penicillin/Streptomycin medium. Cells were allowed to attach for 24 h, washed with 
200 fll warm PBS (37 °C) and serum starved for 24 h in SF-RPMI-1640/PR-:free/0.01% 
BSA!Penicillin/Streptomycin medium. Test medium containing DHT concentrations of 0 
(control) 1.0 and 10 nM +/- 10 or 50 ng/ml IGF-1 or EGF 0 (control) 5, 10 and 50 ng/ml 
was added and replaced every 24 h for a period of 96 h. A total of 16 wells per 
concentration were used. Each replacement of medium included a warm wash with 200 J..tl 
PBS. The MIT dye method was carried out as previously described (McCuJloch et a1. 
2000). Briefly, a standard curve was constructed by seeding doubling increases in LNCaP 
cell number into a 96-well tissue culture plate (Medos) in PR-:free/10% HI-FBS/ RPMI-
1640. The cells were allowed to plate down for 6 h followed by treatment with MIT. 
Absorbance was plotted against cell number to ensure linearity of the MIT assay across the 
range of cell numbers used (4000 - 40,000 cells). The absorbances obtained at the 
completion of the proliferation assays were extrapolated to cell number using this standard 
curve. Statistical analysis was carried out by one-way ANOVA, followed by a Tukey Post-
Hoc analysis to determine significance between all treatments and respective controls. 
6.2.2 Quantitative RT-PCR analysis 
Primer design 
Full-length sequences for both ADAM-9 and -10 were downloaded from the Genbank 
database, accession numbers NM_003807 and NM_OOillO, respectively, and saved as a 
text (.txt) file. Each sequence was individually imported into the software application 
Primer Express (PE Biosystems). The parameters for primer design were set according to 
the manufacturer's default setting recommendations. Primer Express automatically 
generated primers deemed suitable for downstream real-time PCR application. More 
optimal primers, as determined again by Primer Express software using a 'penalty score' 
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system, were individually analysed for prirner-dimer and hairpin formation. Primers with 
little or no secondary structure or complementary binding were chosen (Table 6.1) and 
subsequently purchased from Proiigo (Southern Cross University, Australia). PSA primers 
(Table 6.1) were designed in a similar fashion by Dr. Jin Gao and the 18s housekeeping 
gene primer set (Table 6.1) was already in routine use in this laboratory. 
Table 6.1 Primer sets for Quantitative PCR 
Primer Sequence PCR Product 
Size(bp) 
ADAM-9Fprexp (Forward) 5'-GGACCAATGGAAACCTGATCAA-3 106 
ADAM-9Rprexp (Reverse) 5'-ACTGTCATGTCTCCGACGTGTG-3' 
ADAM-lOFprexp (Forward) 5'-TCCACAGCCCATTCAGCAA-3' 105 
ADAM-1 ORprexp (Reverse) 5'-AGGCACTAGGAAGAACCAA-3' 
PSA-F 5' -AGTGCGAGAAGCATTCCCAAC-3' 140 
PSA-R 5'-GACCCAGCAAGATCACGCTTT-3' 
18srRNA (Forward) 5'-TTCGGAACTGAGGCCATGAT-3' 151 
18srRNA(Reverse) 5'CGAACCTCCGACTTTCGTTCC-3' 
Table 6.1 shows the primers used and their expected PCR product size, for Quantitative 
PCR analysis, designed on the Primer Express software (PE Biosystems). 
RT 
5 !lg of RNA extracted :from control and growth factor treated LNCaP cells from three 
independent experiments were reverse transcribed as described in Chapter 2. All cDNAs 
were screened for gDNA contamination with f3-actin primers, which span an intron 
(Chapter 2), and found to be free of gDNA contamination. 
Quantitative PCR 
PCR was carried out on a PE Biosystems 7000 ABI Prism using the following 
thermocycling protocol; 95 °C I 0 min, 40 cycles of 95 °C 30 sec and 60 °C 1 min with the 
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fluorescence emitted from the SYBR green being read by the instrument after each 
thermocycle. The following reaction conditions were used; 2X SYBR Green master mix 
(PE Biosystems), 50 nM each ADAM-9, ADAM-10, PSA or I8s (housekeeping gene) 
forward and reverse primer (Table 6.1), 1 Ill of eDNA template in a final reaction volume 
of 20 f!L Each growth factor treatment was run in triplicate for either ADAM-51, -W or 
PSA. 18s was also quantitated in the same PCR in triplicate for each growth factor 
treatment in a 96-well PCR plate format. 
Quantitation of ADAM-9 and -10 mRNA transcript 
Each primer set was validated for quantitation using the 'ct - value' direct comparison 
method, as per the manufacturer's recommendations. Briefly, eDNA from LNCaP cells 
was serially diluted and underwent a PCR under the same conditions described above. The 
ct value was graphed against eDNA concentration and an R2 value of>0.97 was obtained, 
showing that these primer sets could effectively detect relative changes of target message 
(ADAM-9, -10, PSA or 18s), in a linear fashion, in the eDNA from the ceil line to be used 
for subsequent mRNA level quantitation. 
The ABI-Prism 7000 measures the changes in fluorescence emitted, in this case, from the 
SYBR green dye bound to the dsDNA PCR product after each PCR cycle. Data are 
expressed as a cycle threshold (ct) value where the increase in fluorescence above a set 
background is first detected. The lower the ct-value, the higher the amount of the transcript 
of interest is present in the starting eDNA sample. The difference in ct-values between the 
control and each test condition is indicative of the relative changes in :m.Rr1>,JA transcript, as 
a result of the test condition, in this case, hormone/growth-factor treatment. Variations in 
the amount ofmRNA added to the initial RT reaction were corrected by measuring the ct-
values for the 18s rRNA housekeeping gene in the same eDNA sample, in the same PCR. 
Changes in ct-values between the control group and the test group indicate, with the 
appropriate statistical validation, whether the levels of the transcript of interest are 
significantly elevated or decreased. 
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6.2.3 Western Blot Analysis 
Protein extraction- whole cell lysate 
Cell pellets of control or growth factor treated LNCaP cells were resuspended in 500 f.!l of 
lysis buffer, processed and quantitated using the BCA protein assay reagent as described in 
Chapter2. 
Protein extraction- nuclear fractionation 
Cellular compartmentalisation from control or EGF treated LNCaP cells was achieved by 
using the NePer nuclear/cytoplasmic :fractionation kit (Pierce) as per manufacturer's 
recommendations, as described in Chapter 2. 
Western blot 
5 11g of protein from each growth factor treated cell pellet was suspended in a reducing 
loading buffer and boiled for 3 min prior to loading onto a 10% SDS-PAGE gel, followed 
by a standard Western blotting procedure (Chapter 2). For ADAM-9Dis and ADAM-
I OCterm antibodies, 0.2 f.!g/ml was used. For the housekeeping gene antibodies, !3-Tubulin 
and PCNA, 0.2 f.!g/ml were also used. 
Quantitation of signal intensity 
For the housekeeping genes tubulin-!3 and PCNA, autoradiographic detections were 
subjected to over- and under-exposures to determine that the signal detected on the X-ray 
film was in the linear range, and able ·to be used effectively for accurate densitometric 
analysis. Densitometric analysis was carried out using a GS-690 image densitometer 
(Biorad). Signal intensity obtained for ADAM-9 and -10 expression was normalised for 
the signal obtained for 13-tubulin or PCNA for the same sample on the same Western blot. 
All Western blots were performed on protein samples collected from three separate treated 
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cell preparations giving an experimental value for each set of treatments of n=3. Western 
blots for each set of treatments were performed at least in duplicate, unless otherwise 
· indicated, giving possible n values of at least 6 and subsequent densitometric analysis was 
performed for each control and test concentration in triplicate. Absolute ratios of intensity 
between control and test concentrations were calculated and the entire data set was 
subjected to a one-way ANOV A, foiiowed by a Tukey Post-Hoc analysis, or in the cases 
where just two sets of data were analysed, a Student's T -test, to determine significance 
between treatments and their respective controls. 
6.3 Results 
6.3.1 LNCaP cell proliferation 
As a proliferative control to test for biological responsiveness of the LNCaP PCa cen model 
to each of the growth factors used, an MTT ceU proliferation assay was performed. As 
expected, and as shown in Figure 6.1, LNCaP ce1I proliferation was significantly increased 
following the addition ofDHT (19% increase), with a further increase in proliferation with 
the addition ofiGF-1 (additional24 %). IGF-1 alone (in the absence ofDHT) had only a 
minor effect on cell proliferation. For EGF treated cells (Figure 6.2), a significant linear 
increase in cell proliferation was observed, with a 4-fold increase at the highest 
concentration tested (50 ng/ml). These findings paraHel the same proliferative response 
found by Iwamura et ai. (1993) and Guo et al. (2000) demonstrating the expected biological 
response to DHT, IGF-1 and EGF in the LNCaP PCa cell model in our hands. 
6.3.2 Response of PSA mRNA expression to DHT treatment of LNCaP cells 
Quantitative PCR for PSA using SYBR Green assays described above was performed on 
eDNA reverse transcnoed from total RNA extracted from LNCaP cells treated with I OnM 
DHT. Large, significant, relative changes in PSA transcript levels were shown (Figure 6.3) 
indicating that the expected response, that is, DHT upregulating PSA, was effectively 
detected, and further validating the real-time PCR method of quantitation. 
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Figure 6.1: LNCaP cell proliferation in response to DHT and IGF-1 
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Effects of DHT in the presence or absence of IGF-1 on LNCaP cell proliferation were 
carried out in 96 well plates, seeding 10,000 cells/well. LNCaP cells were serum starved for 
24 hand treated with DHT +/- IGF-1 for a further 96 h. The MTT dye method was used to 
determine change in cell number. Data shown are derived from a single experiment with 
each condition replicated in 16 wells on a 96 well plate. Similar results were observed in 
two subsequent cell proliferation assays. The same letters above each histogram represent 
statistical significance: b,ep < 0.05, a,c,d,f,gp < 0.01. 
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Figure 6.2: LNCaP cell proliferation in response to EGF 
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Effect of EGF on LNCaP cell proliferation was carried out in 96 well plates, seeding 10, 
000 cells/well. LNCaP cells were serum starved for 24 h and treated with EGF for a further 
96 h. The MTT dye method was used to determine change in cell number. Data shown are 
derived from a single experiment with each condition replicated in I 6 wells on a 96 well 
plate. Similar results were observed in two subsequent cell proliferation assays. The same 
letters above each histogram represent statistical significance: a,b,cp < 0.01. 
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Figure 6.3: The regulation ofPSA mRNA by DHT in LNCaP cells 
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For the mRNA regulation ofPSA by DHT, LNCaP cells were treated with 0 (control) or 10 
nM DHT and cultured for 48 h. Levels of PSA transcript were determined by quantitative 
PCR and normalised against 18s rRNA levels. Histograms represent the mean +/- SEM 
from three independent experiments (n=3) with each treatment sample being quantitated in 
triplicate in each of two separate PCR reactions. The same letters above each histogram 
represent statistical significance: aP<O.OL 
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6.3.3 Regulation of ADAM-9 mRNA and protein expression in LNCaP cells by DHT, 
IGF-1~ IGF-1 plus DHT and EGF 
rnRNA regulation 
Quantitative PCR using SYBR Green assays described above was performed on eDNA 
reverse transcribed from total RNA extracted from LNCaP cells treated with IGF-1, DHT, 
IGF-1 plus DHT or EGF alone. Neither DHT nor IGF-1 regulated ADAM-9 mRNA levels 
in LNCaP cells (Figure 6.4). However, IGF-1 (50 ng/ml) in the presence of 10 nM DHT 
significantly up-regulated ADAM-9 mRNA transcript when compared to the 10 nM DHT 
treatment in the same experiment (Figure 6.4). For EGF regulation, a significant 
stimulation was also shown in response to 50 ng/ml treatment (Figure 6.5). 
Whole cell lysate protein regulation 
Figure 6.6 shows representative Western blots performed on three separate experiments of 
whole cell protein extracted from LNCaP cells treated with DHT,. IGF-1, or IGF-1 plus 
DHT. Densitometric analysis, using f3-tubuiin as a "housekeeping" marker, was used to 
correct for uneven protein loading between the control and test lanes in each experiment. 
As shown in the histogram below the Western blots, neither DHT nor IGF-1 alone, 
regulated levels of the 84 kDa proform form of ADAM-9 protein. However, like the 
mRNA response, DHT plus IGF-I significantly increased the proform of 84 kDa ADAM-9 
protein levels, ~2-fold. EGF (50 ng/ml), again like the mRNA response, significantly 
stimulated the expression ofunprocessed 84 kDa proform (~1.8- fold) of ADAM-9 (Figure 
6. 7). The processed, active ~60 kDa form was not uniformly seen throughout any of the 
Western blots in these sets of experiments, therefore no analysis of this form of ADAM-9 
could be carried out. 
Nuclear protein regulation in LNCaP cells by EG F 
To investigate the effect ofEGF on the accumulation of ADAM-9 in the nucleus ofLNCaP 
cells, an experiment whereby LNCaP cells were treated with EGF for 48 h, followed by 
subcellular fractionation (described in Chapter 2) was performed. EGF alone did not 
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significantly alter nuclear ADAM-9 unprocessed, 84 kDa protein levels (Figure 6.8), 
However, a significant but modest up regulation was observed for the presumably 
processed, active 60 kDa form (~ 1.5-fold), which unlike LNCaP whole cell lysate 
preparations, was readily detectable in these particular nuclear preparations. The 
proliferating cell nuclear antigen (PCNA) was used as a normalisation control in this case 
as no significant increase in its expression was observed in the growth factor treatment 
when compared with the no treatment control thus reflecting even protein loading as 
determined by BCA protein quantitation assays. 
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Figure 6.4: The regulation of ADAM-9 mRNA expression by DHT, IGF-1 or DHT plus 
IGF-1 in LNCaP cells 
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For the mRNA regulation of ADAM-9 by IGF-1 in the presence or absence of DHT, 
LNCaP cells were treated with 0 (control}, 10 nM DHT, 50 ng/ml IGF-1 plus or minus 10 
nM DHT and cultured for 48 h. Levels of ADAM-9 transcript were determined by 
quantitative PCR and normalised against l&s rRNA levels. Histograms represent the mean 
+/- SEM from three independent experiments (n=3) with each treatment sample being 
quantitated in triplicate in each of t\vo separate PCR reactions. The same letters above each 
histogram represent statistical significance: a,b,cP<O.Ol. 
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Figure 6.5: The regulation of ADAM-9 mRNA expression by EGF in LNCaP cells 
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For the mRNA regulation of ADAM-9 by EGF, LNCaP cells were treated with 0 (control) 
or 50 ng/ml EGF and cultured for 48 h. Levels of ADAM-9 transcript were determined by 
quantitative PCR and normalised against 18s rRNA levels. Histograms represent the mean 
+!- SEM from three independent experiments (n=3) with each treatment sample being 
quantitated in triplicate in each of two separate PCR reactions. The same letters above each 
histogram represent statistical significance: aP<O.Ol. 
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Figure 6.6: The regulation of ADAM-9 protein expression by DHT, IGF-1 or DHT plus 
IGF-1 in LNCaP cells 
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Western blot analysis for ADAM-9 expression in whole cell lysates extracted from LNCaP 
cells treated with DHT, IGF-1 or IGF-1 in the presence of DHT for 48 h. Quantitative 
image analysis is shown in the histograms below the Western blots for the 84 k:Da, ADAM-
9 band. These data are representative of three separate growth factor treated LNCaP whole 
cell lysate preparations. The signal for ADAM-9 was normalised for protein loading with 
the signal from (3-Tubulin on the same membrane. The same letters above each histogram 
represent statistical significance:3P < 0.01. 
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Figure 6.7 The regulation of ADAM-9 protein expression by EGF in LNCaP cells 
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Western blot analysis of ADAM-9 expression in whole cell lysates extracted from LNCaP 
cells treated with EGF for 48 h. Quantitative image analysis is shown in the histograms 
below the Western blots for the 84 kDa, ADAM-9 band. These data are representative of a 
single Western blot of three separate growth factor treated LNCaP whole cell lysate 
preparations. The signal for ADAM-9 was normalised for protein loading with the signal 
from 13-Tubulin on the same membrane. The same letters above each histogram represent 
statistical significance: ap < 0.05. 
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Figure 6.8 The regulation of ADAM-9 nuclear protein expression by EGF in LNCaP cells 
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Western blot analysis for ADAM-9 expression in nuclear protein extracts from LNCaP 
cells treated with EGF for 48 h. Quantitative image analysis is shown in the histograms 
below the Western blots for the unprocessed 84 kDa, and mature 60 kDa, ADAM-9 band. 
These data are representative of a single Western blot of three separate growth factor 
treated LNCaP nuclear protein preparations. The signal for ADAM-9 was normalised for 
protein loading with the signal from the nuclear marker PCNA on the same membrane. The 
same letters above each histogram represent statistical significance: ap < 0.05. 
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6.3.4 Regulation of ADAM-10 mRNA and protein expression in LNCaP cells by DHT~ 
IGF-1, IGF-1 plus DHT and EGF mRNA regulation 
Quantitative PCR using SYBR Green assays as described above was performed on eDNA 
reverse transcribed from total RNA extracted from LNCaP cells treated with IGF-I, DHT, 
IGF-1 plus DHT or EGF. DHT (10 nM) and IGF-1 (50 ng/rnl) significantly decreased 
ADAM-10 mRNA levels in LNCaP cells (Figure 6.9), despite our previous observation that 
DHT alone increased ADAM-I 0 mRNA levels in LNCaP cells (McCulloch et aL 2000). 
Conversely, IGF-1 (50 ng/rnl) in the presence of lOnM DHT significantly increased 
ADAM-10 mRNA when compared to the 10 nM DHT treatment in the same experiment 
(Figure 6.9). In the case of EGF treatments, ADAM-I 0 mRNA levels were also 
significantly elevated in LNCaP cells (Figure 6.1 0). 
Whole cell lysate protein regulation 
DHT or IGF-1 alone did not significantly alter ADAM-10 protein levels (Figure 6.11). 
However, IGF-1 (10 or 50 ng/mi) in the presence of lOnM DHT followed the same pattern 
of response as for mRNA and did up-regulate the unprocessed 100 k:Da proform (~2-fold) 
and significantly increased the levels of processed active 60 k.Da form (~4-fold) (Figure 
6.11). EGF (50 ng/ml), like the mRNA response, also significantly stimulated the 
expression of unprocessed 100 k.Da proform (~1.5-fold) and the processed 60 k.Da 
processed form (~2-fold) of ADAM-10 (Figure 6.12). 
Nuclear protein regulation in LNCaP cells by EGF 
In an experiment carried out as described for ADAM-9 previously, EGF alone did not 
significantly alter nuclear ADAM-10 protein levels (Figure 6.13) (P < 0.07) although a 
trend of increased expression across each Western blot was observed, for the unprocessed 
100 kDa pro form ( ~2-fold) and the processed, active 60 k.Da form ( ~ 1.5-fold). 
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Figure 6.9: The regulation of ADAM-10 mRNA expression by DHT, IGF-1, DHT plus 
IGF-1 in LNCaP cells 
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For the mRNA regulation of ADAM-10 by IGF-1 in the presence or absence of DHT, 
LNCaP cells were treated with 0 (control), 10 nM DHT, 50 ng/ml IGF-1 plus or minus 10 
nM DHT and cultured for 48 h. Levels of ADAM-10 transcript were determined by 
quantitative PCR and normalised against 18s rRNA levels. Histograms represent the mean 
+/- SEM from three independent experiments (n=3) with each treatment sample being 
quantitated in triplicate in each of two separate PCR reactions. The same letters above each 
histogram represent statistical significance: a,cP<O.Ol, bP<0.05. 
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Figure 6.10: The regulation of ADAM-10 mRNA expression by EGF in LNCaP cells 
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For the mRNA regulation of ADAM-10 by EGF, LNCaP cells were treated with 0 (control) 
or 50 ng/ml EGF and cultured for 48 h. Levels of ADAM-10 transcript were determined by 
quantitative PCR and normalised against 18s rRNA levels. Histograms represent the mean 
+/- SEM from three independent experiments (n=3) with each treatment sample being 
quantitated in triplicate in each of two separate PCR reactions. The same letters above each 
histogram represent statistical significance: aP<O.Ol. 
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Figure 6.11: The regulation of ADAM-10 protein expression by DHT, IGF-I, DHT plus 
IGF-1 in LNCaP cells 
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Western blot analysis of ADAM-I 0 expression in whole cell Iysates extracted from LNCaP 
cells treated with DHT, IGF-1 or IGF-1 in the presence ofDHT for 48h. Densitometric 
analysis is shown in the histograms below the Western blots for the 100 k:Da ADAM-10 
(pro-enzyme) and the 60 kDa (processed active enzyme) bands. These data are 
representative of three separate growth factor treated LNCaP whole cell lysate preparations. 
The signal for ADAM-I 0 was nonnalised for protein loading with the signal from J3-tubulin 
on the same membrane. The same letters above each histogram represent statistical 
significance: aP<0.05. 
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Figure 6.12: The regulation of ADAM-10 protein expression by EGF in LNCaP cells 
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Western blot analysis of ADAM-1 0 expression in whole celllysates extracted from LNCaP 
cells treated with EGF for 48 h. Densitometric analysis is shown in the histograms below 
the Western blots for the unprocessed 100 k.Da and the mature 60 k.Da, ADAM-10 bands. 
These data are representative of two Western blots on three separate growth factor treated 
LNCaP whole cell lysate protein preparations. The signal for ADAM-10 was normalised 
for protein loading with the signal from !3-tubulin on the same membrane. The same letters 
above each histogram represent statistical significance: ap < 0.05. 
159 
Figure 6.13 The regulation of ADAM-I 0 nuclear protein expression by EGF in LNCaP 
cells 
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Western blot analysis of ADAM-I 0 expression in nuclear protein extracts from LNCaP 
cells treated with EGF. Quantitative image analysis is shown in the histograms below the 
Western blots for the unprocessed 100 k:Da and mature 60 k:Da ADAM-10 bands. These 
data are representative of two Western blots of three separate growth factor treated LNCaP 
nuclear protein preparations. The signal for ADAM-10 was normalised for protein loading 
with the signal from PCNA on the same membrane. The same letters above each histogram 
represent the statistical P- value: ap < 0.07. 
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6.4 Discussion 
Previous studies from this laboratory focussed on the regulation of ADAM-9 and -10 
mRNA by DHT in the LNCaP cell line (McCulloch et al. 2000). It was found that DHT 
significantly stimulated both of these ADAM mRNA levels. Thus these studies were 
extended to more fully describe the regulation of both ADAM-9 and -10 mRNA and 
protein by each of the prostate growth promoters DHT, IGF-1 and EGF. Because IGF-1 is 
well documented to act in synergy with DHT (Iwamura et al. 1993}, exemplified in this 
study by IGF-1 stimulating a further increase in LNCaP proliferation in the presence of 
DHT, but having no effect on cell growth in response to it alone, the regulation of each 
ADAM by IGF-1 was examined, in the presence and absence of DHT, as well as DHT 
alone. EGF regulation, on the other hand, was studied as a separate growth factor, as it 
alone is able to stimulate LNCaP cell proliferation, documented previously (Guo et at 
2000) and illustrated in this study. 
6.4.1 The regulation of ADAM-9 expression by DHT, IGF-1, DHT plus IGF-1 and EGF 
For ADAM-9, neither IGF-1 nor DHT alone stimulated levels of either mRNA or protein. 
However, IGF-1 in the presence ofDHT significantly stimulated relative levels of ADAM-
9 mRNA, and levels of protein in similar fold increments (-'2 fold}. In the case of EGF 
stimulation, similar trends of stimulation were also observed for ADAM-9 mRNA and 
protein (~ 1.5 to ~ 2-fold), the latter in both whole cell lysate and nuclear protein fractions. 
Although it was anticipated that DHT alone wo:rld stimulate ADAM-9 mRNA levels 
(found previously -McCulloch et al. 2000) in LNCaP cells, this particular study did not 
replicate this result. Inherent differences in these studies include the use of a different 
housekeeping gene for normalisation; in this study l8s rRNA was used whilst the previous 
study used !3-actin. Additionally, a different batch and passage number of the LNCaP cell 
line from American Type Culture Collection (A TCC) was used. This might also contribute 
to discrepancies leading to conflicting data, as Esquenet et al. (1997) reported that 
responses to androgens, retinoic acid and vitamin D differed significantly when 
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proliferation and gene regulation were measured, using two different strains of LNCaP cells 
from ATCC, which had undergone low or high·numbers of passages. 
In this current study, however, the regulation of ADAM-9 protein was also examined, and 
similar trends of synergistic stimulation by IGF-1 and DHT were observed across each of 
the mRNA and protein levels. Similarly, EGF alone also showed trends of significant 
stimulation at both the mRNA and protein level,. making these new observations consistent 
within the same cell model. ADAM-9 has three distinct biological roles defined to date; 
metalloprotease activity due to its active metalloprotease domain (Izumi et aL 1998; 
Roghani et al. 1999; Schwettmann and Tschesche, 2001), integrin-binding capability, due 
to its functional integrin-binding loop (Huovila et al. 1996; Zhou et al. 2001) and cen 
signalling characteristics via its PKA response sites on its cytoplasmic tail (Izumi et al. 
1998). 
An increase in metalloprotease activity might increase ECM degradation and cell 
proliferation (Figure 6.14), as active ADAM-9 is able to degrade fibronectin and gelatin in 
vitro (Schwettmann and Tschesche, 2001) and cleave/solubilize membrane bound Hb-EGF 
(Izumi et al. 1998) (Figure 6.14). This may be pertinent in the transition between 
androgen-dependent and androgen-independent PCa when, presumably, IGF-1 is acting in 
synergy with DHT, on tumour cells not yet androgen-insensitive. 
Integrin binding and resultant cell signalling events are necessary for cell migration, as well 
as to re-establish cell-cell and ceH-ECM contacts when tumour cells colonise secondary 
sites within the body. Again, these events are key mechanistic requirements for successful 
metastasis to occur and may be mediated and intensified by elevated levels of ADAM-9 
integrin binding events. 
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Figure 6.14: Schematic diagram, which outlines the possible consequences of elevated 
levels of ADAM-9 in PCa cells, previously published observations are indicated by blue 
arrows,? indicates that it is not yet known what role ADAM-9 has in the cell nucJeus. 
It is not yet known what role or effect expression of ADAM-9 in the cell nucJeus might 
have in normal or tumorigenic cells. However, recently a nucJear form of Hb-EGF was 
described in Transitional Cell Carcinoma (TCC) of the bla~der (Adam et al. 2003). Hence, 
ADAM-9 may carry out proHb-EGF cJeavage in the perinuclear/nuclear compartment, 
releasing active soluble HB-EGF, not unlike its role on the cell membrane. ADAM-9 may 
also have roles as a nuclear membrane bound receptor, involved in cell signalling through 
its PKC response sites, or as an active metalloprotease, which might function as a 
protein/transcription factor activator. Alternatively, ADAM-9 may directly interact with 
DNA, regulating transcriptional events related to cellular function . Whichever the case, an 
elevation of levels of this protein in the nucleus may have direct implications in disrupting 
normal cellular events in tumorigenic cell types. 
6.4.2 The regulation of ADAM-10 expression by DHT, IGF-1, DHT plus IGF-1 and 
EGF 
In the case of ADAM-I 0 mRNA regulation, IGF-I significantly decreased the relative 
levels of ADAM-I 0 mRNA, whilst DHT also slightly decreased the relative levels of 
mRNA. Conversely, IGF-I in the presence of DHT significantly stimulated the relative 
levels of ADAM-IO mRNA. For ADAM-10 protein, neither IGF-1 nor DHT alone had a 
regulatory effect. However, like the mRNA response, IGF-1 plus DHT increased ADAM-
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10 protein levels ~2-fold (unprocessed 100 kDa) and ~4-fold (processed, 60 kDa). 
DHT alone did not stimulate ADAM-10 mRNA levels as previously shown, (McCulloch et 
al. 2000) where a bell-shaped, dose response curve to DHT in LNCaP cells was 
demonstrated. In the previous study, 10 nM DHT decreased levels of ADAM-10 mRNA 
from a greater than 4-fold increase, to a smaHer than 2-fold increase. It is possible that the 
deliberate choice of the higher 10 nM stimulatory dose of DHT for the present study (to 
allow for potential additive effects of I GF -1) may have led to the loss of a DHT stimulatory 
effect due to the bell-shaped, declining stimulation seen in the previous study. In hindsight, 
the maximal dose of 1.0 nM DHT may have been preferable, rather than the higher dose of 
10 nM. Additional to this, the inherent discrepancies between these two studies discussed 
above for ADAM-9, still apply in this case and may have compounded the effects of the 
differential observations. 
Of particular note are the preferentially increased levels of mature 60 kDa ADAM-I 0 (by a 
factor of2) compared to unprocessed 100 kDa ADAM-10, in response to IGF-1 plus DHT 
(whole cell lysate). ADAM-I 0 has recently been shown to disrupt hemidesmosome 
linkages between cells and the ECM by the cleavage of the protein L 1 (Mechtersheimer et 
al. 2001). This loss of cell adhesion might assist the cell to migrate through the degraded 
ECM (Figure 6.15) as in the case of metastasis. The active form of MADM (bovine 
ADAM-10 orthologue) has potent collagenase activity in vitro (Millichip et al. 1998). If 
the same activity is conserved for human ADAM-I 0, this may assist cell invasion through 
the basement membrane (Figure 6.15). 
Such hormonal regulation is consistent with the known roles of combined DHT and IGF-1 
in the early stages ofPCa (Culig et al. 1994). The subsequent loss of androgen-dependence 
in late-stage PCa might be expected to cause a decrease in ADAM-10, as IGF-1 alone was 
unable to increase ADAM-10 in vitro. However, since ADAM-10 is maintained at 
equivalent or greater levels in cancer glands in vivo (reviewed in Chapter 1) then it would 
appear that additional regulatory factors like EGF are involved in regulating ADAM-10 
expression. 
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Figure 6.15: Schematic diagram of the possible consequences of elevated levels of 
ADAM-I 0 in PCa celJs, previously published observations are indicated by blue arrows, ? 
indicates that it is not yet known what role ADAM-I 0 has in the celJ nucleus. 
In the case of EGF, similar trends of stimulation were observed for ADAM-I 0 mRNA and 
protein (~ I.5 to 2-fold, unprocessed 100 kDa and processed 60 kDa forms) in both whole 
celJ lysate and nuclear fractions. Alongside these observations there is existing 
immunohistochemical data, which show a high expression profile for nuclear localised 
ADAM-I 0, in this study, and EGF in high-grade PCa tumour biopsies (Russell et al. 1998). 
A recent study (Y an et al. 2002) linked ADAM-I 0 to the transactivation of the EGF 
receptor (EGFR). In this study, the peptide hormone bombesin, through the subsequent 
activation of G-coupled protein receptors was shown to transactivate the EGFR, with the 
levels of transactivated EGFR being stimulated when an increase in levels of mouse 
ADAM-I 0 were introduced in the celJ system. This type of activity may lead to enhanced 
cell proliferation effects (Figure 6.15). With respect to its nuclear expression, it is not yet 
known whether ADAM-I 0 acts as a growth factor activator, a membrane-bound nuclear 
receptor, or an intermediate cell signal transducer, or directly as a transcription factor. 
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6.4.3 Conclusion 
The synergistic up-regulation by the combined DHT and IGF-1 treatment for both ADAM-
9 and -10 proteins supports the hypothesis that these ADAMs may have functional 
consequences in PCa where these hormone/ growth factors have a central role in its 
development from early stage, androgen sensitive to late stage, androgen insensitive 
phenotype. This study significantly extends our understanding of the potential roles that 
ADAM-9 and -10 may have in androgen-sensitive PCa, where IGF-I can effectively act in 
synergy, stimulating a plethora of cellular responses. Similarly, the regulation of these two 
proteins by EGF provides further regulation data, again suggesting a role for both of these 
ADAMs in PCa, especially where elevated levels of EGF have been shown. This study 
shows for the first time, evidence that, at the protein level, ADAM-9 and -10 can be 
regulated by growth factors involved in PCa development. Ongoing studies are now clearly 
needed to link these observations to the :fi.mctional consequences of ADAM protein 
expression in metastatic cancer types. 
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CHAPTER SEVEN 
7.0 GENERAL DISCUSSION 
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7.llntroduction 
At the outset of this study, little was known with respect to most of the members of the 
ADAMs family in any cancer type. This family of proteins has since expanded to 34 
members characterised thus far. There were a few studies implicating ADAM expression 
in some cancer cell types, in haematological malignancies (Wu et al. 1997), for example, 
and in our own laboratory, in choriocarcinoma ceU lines (Whiteside et ai. Unpublished). 
Before commencing this major study, one year of research for preliminary evidence to 
connect the ADAMs to PCa development and progression was carried out. These studies 
found that ADAM-9, -10, -11, -15 and -17 were expressed in PCa cell lines representing 
androgen-dependent and androgen-independent PCa (McCulloch et aL 2000}. Further 
regulation analysis provided evidence that ADAM-9 and -10 mRNA levels were elevated 
by dihydrotestosterone (DHT). Given this information and the potential 'dual' nature of the 
ADAMs, that is, potential mediators of cell-cell and cell-ECM contacts and active 
metalloprotease activity, capable of degrading ECM components, it was hypothesised that 
ADAMs, -9 and -10 may be implicated in the progression, maintenance and survival ofPCa 
by way ofhormonallgrowth factor regulation. 
An additional novel observation that emerged early in the time frame of this larger study 
was that of the nuclear localisation of ADAM-10 in high-grade PCa. This study, carried 
out as an honours year project by Pascal Akl (2000), involved an IHC study of the cellular 
localisation of ADAMs -10 and -17 in pathology sections oftissue from men with prostate 
disease. A major finding was the dramatic change in localisation of ADAM-1 0 and -17 
from the membrane and cytoplasm of benign secretory and basal epithelial cells of the 
prostate, to nuclear localisation in secretory cells oftumorigenic glands (See Chapter 1). 
ADAM-17 had been previously reported to be perinuclear/nuclear localised (Schlondorff et 
aL 2000) and although this was not in a tumorigenic cell type, it gave some strength to the 
observations in our laboratory. It was decided to extend these findings in normal prostate 
and PCa cell lines since it raised particular and novel questions about the possible roles of 
the cancer specific, nuclear ADAMs. Those nuclear roles would presumably be quite 
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distinct from the classically recognised roles of cell-cell and cell-ECM attachment, ECM-
degradation, and membrane-bound sheddase activity. 
The aims of this study were 1) to further characterise the cellular expression of both 
ADAM-9 and -10 in various prostate pathologies including prostate cell lines and prostate 
secondary tumour metastases 2) to generate an ADAM-I 0 over-expressing prostate cell line 
model, with a view to assessing their roles in the prostate via functional assays such as ceil 
migration, attachment and invasion, and 3) to choose a growth-factor responsive model to 
assess the regulation status of both ADAMs in response to hormones and gro-vvth factors, 
which are highly implicated in prostate growth, specifically DHT, IGF-1 and EGF. By 
obtaining extensive information with respect to cellular localisation, expression levels, 
effects on cell behaviour, and growth factor regulation, major advances may be possible in 
our understanding of the functions of ADAM-9 and -l 0 in PCa. 
7.2 The Expression ofADAM-9 and -10 in PCa 
It was found that both ADAM-9 and -10 had readily detectable levels of mRNA and protein 
expression across cell models which represented normal pathology and low through high-
grade metastatic PCa. The abovementioned primary tumour expression study was extended 
to bone metastases :from patients undergoing biopsies, these metastases showed differential 
membrane/cytoplasmic and nuclear staining for both ADAMs. An expression profi1e such 
as this, found for both ADAMs in bone metastases suggests ADAM-9 and -10 may be 
involved in the local colonisation ofPCa tumour cells after the event of migration. 
Since both of these ADAMs are active rnetalloproteases, it is possible that their 
metalloprotease activity will be involved in the degradation of the surrounding tissue 
environment to allow for the tumour cell mass to expand. Additionally,. the cleavage, 
solubilisation and activation of growth factors and cytokines may contribute by maintaining 
the levels of such growth factors, so that additional growth can occur. Specifically, 
ADAM-9 has recently been found to cleave IGF-BPs in a bone-derived cell line in vitro 
(Mohan et al. 2002), and such activity in bone metastases could readily free biologically 
169 
active IGF-1 so that its well ·known mitogenic effect can be exerted on cells in the 
surrounding bone environment. Increased bioavailabiHty of growth factors such as IGF-1 
might also contribute to enhanced, abnormal osteoblast and osteoclast activation and 
regulation, hence bone turnover. Increases in these activities are already well documented 
in the case of other bone metastases such as those from the breast (Mundy and Y oneda, 
1996), for example, where abnormal amounts ofMMP activity are thought to contribute to 
this process (Okada et al. 1995). The differential membrane/cytoplasm and nuclear 
expression demonstrated b~:tween cells in the same metastasis illustrated in this study, 
might reflect the tumour cells undergoing a transformation to a phenotype that is co Ionising 
a tumour, rather than 'breaking free' from a primary tumour cell mass, as reflected in high-
grade primary tumour cells in which ADAM-I 0 is predominately nuclear localised. 
For in vitro cellular localisation data, cell lines were examined by subcellular fractionation, 
leading to the fmding that both ADAMs had representative forms in each of the cell line's 
nuclear fractions. Further to this, ADAM-10 had two isoforms of its presumably active 
enzyme, which were differentially expressed in the ceil cytoplasm and the cell nucleus. 
The difference in size of these two isoforms was ~2 kDa and may reflect differential N-or 
0-glycosylation as a result of differential proximity and processing through the Golgi 
apparatus. Additionally, the presumably active form of ADAM-9 was also readily 
detectable in the cell nucleus. The presence of both the pro- and active form of both 
ADAMs in the cell nucleus raises new questions as to what role/s these particular ADAMs 
may have, and how they are distinct from classical membrane sheddase activity. 
These roles, to date are unclear, however it is hypothesised that the ADAMs could be 
involved in the activation of nuclear-localised growth factors such as proHb-EGF, for 
example, which is another example of a classically membrane-bound protein that has been 
recently found in the cell nucleus (Adam et al. 2003). Both ADAM-9 and -10 
metalloprotease activities have the capability to activate Hb-EGF on the cell surface in vitro 
(Izumi et aL 1998; Y an et al. 2002) and it is therefore entirely possible that the same role is 
carried out in a different location within the cell. Another role for the ADAMs might be 
that of protein/DNA interaction, where one or both ADAMs may act on DNA directly as an 
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additional transcription factor. Interestingly, ADAM-10 has a proline rich sequence, C-
terminally located, which is a typical feature of the trans activation domain for transcription 
factors. Such DNA binding activity can be tested by the co-transfection of fragments of 
ADAM-9 or -10, :fused to a Gal-4 DNA binding domain vector (Kato et al., 1990) and a 
luciferase reporter gene vector containing Gal-4 binding sites. Transcriptional 
transactivation can be subsequently tested using a luminometer (Kato et aL 1990). 
Further examination, in this study, ofthe expression ofboth ADAM-9 and -10 by Laser 
Capture Microdissection (LCM), in homogenous populations of epithelial cells from benign 
and malignant prostate glands was performed. Although the data were limited, it was 
concluded that the smaller ADAM-I 0 isoform, which appears to be nuclear localised in 
vitro, is indeed present, with the larger isoform, in epithelial cells of the prostate and may 
be the isoform that is predominantly expressed in high-grade PCa in primary tumours as 
shown by IHC (See Chapter I). Molecular weight bands similar to those observed in vitro 
in cytoplasmic and nuclear cellular fractions were also shown for ADAM-9. An assay for 
the detection of differences in mRNA and protein expression of both ADAMs across 
benign, low through high-grade PCa pathologies was successfully developed and may now 
be undertaken, once enough material becomes available to substantiate this study. 
Technology that has some advantages over LCM is now available and is known as the 
"Pulse Assisted Laser Microbeam" (PALM) catapulting system (Arcturis Engineering) 
With this technique, like LCM, a laser pulse guides the removal of homogeneous ceH types 
:from a heterogenous tissue, but it does not rely on a flat surface, making micro-dissection 
accessible to metastatic tissue samples such as those :from the bone where calcification 
particularly contributes to an uneven surface. Using this technology, further expression 
data can be generated from metastatic biopsies to give a more complete expression profile 
of the ADAMs. 
To better understand the importance and role of nuclear ADAMs, further studies to 
elucidate the mechanism by which ADAM-9 and -10 are imported into the cell nucleus, 
would prove valuable. Evidence for possible implication of the a/~ importin system in this 
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mechanism was presented by finding appropriate Nuclear Localisation Sequences (NLS) in 
the primary amino acid sequence of ADAM-9 and. moreso, in ADAM-10. Studies which 
knockout the a/~ importin system by way of inactivating antibodies or antisense 
oligonucleotides (Palacios et aL 1997), followed by subcellular fractionation and ADAM-9 
and -10 Western blot analysis should show whether or not these ADAMs are imported to 
the nucleus via these mechanisms. 
This study also reported the observation that protein bands corresponding to the Mr of both 
ADAM-9 and -10 pro- and active forms could be detected in the extracellular environment 
in membrane vesicles shed from the cell surface of PCa cell lines. This experiment was 
based on a study by Taraboletti et al. (2002) who outlined the presence and phenomena of 
membrane vesicle budding. Membrane vesicles are released, or bud, from the cell 
membrane into the medium and contain cellular and membrane-associated proteins. Active 
MMP expression was found in these membrane vesicles (Taraboletti et al. 2002) and 
further, such vesicles facilitate the migration of other cell types, when added in cell culture 
media in in vitro cell migration assays (Angelucci et al. 2000). 
The role that active ADAM-9 and -10 may have in the extracellular environment could be 
to degrade ECM proteins such as collagen and fibronectin, thus facilitating cell invasion in 
metastasis. Alternatively, given the ECM is rich in growth factors, ADAMs such as -9 and 
-10 might serve as growth-factor activators or binding protein proteases such as the IGF-
BPs or growth hormone BPs. These actions would release or make available high levels of 
biologically active growth factors to exert their mitogenic affects. thereby stimulating 
further proliferation of tumorigenic cells. Further studies measuring the activity of both 
ADAMs in the extracellular environment using fluorogenic peptide substrates (such as 
those described by Vankemmeibeke et al. 2003 for ADAM-10) might confirm that such 
ADAM activity is indeed present in membrane vesicles shed from the cell surface of PCa 
cell lines. 
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7.3 Over-expression o{ADAM-10 in prostate cell lines: 
To examine the functional consequences of ADAM-10 expression in PCa, the process of 
constructing ADAM-10 mammalian expression vectors was carried out, in the hope that 
stably transfected normal prostate and PCa cell lines might over-express ADAM-10, 
whereby functional ceil-based assays could prevaiL Three different expression vectors 
containing full length ADAM-I 0 inserts (two in this study and one in another study in this 
laboratory - Dr. Dimitri Odorico) were not capable of achieving significant over-expression 
of ADAM-1 0 protein in each of the prostate cell lines tested in this study and additional cell 
lines tested by Dr. Dimitri Odorico, by way of transient transfection. 
As outlined in Chapter 5, the natural Kozak sequence for human ADAM-10 (hADAM-10) 
was used as the crucial DNA base-positions for the strong promotion of translation within a 
Kozak sequence (A at -3, and Gat +4) (Kozak, 1997) were conserved. Other studies that 
have examined the function of ADAM-I 0 using mammalian expression vectors (Anders et 
al. 2001) have utilised bovine ADAM-10 (MADM). This particular study demonstrated an 
increase in ~-APP processing with an increase in MADM expression, by measuring the 
levels of secreted B-APP. Interestingly, this study only showed MADM expression using a 
Hemagglutinin-tag antibody in Western immunoblots, however, there was no indication of 
a fold increase of overall ADAM-1 0 production. In our cen system, translation of ADAM-
I 0 from our vector templates may well have taken place, however the vector in this study 
did not contain a tag for this kind of analysis. Nonetheless, marked over-expression was 
not observed. Another recent study (Y an et al. 2002) used an expression construct with full-
length mouse ADAM-I 0, which has a Kozak sequence almost identical to MADM but also 
differs in the same place as hADAM-10 (Chapter 5). This study found that the over 
expression ofMADM but not human ADAM-9lead to an increase in the trans-activation of 
the EGFR. However, no indication of the overall changes of levels of MADM was 
indicated. Yet another group (Franzke et al. 2002) introduced human ADAM-9, mouse 
ADAM-17 and the bovine ADAM-IO orthologue, MADM to assess the expression in a 
keratinocyte cell line, which in the case of all three ADAMs, lead to the enhanced cleavage 
of Collagen XVII. To test for ADAM-I 0 over-expression, immunofluorescence using the 
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same ADAM-1 OCterrn antibody did confirmed over-expression in HaCat cells transiently 
tran~fected with high levels of construct DNA using electroporation. No full-length human 
ADAM-10 mammalian expression vector, to date, to our knowledge, is available for this 
kind of research. 
The difficulties associated with ADAM-1 0 over expression need further attention so that 
the functional consequences of the expression of both ADAMs, an original part of this 
study, can effectively be assessed in vitro. Different approaches need to be undertaken 
whereby a full consensus Kozak sequence, or that homologous to the bovine and mouse 
ADAM-1 0 orthologues, both successful in ADAM-1 0 protein induction (Franzke, et al. 
2002; Yan et al. 2002) is introduced 5' to the translation start site, instead of the naturally 
occurring human ADAM-10 Kozak sequence. Also, the use of a tagged vector system such 
as pcDNAHis, for example, might show whether the introduced vector stimulates ADAM-
I 0 levels. Additionally, a non-ADAM-1 0 expressing cell line would be useful, so that a 
comparison between endogenous and introduced levels of ADAM-10 protein expression 
can be made. 
Once an ADAM-10 over-expressing PCa cell system i:s ultimately established, cell based 
assays can be performed, including cell attachment, migration and invasion assays, 
whereby, the PCa cells are seeded onto synthetic ECM (Matrigel) or components of the 
ECM such as Fibronectin, Vitronectin and various types of Collagen. These types of 
assays are well established and have been used successfuiJy for some years by other 
members of this laboratory (Leavesley et aL 1993; Leavesley et al. 1994). Over time, 
cellular behaviour can be monitored so that a change in ADAM-I 0 expression may be 
correlated with a change in cellular behaviour and properties. Also, the same in vitro cell 
based assays can be performed on PCa cells, in which endogenous levels of ADAM-1 0 
have been knocked out, for example, with morpholino antisense oligonucleotides, as used 
in previous ADAM-10 studies (Yan et al. 2002), or the utilisation of the newly developed 
small interference RNAs (siRNAs) technology. Once these experiments are performed, 
important data pertaining to the functional consequence of ADAM-I 0 protein expression in 
PCa cells can be obtained. 
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7.4 The regulation o(ADAM-9 antl-10 by DHT, JGF-1 and EGF 
The final part of this study focussed on the regulation ofboth ADAM-9 and -10 by the PCa 
growth promoters DHT, IGF-1 in the presence or absence of DHT, or EGF alone. The 
expression ofboth ADAM-9 and -ro mRNA and protein was synergistically stimulated by 
IGF-1 and DHT, and elevated by EGF alone. Preliminary nuclear regulation data also 
showed that EGF stimulates the levels of these proteins, which reside in the cell nucleus. A 
synergistic regulation in response to IGF-1 plus DHT suggests that both ADAMs are 
elevated in androgen sensitive PCa, where IGF -1 is able to exert its biological affects 
synergistically. The regulation of both ADAMs by EGF suggests: that elevated levels of 
this growth factor, as shown with increasing PCa severity (Russel et al. 1998),. might 
maintain protein levels such as ADAM-9 and -10. 
An increase in the metalloprotease activity of ADAM-9 and -10, as a result of elevated 
levels of active enzyme, might increase ECM and basement membrane degradation. As 
outlined previously in Chapter 6, active ADAM-9 is able to degrade fibronectin and gelatin 
(Schwettmann and Tschesche, 2001) and the active form of MADM (bovine ADAM-10 
orthologue) has potent collagenase activity, in vitro (Millichip et al. 1998) and it is likely 
that human ADAM-10 has the same activity. An additional role for both of these ADAMs 
is the cleavage and solubilisation of proHb-EGF, which is known to promote cell 
proliferation through signalling via the EGFR pathway. Elevated levels of ADAM-10 have 
also been linked to the transactivation of the EGF receptor (EGFR) (Y an et al. 2002), and 
this type of activity may also lead to enhanced cell proliferation. 
With respect to the consequences of elevated levels of AD AM-9 and -10 in the cell nucleus, 
shown in this study in response to EGF treatment, recently a nuclear form ofHb-EGF was 
described in Transitional Cell Carcinoma (TCC) of the bladder (Adam et al. 2003). 
Therefore, it is likely that Hb-EGF will be nuclear localised in PCa, hence ADAM-9 and/or 
-1 0 protease activity may carry out increased proHb-EGF cleavage in the 
perinuclear/nuclear compartment, releasing active soluble HB-EGF, not unlike its role on 
the cell membrane, again leading to an increase in cell proliferation through nuclear 
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localised EGFR (Y an et al. 2002). 
Integrin binding and resultant cell signalling events are necessary for cell migration, as well 
as to re-establish cell-cell and ce11-ECM contacts when tumour cells colonise secondary 
sites within the body. These events are key mechanistic requirements for successful 
metastasis to occur and may be mediated and intensified by elevated levels of ADAM-9 
integrin binding events. ADAM-1 0, on the other band, has no documented interaction 
with integrins but bas recently been shown to disrupt hemidesmosome linkages between 
ce11s and the ECM by the cleavage of the protein Ll (Mechtersheimer et al. 2001). This 
loss of cell adhesion might assist the cell to migrate through the degraded ECM in the case 
of metastasis. 
Future studies are now required to confirm the regulation of ADAM-9 and -10 in the 
nucleus and elucidate a function for each of these ADAMs in the nuclear compartment. 
Also, additional studies are needed to fully characterise the responsiveness of membrane 
vesicle shedding, and the subsequent levels and activity of ADAM-9 and -10, to DHT, IGF-
1 and EGF. As outlined earlier, similar studies, which have measured MMP activity, 
suggest hormones and growth factors are able to stimulate membrane shedding events in as 
little as 4 hours (Taraboletti et aL 2002) in cells. The employment of specific ADAM 
activity substrates alongside Western blot analysis might, after growth factor treatment, 
give an indication of possible changes in ADAM levels and activity in the extracellular 
environment, potentially contributing to ECM proteolysis and growth factor activation, 
hence metastasis. 
7.5 Conclusion 
This study has extensively characterised the expressmn and hormonai!growth-factor 
responsiveness in PCa of ADAM-9 and -10, two ADAMs in an extended family of 34 
members. Due to their pattern of expression from early through late stage, metastatic 
disease, and their elevated levels in response to hormones and growth factors that mediate 
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PCa progression, ADAM-9 and -10 are likely candidates for the assistance of PCa growth 
and development. 
This study provides novel data, which builds a strong basis for further research, with 
respect to the functional consequences of ADAM-9 and -10, and other ADAMs in PCa, as 
well as in other cancers that are aggressive and metastatic in nature. The identification and 
characterisation of such candidate proteins, in a study such as this, is important in acquiring 
a full understanding of the underlying mechanisms of cancer progression. Once these 
mechanisms are fully understood, effective treatment regimens can be developed for the 
prevention, survival and improvement of the quality of life of sufferers with cancers such as 
that which originates from the prostate gland. 
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APPENDIX ONE 
A) Table of common MMPs, their synonyms and extrtacellular matrix substrates: 
Enzyme Synonym Molecular Weight Collagen Additional 
(Latent/Active) Substrates Substrates 
MMP-1 Collagenase-1, Rbroblast 55,000/45,000 !,II,II!,VH,Vlii,X Aggrecan, Gelatin, 
Collagenase, Interstitial MMP-2, MMP-9 
Collagenase, Tissue 
Collagenase 
MMP-2 72 kDa Gelatinase, 72 kDa 72,000/66,000 1,11, Ill, IV, V, Aggrecan, Elastin, 
Gelatinase/Type IVCollagenase, Vlf,X,XI Fibronectin, 
Gelatinase A, TBE-1 · Gelatin, Laminin, 
MMP-9, MMP-13 
MMP-3 Procollagenase, PTR1 protein, 57,000/45,000 II, Ill, IV, IX, Aggrecan, Elastin, 
SL-1, X, XI Fibronec!in, 
Stromelysin-1, Transin-1 Gelatin, Laminin, 
MMP-7, MMP-8, 
MMP-13 
MMP-7 Matrilysin, Matrin, PUMP-1 28,000/19,000 IV, X Aggrecan, Elastin, 
· Protease, Uterine Fibronectin, 
Metalloproteinase Gelatin, Laminin, 
MMP-1, 
MMP-2, MMP-9 
MMP-8 Collagenase-2, Neutrophil 75,000/58,000 t,l!,III,V,VII, Aggrecan, Elastin, 
Collagenase, Vlll,X Rbronectin, 
Gelatin, Laminin 
MMP-9 92 kDa Gelatinase, 92 kDa 92,000/86,000 IV, V, VII, X, Aggrecan, Elastin, 
Gelatinase!Type IV XIV Fibronectin, 
Collagenase, Gelatinase B Gelatin 
MMP-10 SL-2, Stromelysin-2, Transin-2 57,000/44,000 Ill, IV, V Aggrecan, Elastin, 
Fibronectin, 
Gelatin, Laminin, 
MMP-1, MMP-8 
MMP-11 SL-3, Stromelysin-3, ST-3 54,000/45,000 IV Elastin, 
and 22,000 Fibronectin, 
Gelatin, Laminin 
MMP-13 Collagenase-3 60,000!48,000 I, II, II!, IV Aggrecan, Gelatin 
MMP-18 Xenopus Collagenase-4, xCot4 70,000/53,000 
MMP-19 RASI-1 54,000/45,000 IV Fibronectin, 
Aggrecan, COMP, 
Laminin, Gelatin 
MMP-20 Enamelysin 54,000/22,000 Aggrecan, 
Amelogenin, 
COMP 
MMP-23 CA-MMP 
MMP-26 Matrilysin-2, Endometase 28,000/19,000 IV Gelatin, 
Fibronectin 
MMP-28 Epilysin 
MT1-MMP MMP-14, Membrane-Type 66,000/56,000 I, 11,111 Aggrecan, Elastin, 
Metalloproteinase-14 Fibronectin, 
Gelatin, Laminin, 
MMP-2, MMP-13 
MT2-MMP MMP-15, Membrane-Type r2,000160,000 Fibronectin, 
Metalloproteinase-15 Gelatin, Laminin, 
MMP-2 
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Enzyme Synonym Molecular Weight Collagen Additional 
(latent/Active) Substrates Substrates 
MT3-MMP MMP-16, Membrane-Type 64,000/52,000 MMP-2 
Metalloproteinase-16 
MT4-MMP MMP-17, Membrane-Type 57,000/53,000 Fibrin, Gelatin 
Metalloproteinase-17 
MT5-MMP MMP-24 -/62,000 
MT6-MMP MMP-25, leukolysin IV Gelatin, 
Fibronectin, 
laminin-1 
(Calbiochem- Oncogene Research Products, Volume 2, January 2002; 
www .calbiochem.com) 
B) Illustration comparing the typical domain structure of an MMP and an ADAM: 
MMPs 
( 
Signal 
peptide 
r 
Sgnal 
peptide 
Propeptide 1\ 1no-terminal 
catalytic domain 
Nature Reviews Neuroscience 2:502-511 (2001) 
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Gart:>oxy-terminal 
hemopexin li o 
domain 
EG Cytoplasmic 
1 ~ 
C) Table of the ADAMs, their synonyms and their expression/functions known te 
date: 
ADAM Synonym 
ADAM1 Fertilin a 
PH-30a 
ADAM2 Fertifin f) 
PH-30 ~ 
ADAM3A Cyritestin 1 (CYRN1} 
tMDCI 
ADAM3B Cyritestin 2 (CYRN2) 
ADAM4 tMDCV 
ADAMS tMDC II 
ADAMS tMDC IV 
ADAMT EPA I 
ADAMS CD156MS2 
ADAMS MDC9 Meltrin y 
ADAM10 Kuzbanian (KUZ) MADM 
ADAM11 MDC 
ADAM12 Meltrina 
ADAM'l3 
ADAM14 ADM-'! 
ADAM15 MDC15 Metargidin 
ADAM16 MDC16 
ADAM17 TACE 
ADAM18 tMDC ltl ADAM27 
ADAM19 Meltrin (} 
ADAM20 
ADAM21 
ADAM22 MDC2 
ADAM23 MDC3· 
ADAM24 Testase-1 
ADAM25 Testase-2 
ADAM26 Testase-3 
ADAM28 MDC-Lm MDC-Ls eMDCU 
ADAM29 
ADAM30 
ADAM31 
ADAMTS1 METH1 
ADAMTS2 PCNP 
ADAMTS3 
Expression/Function 
Subunit of a sperm surface protein involved in sperm-egg fusion; pseudo· gene in human 
Essential for fertilization in mice; interacts with egg integrin as!)" a sperm receptor 
Two human genes (ADAM3A and ADAM3B) and one mouse gene (ADAJ\A3) encoding 
cyritestin, a sperm protein involved in gamete interaction and sperm-egg plasma membrane 
adhesion and fusion 
Cyristestin is a polymorphic protein that consists of both membrane-
anchored and soluble forms 
ADAMs 4-6 cloned from a mouse testis eDNA library; primarily expressed in testis 
Primarily expressed in testis 
Primarily expressed in testis 
A mammalian epididymal protein that may play a role in sperm maturation 
Expressed in myelomonocytes and may play a role in extravasation of leukocytes 
Widely expressed, interacts with SH3 proteins; cleaves insulin 8-chain and severat 
synthetic peptides; has a-secretase activity 
Widely expressed, processes NOTCH and mediates lateral inhibition in neurogenesis; 
cleaves TNF, myelin basic protein, type IV colfagen; has a-secretase activity 
The gene is somatically rearranged in two primary breast cancers 
Cleave u2-macrogfobulin; has IGFBP-3 protease activiT)'; binds to a-actinin-2; participates 
in myoblast fusion 
A Xenopus gene most closety related to mouse ADAM"!2; located to semitic mesoderm and 
cranial neural crest cells 
Expressed in syncytial organs, sperm and sheath cells of sensory organs 
RGD-containing ADAM15 interacts with av~3 integrin; more than half of mature mouse 
protein is intracellular 
Interaction of ADAMs, 16, 9 and 13 with integrin receptors may be necessary for frog 
fertilization 
Processes TNF, TNF receptor, Notch 1 receptor,l-selectin, TRANCE and HER4 JM-a; has 
a-secretase activiT)' 
Protein processed on the sperm surface during epididymal transit 
A novel marker for dendritic cell differentiation and may play a role in osteoblast 
differentiation 
T estis-specifica!ly expressed gene without intron 
Testis-specifica!ly expressed gene without intron 
Expressed predominantly in brain 
Expressed predominantly in brain 
Testis-specifically expressed gene 
Testis-specifically expressed gene 
Testis-specifically expressed gene 
Expressed in human lymphocytes and possesses autocatalytic activity to remove the pro 
domain 
Testis-specificafly expressed gene 
Testi'!-specifically expressed gene 
Highly expressed in specialized epithelia 
An active protease associated with ECM and essential for normal growth, fertility, and 
organ morphology and function; cleaves aggrecan at Gtu187"! and Leu1872; cleaves az-
macroglobulin 
Procol!agen N-proteinase involved in coHagen biosynthesis and may play a rofe in 
deirelopment 
Cloned from brain 
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ADAM Synonym 
ADAMTS4 Aggrecanase-1 
Expression/Function 
Cleaves aggrecan at Glu373 and Ala37 4; cleaves brevican, a brain specific ECM protein, at 
Glu395 and Ser396 
ADAMTS5 Aggrecanase-2 ADAMTS11 Cleaves aggrecan at Glu373 and A!a37 4 
ADAMTS6 
ADAMTS7 
ADAMTS8 METH-2 
ADAMTS9 
SUP-17 
MIG-17 
Decysin 
Expressed at tow levels, primarily in placenta 
Widely expressed 
ADAMTs 8 and 1 disrupt angiogenesis in vivo 
Expressed in all fetal tissues examined and some adult !issues 
May be ADAM10 in C. elegans and play a rote in LIN-12/NOTCH signali11g 
A protease in C. efegans that directs migration of distal tip ceHs by remo<.lefmg the 
basement membrane 
Highly expressed in mature dendritic cells 
(http://www.rndsysterns.com/asp/g_SiteBuilder.asp?BodyiD=303) 
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APPENDIX TWO 
A) PGEMTeasy (Promega) -an intermediate vector used for full length ADAM-10 
sub-cloning into the mammalian expression vectors below. 
B) pcDNA3.1 (Invitrogen)- a mammalian expression vector, driven by the CMV 
promoter~ full length ADAM-10 was cloned in the forward(+) direction using the 
BamHl restriction digest site. 
pci)NA3~l (+1-l 
. . . ~-4~815421 ~p .. 
~2 
0 
.: tJaooS; 1022-:1009 
sQs 11l28-1252. 
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C) pMEP4 (Invitrogen) - a mammalian expression vector, driven by the inducible 
metallothionine (phMTIIA) promoter, .full length ADAM-10 was cloned in the 
forward direction using the BamHl restriction digest site. 
pME.P;4 
. 1(h4kb 
srul 
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